in O
this O
case O
, O
interferon B-DRUG
alpha I-DRUG
induced O
polymyositis O
and O
cardiomyopathy B-ADR
is O
diagnosed O
in O
a O
33-yr-old O
male O
patient O
with O
history O
of O
chronic O
hepatitis O
b O

an O
asymptomatic O
hiv-infected O
woman O
experienced O
right-sided O
renal B-ADR
colicky I-ADR
pain I-ADR
during O
treatment O
with O
indinavir B-DRUG

in O
view O
of O
our O
experience O
in O
the O
present O
case O
, O
it O
should O
be O
stressed O
that O
close O
monitoring O
of O
coagulation O
capacity O
is O
necessary O
in O
critically O
ill O
patients O
in O
order O
to O
avoid O
fatal B-ADR
haemorrhage I-ADR
after O
initiating O
warfarin B-DRUG
therapy O
regardless O
of O
the O
dosage O

methods O
/ O
results O
: O
this O
paper O
presents O
a O
new O
case O
of O
rifabutin B-DRUG
uveitis B-ADR
and O
a O
review O
of O
the O
various O
published O
reports O
to O
date O

in O
the O
present O
paper O
, O
we O
describe O
two O
patients O
with O
active O
uc O
who O
developed O
a O
severe B-ADR
systemic I-ADR
cmv I-ADR
infection I-ADR
during O
a O
treatment O
with O
an O
oral O
microemulsion O
form O
of O
cyclosporine B-DRUG

esophageal B-ADR
candidiasis I-ADR
was O
diagnosed O
at O
endoscopy O
in O
two O
patients O
receiving O
omeprazole B-DRUG
therapy O

background O
: O
methotrexate O
( O
mtx B-DRUG
) O
may O
induce O
liver B-ADR
damage I-ADR
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis O
or O
cirrhosis O

he O
was O
started O
on O
digoxin B-DRUG
, O
0.25 O
mg O
daily O
, O
because O
of O
echocardiographically O
demonstrated O
left B-ADR
ventricular I-ADR
dilatation I-ADR
and O
functional O
impairment O
; O
he O
died O
of O
ventricular O
fibrillation O
15 O
days O
later O

objective O
: O
1 O
) O
to O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
receiving O
adalimumab B-DRUG
who O
developed O
fever O
, O
pancytopenia O
, O
splenomegaly B-ADR
, O
and O
extreme O
hyperferritinemia O

neutropenic B-ADR
colitis I-ADR
during O
standard O
dose O
combination O
chemotherapy O
with O
nedaplatin O
and O
irinotecan B-DRUG
for O
testicular O
cancer O

we O
conclude O
that O
( O
a O
) O
cyclophosphamide B-DRUG
is O
a O
human B-ADR
teratogen I-ADR
, O
( O
b O
) O
a O
distinct O
phenotype O
exists O
, O
and O
( O
c O
) O
the O
safety O
of O
cp O
in O
pregnancy O
is O
in O
serious O
question O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia B-ADR
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

we O
reported O
3 O
patients O
who O
developed O
acute B-ADR
generalized I-ADR
dystonia I-ADR
and O
akinetic O
rigid O
syndrome O
following O
an O
initial O
therapy O
with O
d-penicillamine B-DRUG
125-500 O
mg O
daily O

paradoxical B-ADR
pulmonary I-ADR
vasoconstriction I-ADR
induced O
by O
nitroglycerin B-DRUG
in O
idiopathic O
pulmonary O
hypertension O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline O
, O
with O
nondetectable O
sertraline O
and O
desmethylsertraline B-DRUG
blood O
levels O
, O
resulted O
in O
a O
doubling B-ADR
of I-ADR
the I-ADR
lamotrigine I-ADR
blood I-ADR
level I-ADR
with O
symptoms O
of O
toxicity O

phenytoin-induced O
hypersensitivity B-ADR
reactions I-ADR

anaphylaxis B-ADR
to O
intrathecal O
diamorphine B-DRUG

within O
3 O
weeks O
of O
beginning O
continuous O
daily O
isoniazid O
and O
rifampin B-DRUG
therapy O
for O
pulmonary O
tuberculosis O
, O
a O
patient O
developed O
acute B-ADR
renal I-ADR
failure I-ADR

he O
developed O
fever O
, O
nausea O
, O
diarrhea O
, O
and O
malaise B-ADR
and O
stopped O
taking O
on O
the O
third O
day O
after O
commencing O
pentasa B-DRUG

we O
describe O
a O
case O
of O
clozapine-induced O
seizures B-ADR
in O
a O
patient O
with O
treatment-resistant O
schizophrenia O

rifampin-induced O
hypothyroidism B-ADR
without O
underlying O
thyroid O
disease O

the O
case O
of O
a O
patient O
with O
infectious O
mononucleosis O
treated O
with O
cephalexin B-DRUG
who O
later O
showed O
a O
rash B-ADR
is O
presented O
and O
the O
previous O
literature O
is O
reviewed O

methods O
: O
a O
68-year-old O
man O
developed O
intense O
conjunctival O
hyperemia O
and O
cystoid O
macula O
edema O
after O
switching O
from O
latanoprost O
to O
bimatoprost B-DRUG
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low-risk O
for O
this O
cystoid B-ADR
macular I-ADR
edema I-ADR

the O
potential O
development O
of O
sjs B-ADR
/ O
ten O
, O
a O
severe O
life-threatening O
illness O
, O
emphasizes O
the O
need O
for O
judicious O
use O
of O
tmp-sx B-DRUG
and O
close O
monitoring O
and O
follow-up O
for O
patients O
who O
were O
given O
tmp-sx B-DRUG
for O
sstis O

transient O
leucopenia B-ADR
and O
thrombocytopenia O
associated O
with O
sodium B-DRUG
nitroprusside I-DRUG
infusion O

transtubular O
potassium O
gradient O
( O
ttkg O
) O
also O
decreased O
and O
an O
inverse O
correlation O
was O
found O
between O
ttkg O
and O
doses O
of O
phosphate B-DRUG
( O
r O
= O
- O
0.37 O
; O
p O
< O
0.02 O
; O
n O
= O
38 O

methotrexate-associated O
nephropathy B-ADR
is O
a O
rare O
complication O
in O
pediatric O
oncology O
, O
and O
a O
review O
of O
the O
literature O
suggests O
that O
exposure O
to O
nephrotoxic O
agents O
may O
be O
a O
significant O
but O
perhaps O
underrecognized O
risk O
factor O
for O
its O
development O

she O
was O
placed O
on O
adjuvant O
adriamycin B-DRUG
( O
doxorubicin O
) O
chemotherapy O
, O
but O
6 O
months O
later O
died O
of O
adriamycin B-ADR
toxicity I-ADR

a O
toxic O
encephalopathy O
characterized O
by O
depressed B-ADR
level I-ADR
of I-ADR
consciousness I-ADR
, O
marked O
irritability O
, O
and O
ataxia O
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital O
and O
pyrilamine B-DRUG
maleate I-DRUG

flare O
of O
kaposi O
's O
sarcoma O
( O
ks B-ADR
) O
is O
well O
described O
in O
immunosuppressed O
patients O
treated O
with O
corticosteroids O
and O
rituximab B-DRUG
, O
but O
has O
not O
yet O
been O
reported O
during O
treatment O
with O
imatinib O

the O
authors O
describe O
a O
case O
of O
combined O
lithium O
and O
haloperidol B-DRUG
toxicity O
characterized O
by O
hyperpyrexia O
, O
severe O
rigidity O
, O
mutism O
, O
and O
development O
of O
irreversible B-ADR
tardive I-ADR
dyskinesia I-ADR

the O
cause O
of O
these O
previously O
unreported O
side O
effects O
of O
niacin B-DRUG
therapy O
is O
uncertain O
but O
may O
be O
related O
to O
prostaglandin-mediated O
vasodilatation O
, O
hyperalgesia B-ADR
of I-ADR
sensory I-ADR
nerve I-ADR
receptors I-ADR
, O
and O
potentiation O
of O
inflammation O
in O
the O
gingiva O
with O
referral O
of O
pain O
to O
the O
teeth O

both O
colchicine O
and O
statin B-DRUG
therapy O
may O
be O
associated O
with O
myopathy B-ADR
, O
which O
usually O
occurs O
after O
several O
months O
of O
therapy O

a O
22-year-old O
black O
man O
developed O
fever O
, O
chills O
, O
fatigue O
, O
night O
sweats O
, O
tender O
lymphadenopathy O
, O
and O
a O
generalized B-ADR
, I-ADR
pruritic I-ADR
, I-ADR
macular I-ADR
eruption I-ADR
3 O
weeks O
after O
starting O
minocycline B-DRUG
therapy O
for O
acne O

acute B-ADR
myelogenous I-ADR
leukemia I-ADR
in O
patients O
receiving O
chlorambucil B-DRUG
as O
long-term O
adjuvant O
chemotherapy O
for O
stage O
ii O
breast O
cancer O

delayed B-ADR
hypersensitivity I-ADR
to O
flurbiprofen B-DRUG

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin B-ADR
syndrome I-ADR
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

the O
findings O
were O
judged O
to O
be O
consistent O
with O
soft-tissue B-ADR
injury I-ADR
associated O
with O
intravenous O
administration O
of O
phenytoin B-DRUG
, O
also O
termed O
purple O
glove O
syndrome O

we O
report O
on O
a O
young O
adolescent O
with O
benign B-ADR
intracranial I-ADR
hypertension I-ADR
which O
we O
attribute O
to O
the O
use O
of O
minocycline B-DRUG
for O
acne O

we O
describe O
a O
57-year-old O
man O
with O
acral O
erythrocyanosis O
progressing O
to O
acute O
digital O
ischemia O
and O
gangrene B-ADR
that O
developed O
after O
combined O
chemotherapy O
( O
bleomycin O
and O
methotrexate B-DRUG
) O
used O
to O
treat O
a O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
hypopharynx O

we O
report O
a O
4-year-old O
girl O
who O
presented O
with O
acute O
bilateral O
blindness O
, O
a O
focal O
seizure O
and O
hypertension B-ADR
10 O
days O
after O
commencing O
oxybutynin B-DRUG
to O
treat O
enuresis O

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea B-ADR
, O
stomatitis O
, O
mucositis O
, O
myelosuppression O
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

acute B-ADR
ischaemia I-ADR
of I-ADR
the I-ADR
leg I-ADR
following O
accidental O
intra-arterial O
injection O
of O
dissolved O
flunitrazepam B-DRUG
tablets O

this O
profile O
should O
trigger O
a O
" O
red O
flag O
" O
as O
to O
the O
possibility O
of O
phenobarbital B-DRUG
behavioral O
side O
effects O
or O
exacerbation B-ADR
of I-ADR
preexisting I-ADR
maladaptive I-ADR
behaviors I-ADR

we O
report O
a O
case O
of O
thrombotic B-ADR
thrombocytopenic I-ADR
purpura I-ADR
occurring O
as O
an O
allergic O
response O
to O
trimethoprim-sulfamethoxazole O
therapy O
( O
bactrim O
, O
septra O
) O
in O
a O
jehovah O
's O
witness O
patient O

both O
patients O
developed O
hypoadrenalism B-ADR
while O
on O
o,p B-DRUG
'- I-DRUG
ddd I-DRUG
and O
apparently O
adequate O
dexamethasone O
replacement O
therapy O

ballistic B-ADR
movements I-ADR
due O
to O
ischemic O
infarcts O
after O
intravenous O
heroin B-DRUG
overdose O
: O
report O
of O
two O
cases O

although O
they O
had O
complex O
medical O
problems O
, O
the O
high O
serum O
concentrations O
of O
ampicillin B-DRUG
at O
the O
time O
of O
seizures B-ADR
without O
their O
recurrence O
after O
discontinuing O
the O
antibiotic O
suggest O
that O
the O
seizures B-ADR
were O
related O
to O
the O
ampicillin B-DRUG
therapy O

a O
7-year-old O
with O
congenital O
toxoplasmosis O
who O
took O
pyrimethamine B-DRUG
and O
sulfadiazine O
for O
reactivated O
chorioretinitis O
developed O
fever O
, O
severe O
cutaneous O
involvement O
, O
swelling O
, O
abdominal O
pain O
and O
transaminitis B-ADR
, O
persisting O
weeks O
after O
withholding O
medicines O

a O
case O
of O
priapism B-ADR
associated O
with O
trazodone B-DRUG
is O
described O

postoperative O
hypocalcemic B-ADR
tetany I-ADR
caused O
by O
fleet O
phospho-soda O
preparation O
in O
a O
patient O
taking O
alendronate B-DRUG
sodium I-DRUG
: O
report O
of O
a O
case O

we O
report O
a O
cae O
of O
paranoid B-ADR
psychosis I-ADR
following O
use O
of O
a O
decongestant O
containing O
ppa B-DRUG
and O
summarize O
the O
case O
report O
literature O
of O
psychiatric O
adverse O
effects O
to O
ppa B-DRUG
in O
which O
doses O
were O
known O
and O
stated O
to O
be O
within O
recommended O
guidelines O

case O
summary O
: O
a O
25-year-old O
postpartum O
white O
woman O
developed O
multiple O
watery O
stools O
and O
abdominal B-ADR
cramping I-ADR
on O
day O
6 O
of O
therapy O
with O
clindamycin B-DRUG
vaginal O
cream O
for O
bacterial O
vaginosis O

a O
diagnosis O
of O
masked O
theophylline B-ADR
poisoning I-ADR
should O
be O
considered O
in O
similar O
situations O
involving O
a O
rapid O
decrease O
of O
insulin O
requirements O

the O
case O
histories O
are O
presented O
of O
two O
patients O
who O
developed O
lung O
disease O
associated O
with O
the O
use O
of O
nitrofurantoin B-DRUG
with O
histological O
features O
of O
bronchiolitis B-ADR
obliterans I-ADR
organising I-ADR
pneumonia I-ADR
( O
boop O
) O
, O
a O
rare O
but O
recognised O
form O
of O
drug O
induced O
injury O

because O
the O
combination O
of O
bleomycin B-DRUG
and O
vinca O
alkaloids O
is O
commonly O
used O
for O
the O
treatment O
of O
aids-related O
kaposi O
's O
sarcoma O
, O
clinicians O
should O
be O
aware O
of O
the O
risk O
of O
provoking O
acral B-ADR
necrosis I-ADR
in O
patients O
who O
develop O
raynaud O
's O
phenomenon O
under O
chemotherapy O

two O
patients O
with O
extrinsic O
asthma O
and O
coexistent O
insulin-dependent O
diabetes O
mellitus O
sustained O
an O
anaphylactoid B-ADR
reaction I-ADR
after O
the O
intravenous O
administration O
of O
50 O
% O
solution O
of O
dextrose B-DRUG

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general B-ADR
erythema I-ADR
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general B-ADR
erythema I-ADR
, O
and O
fever O

although O
its O
side O
effects O
are O
few O
, O
tamoxifen B-DRUG
increases O
the O
incidence O
of O
proliferative B-ADR
lesions I-ADR
of I-ADR
the I-ADR
endometrium I-ADR
, O
which O
theoretically O
should O
be O
preventable O
with O
progestational O
agents O

we O
present O
a O
case O
of O
stroke B-ADR
after O
ppa B-DRUG
ingestion O
that O
occurred O
4 O
months O
after O
the O
recall O
in O
an O
8-year-old O
boy O
on O
chronic O
peritoneal O
dialysis O

intracranial B-ADR
hemorrhage I-ADR
and O
focal O
seizures O
secondary O
to O
use O
of O
l-asparaginase B-DRUG
during O
induction O
therapy O
of O
acute O
lymphocytic O
leukemia O

drug O
induced O
polymyositis B-ADR
secondary O
to O
leuprolide B-DRUG
acetate I-DRUG
( O
lupron O
) O
therapy O
for O
prostate O
carcinoma O

administration O
of O
steroid O
and O
decreasing O
the O
dose O
of O
ptu B-DRUG
produced O
a O
good O
clinical O
response O
and O
the O
anca B-ADR
disappeared O

the O
cough B-ADR
continued O
for O
the O
duration O
of O
therapy O
with O
quinapril B-DRUG

conclusion O
: O
significant O
weight B-ADR
loss I-ADR
is O
a O
potential O
adverse O
event O
in O
patients O
with O
rheumatoid O
arthritis O
treated O
with O
leflunomide B-DRUG

rapamycin O
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune B-DRUG
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression O
, O
hypertension O
, O
hyperlipidemia B-ADR
, O
and O
infection O

angioimmunoblastic B-ADR
lymphadenopathy I-ADR
with I-ADR
dysproteinemia I-ADR
following O
doxycycline B-DRUG
administration O

the O
results O
clearly O
demonstrate O
that O
cph82 B-DRUG
was O
associated O
with O
suppression B-ADR
of I-ADR
the I-ADR
endogeneous I-ADR
production I-ADR
of I-ADR
acth I-ADR
and I-ADR
cortisol I-ADR
with O
a O
concomitant O
paradoxical O
picture O
of O
clinical O
hypercortisolism O

from O
1996 O
to O
2002 O
several O
medications O
were O
changed O
due O
to O
their O
adverse O
effects O
: O
indinavir B-DRUG
( O
renal B-ADR
colic I-ADR
and O
fever O
) O
, O
nelfinavir O
( O
cutaneous O
rash O
) O
, O
and O
efavirenz O
( O
nausea O
and O
temporary O
memory O
loss O

rifampicin-induced O
renal B-ADR
failure I-ADR

this O
communication O
describes O
a O
patient O
who O
developed O
schneiderian B-ADR
first-rank I-ADR
symptoms I-ADR
in O
the O
course O
of O
treatment O
with O
fluvoxamine B-DRUG

it O
was O
concluded O
that O
potassium O
loss O
occurred O
by O
a O
non-renal O
( O
intestinal O
) O
route O
in O
phosphate-induced O
hypokalemia B-ADR

data O
synthesis O
: O
genetic O
deficiencies O
in O
dpd O
, O
the O
rate-limiting O
enzyme O
responsible O
for O
5-fu B-DRUG
catabolism O
, O
may O
occur O
in O
3 O
% O
or O
more O
of O
patients O
with O
cancer O
putting O
them O
at O
increased O
risk O
for O
unusually O
severe O
adverse O
reactions O
( O
e.g. O
, O
diarrhea B-ADR
, O
stomatitis O
, O
mucositis O
, O
myelosuppression O
, O
neurotoxicity O
) O
to O
standard O
doses O
of O
5-fu B-DRUG

he O
had O
an O
immediate O
hypersensitivity O
reaction O
during O
the O
initiation O
of O
the O
mtx B-DRUG
infusion O
with O
diffuse O
urticaria O
, O
facial O
swelling O
, O
cough O
, O
and O
chest B-ADR
tightness I-ADR

methods O
: O
a O
68-year-old O
man O
developed O
intense B-ADR
conjunctival I-ADR
hyperemia I-ADR
and O
cystoid O
macula O
edema O
after O
switching O
from O
latanoprost O
to O
bimatoprost B-DRUG
9 O
months O
after O
cataract O
surgery O
in O
an O
eye O
at O
low-risk O
for O
this O
cystoid O
macular O
edema O

thoracoscopic O
biopsy O
to O
confirm O
metastasis O
revealed O
instead O
fibrotic B-ADR
lesions I-ADR
apparently O
attributable O
to O
bleomycin O
or O
cyclophosphamide B-DRUG

one O
patient O
had O
mri B-ADR
t2 I-ADR
abnormalities I-ADR
compatible O
with O
cyclosporin B-DRUG
neurotoxicity O

l-asparaginase-induced O
pancreatitis O
is O
an O
uncommon O
but O
potential O
lethal B-ADR
complication I-ADR
of O
the O
treatment O
of O
leukemia O

we O
report O
the O
case O
of O
a O
lung O
cancer O
patient O
with O
bronquiloalveolar O
carcinoma O
( O
bac O
) O
presenting O
with O
boop O
after O
chemotherapy O
with O
docetaxel B-DRUG
and O
gemcitabine O
producing O
severe B-ADR
respiratory I-ADR
insufficiency I-ADR
, O
and O
simulating O
a O
progression O
of O
the O
tumor O

allergic B-ADR
contact I-ADR
dermatitis I-ADR
from O
4-chloro-7-nitrobenzofurazan B-DRUG

despite O
a O
response O
of O
the O
meningeal O
tumor O
the O
patient O
developed O
in O
the O
third O
week O
of O
mtx O
treatment O
a O
progressive O
visual O
loss O
and O
loss O
of O
consciousness O
which O
worsened O
during O
subsequent O
ara-c B-DRUG
treatment O
and O
led O
to O
death B-ADR
within O
3 O
weeks O

therapy O
with O
ifn-beta B-DRUG
has O
rarely O
been O
associated O
with O
the O
development O
of O
autoimmune B-ADR
disorders I-ADR

a O
transient O
tonic O
pupillary O
response O
, O
denervation B-ADR
supersensitivity I-ADR
, O
and O
abnormal O
visual-evoked O
potentials O
in O
quinine B-DRUG
toxicity O
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O

serious O
phenytoin B-DRUG
hypersensitivity B-ADR
reactions I-ADR
may O
appear O
as O
dermatologic O
, O
lymphoid O
, O
or O
hepatic O
syndromes O

a O
33-year-old O
man O
with O
a O
history O
of O
recreational O
benztropine B-DRUG
abuse O
presented O
to O
the O
emergency O
department O
with O
confusion B-ADR
, O
abdominal O
pain O
, O
and O
distention O

patients O
: O
two O
patients O
, O
ages O
40 O
and O
51 O
years O
, O
undergoing O
treatment O
with O
interferon B-DRUG
alfa I-DRUG
for O
malignant O
neoplasms O
experienced O
sudden B-ADR
bilateral I-ADR
, I-ADR
sequential I-ADR
visual I-ADR
loss I-ADR
with O
disc-related O
field O
defects O
and O
segmental O
optic O
disc O
edema O

however O
, O
an O
association O
of O
ritalin B-DRUG
with O
glaucoma B-ADR
has O
been O
reported O

we O
report O
two O
patients O
with O
anhedonic B-ADR
ejaculation I-ADR
( O
ejaculation O
without O
orgasm O
) O
associated O
with O
initiation O
of O
treatment O
with O
desipramine B-DRUG

cicatricial B-ADR
entropion I-ADR
associated O
with O
chronic O
dipivefrin B-DRUG
application O

based O
on O
the O
clinical O
status O
of O
the O
patient O
, O
it O
was O
suspected O
that O
several O
conditions O
contributed O
to O
the O
abnormal B-ADR
hypersensitivity I-ADR
to O
warfarin B-DRUG

we O
describe O
two O
women O
who O
developed O
hus B-ADR
after O
mmc B-DRUG
therapy O
and O
presented O
massive O
pulmonary O
bleeding O

bleomycin B-DRUG
and O
cyclophosphamide O
toxicity O
simulating O
metastatic B-ADR
nodules I-ADR
to O
the O
lungs O
in O
childhood O
cancer O

we O
describe O
a O
case O
of O
disseminated O
muscular O
cysticercosis O
followed O
by O
myositis O
( O
fever O
, O
diffuse O
myalgia O
, O
weakness O
of O
the O
lower O
limbs O
, O
and O
inflammatory B-ADR
reaction I-ADR
around I-ADR
dying I-ADR
cysticerci I-ADR
) O
induced O
by O
praziquantel B-DRUG
therapy O
, O
an O
event O
not O
described O
previously O

in O
this O
report O
, O
one O
patient O
who O
developed O
gangrene B-ADR
after O
bleomycin O
and O
vincristine B-DRUG
/ O
vinblastine O
chemotherapy O
for O
aids-related O
kaposi O
's O
sarcoma O
and O
another O
hiv-infected O
patient O
who O
exhibited O
symptoms O
of O
severe O
raynaud O
's O
phenomenon O
related O
to O
the O
same O
regimen O
are O
presented O

purple O
glove O
syndrome O
, O
named O
for O
its O
distinctive O
purple B-ADR
discoloration I-ADR
and O
swelling O
of O
the O
hands O
in O
the O
distribution O
of O
a O
glove O
, O
is O
an O
uncommon O
complication O
of O
intravenous O
phenytoin B-DRUG
administration O
through O
small O
dorsal O
veins O
of O
the O
hands O

a O
retrospective O
review O
of O
ttp O
patients O
with O
quinine-associated O
thrombotic B-ADR
microangiopathy I-ADR
( O
tma O
) O
for O
whom O
adamts13 O
was O
measured O
before O
plasma O
exchange O
was O
performed O

conclusions O
: O
amphotericin B-DRUG
b I-DRUG
seems O
to O
be O
the O
probable O
cause O
of O
the O
seizures B-ADR

5-fluorouracil B-DRUG
cardiotoxicity B-ADR
complicating O
treatment O
of O
stage O
iib O
cervical O
cancer O
-- O
case O
report O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin B-ADR
syndrome I-ADR
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

in O
case O
no O
. O
2 O
, O
the O
pathogenic O
mechanism O
seemed O
to O
be O
persistent O
light O
reaction O
preceded O
by O
systemic O
photoallergy O
, O
as O
he O
had O
taken O
mequitazine B-DRUG
for O
6 O
months O
, O
and O
there O
were O
strong O
positive O
photopatch O
test O
results O
with O
immediate O
erythema O
reaction O
, O
cross-reaction O
to O
promethazine O
, O
decreased O
med O
to O
both O
uva O
and O
uvb O
, O
and O
persistence B-ADR
of I-ADR
the I-ADR
photosensitivity I-ADR
over O
a O
3-year O
follow-up O
period O
after O
discontinuation O
of O
the O
mequitazine B-DRUG

rhabdomyolysis B-ADR
has O
been O
recognized O
as O
a O
complication O
of O
tocolytic O
therapy O
with O
ritodrine B-DRUG
hydrochloride I-DRUG

successful O
treatment O
of O
visceral O
leishmaniasis O
with O
allopurinol O
plus O
ketoconazole O
in O
an O
infant O
who O
developed O
pancreatitis B-ADR
caused O
by O
meglumine B-DRUG
antimoniate I-DRUG

anaphylactoid B-ADR
shock I-ADR
, O
disseminated O
intravascular O
coagulation O
, O
and O
anuric O
renal O
failure O
requiring O
dialysis O
occurred O
in O
a O
patient O
receiving O
zomepirac B-DRUG
sodium O
for O
toothache O

a O
51-yr-old O
nonsmoking O
male O
patient O
without O
any O
history O
of O
previous O
allergies O
, O
asthma O
, O
hay O
fever O
, O
or O
urticaria O
developed O
attacks B-ADR
of I-ADR
asthma I-ADR
when O
captopril O
was O
added O
to O
the O
nadolol O
and O
dyazide B-DRUG
treatment O
for O
his O
high O
blood O
pressure O

we O
reported O
a O
case O
of O
disulfiram-induced O
hepatitis B-ADR
with O
unique O
clinical O
features O
and O
compared O
our O
case O
with O
others O
in O
the O
literature O

we O
consider O
asterixis O
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-ADR
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium O
or O
clozapine B-DRUG
are O
used O
in O
combination O
with O
cbz O

we O
report O
a O
case O
of O
a O
patient O
with O
pulmonary O
hypertension O
and O
undifferentiated O
connective O
tissue O
disease O
who O
, O
after O
2 O
months O
of O
treatment O
with O
epoprostenol B-DRUG
, O
presented O
with O
rapidly O
progressive O
erythema O
, O
scaling O
, O
nausea B-ADR
and O
vomiting O
, O
and O
fever O

two O
patients O
are O
described O
who O
developed O
sensory B-ADR
neuropathy I-ADR
after O
the O
ingestion O
of O
30.6 O
and O
114 O
g O
metronidazole B-DRUG
respectively O

the O
cause O
of O
these O
previously O
unreported O
side O
effects O
of O
niacin B-DRUG
therapy O
is O
uncertain O
but O
may O
be O
related O
to O
prostaglandin-mediated O
vasodilatation O
, O
hyperalgesia O
of O
sensory O
nerve O
receptors O
, O
and O
potentiation B-ADR
of I-ADR
inflammation I-ADR
in I-ADR
the I-ADR
gingiva I-ADR
with O
referral O
of O
pain O
to O
the O
teeth O

agranulocytosis B-ADR
and O
granulocytopenia O
associated O
with O
quetiapine B-DRUG

a O
patient O
is O
described O
with O
the O
characteristic O
features O
of O
phenytoin B-DRUG
hypersensitivity O
syndrome O
( O
phs O
) O
including O
fever O
, O
erythroderma O
, O
tibial B-ADR
and I-ADR
facial I-ADR
oedema I-ADR
, O
pinhead-sized O
facial O
pustules O
and O
abnormal O
liver O
function O
tests O

treatment O
with O
infliximab B-DRUG
is O
known O
to O
produce O
an O
increase O
of O
autoantibodies O
( O
antinuclear B-ADR
antibodies I-ADR
, O
anti-double-stranded O
dna O
) O
, O
but O
not O
clinical O
disease O

he O
developed O
recurrent O
skin O
rash O
, O
fever B-ADR
, O
hypereosinophilia O
, O
and O
acute O
renal O
failure O
after O
rechallenge O
with O
chlorambucil B-DRUG

bleomycin B-DRUG
pneumonitis B-ADR
potentiated O
by O
oxygen O
administration O

the O
present O
report O
suggests O
that O
clarithromycin O
coadministration O
induces O
increased O
plasma O
carbamazepine B-DRUG
concentrations O
, O
which O
may O
result O
in O
carbamazepine B-ADR
toxicity I-ADR

we O
suggest O
that O
sarcoidosis B-ADR
may O
develop O
in O
chronic O
hepatitis O
c O
patients O
during O
interferon O
alpha O
and O
/ O
or O
ribavirin B-DRUG
treatment O
, O
and O
diagnostic O
tests O
for O
this O
adverse O
effect O
should O
be O
performed O
during O
the O
follow-ups O

the O
authors O
postulate O
that O
two O
types O
of O
combined O
lithium-neuroleptic O
toxicity O
occur O
: O
a O
neuroleptic O
malignant O
extrapyramidal O
syndrome O
and O
a O
lithium B-ADR
toxicity I-ADR
that O
occurs O
in O
combination O
with O
phenothiazines O
, O
primarily O
thioridazine B-DRUG

methods O
: O
in O
an O
institutional O
practice O
setting O
, O
two O
women O
, O
aged O
25 O
and O
45 O
, O
developed O
acute B-ADR
myopia I-ADR
after O
starting O
topiramate B-DRUG
for O
epilepsy O

transient B-ADR
anuria I-ADR
following O
administration O
of O
angiotensin O
i-converting O
enzyme O
inhibitor O
( O
sq B-DRUG
14225 I-DRUG
) O
in O
a O
patient O
with O
renal O
artery O
stenosis O
of O
the O
solitary O
kidney O
successfully O
treated O
with O
renal O
autotransplantation O

intravenous O
verapamil B-DRUG
therapy O
in O
babies O
may O
cause O
apnea B-ADR
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine O
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

conclusions O
: O
topical O
brimonidine B-DRUG
may O
be O
associated O
with O
central B-ADR
nervous I-ADR
system I-ADR
depression I-ADR
in O
infants O

stroke-like B-ADR
syndrome I-ADR
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
induced O
vasomotor O
reaction O

colonic B-ADR
necrosis I-ADR
is O
known O
as O
a O
rare O
complication O
following O
the O
administration O
of O
kayexalate O
( O
sodium B-DRUG
polystryrene I-DRUG
sulfonate I-DRUG
) O
in O
sorbitol O

temporary B-ADR
neurologic I-ADR
abnormalities I-ADR
were O
observed O
in O
one O
out O
of O
23 O
patients O
undergoing O
chemotherapy O
with O
high-dose O
methotrexate B-DRUG
( O
hd-mtx O
) O
for O
osteogenic O
sarcoma O

although O
major O
hazards O
of O
treatment O
of O
hypophosphatemic O
osteomalacia O
with O
phosphate B-DRUG
and O
calcitriol O
are O
secondary O
hyperparathyroidism O
and O
vitamin O
d O
intoxication O
, O
potassium B-ADR
loss I-ADR
also O
should O
be O
kept O
in O
mind O

vogt-koyanagi-harada B-ADR
disease I-ADR
occurring O
during O
interferon B-DRUG
alpha I-DRUG
therapy O
for O
chronic O
hepatitis O
c O

purpose O
: O
to O
report O
a O
case O
of O
angiographically O
documented O
cystoid B-ADR
macula I-ADR
edema I-ADR
occurring O
after O
switching O
a O
pseudophakic O
patient O
from O
latanoprost O
to O
bimatoprost B-DRUG

conclusions O
: O
hypersensitivity B-ADR
reactions I-ADR
to O
cyclosporine O
are O
due O
to O
cremophor B-DRUG
el I-DRUG

cisplatin-induced O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
in O
a O
patient O
with O
neuroendocrine O
tumor O
of O
the O
cervix O
: O
a O
case O
report O
and O
review O
of O
the O
literature O

in O
addition O
, O
an O
immediate O
erythematous B-ADR
macule I-ADR
was O
observed O
on O
the O
photopatch O
test O
site O
of O
mequitazine B-DRUG
directly O
after O
uv O
exposure O
which O
was O
similar O
to O
the O
immediate O
erythema O
noted O
in O
chlorpromazine O
photoallergy O

we O
strongly O
suspect O
that O
this O
lethal B-ADR
anuria I-ADR
was O
mainly O
due O
to O
ifosfamide B-DRUG
, O
occurring O
in O
a O
patient O
having O
received O
previous O
cisplatin O
chemotherapy O
and O
with O
poor O
kidney O
perfusion O
due O
to O
transient O
hypotension O

de B-ADR
novo I-ADR
absence I-ADR
status I-ADR
of O
late O
onset O
following O
withdrawal O
of O
lorazepam B-DRUG
: O
a O
case O
report O

we O
report O
an O
additional O
case O
of O
isotretinoin B-DRUG
teratogenicity O
in O
which O
the O
patient O
had O
agenesis B-ADR
of I-ADR
the I-ADR
cerebellar I-ADR
vermis I-ADR
, O
multiple O
leptomeningeal O
neuroglial O
heterotopias O
, O
hydrocephalus O
, O
and O
abnormalities O
of O
the O
corticospinal O
tracts O

the O
purpose O
of O
this O
report O
is O
to O
document O
a O
new O
case O
of O
in O
utero O
cp B-DRUG
exposure O
with O
multiple O
congenital O
anomalies O
and O
to O
establish O
an O
apparent O
cp B-DRUG
embryopathy B-ADR
phenotype O

when O
sasp O
was O
changed O
to O
5-aminosalicylic O
acid O
( O
5-asa B-DRUG
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness B-ADR
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait O
disturbance O

discontinuation O
of O
simvastatin B-DRUG
and O
cyclosporine O
resulted O
in O
resolution O
of O
rhabdomyolysis B-ADR
and O
normalization O
of O
renal O
function O

a O
patient O
is O
described O
who O
developed O
a O
poorly O
differentiated O
sarcoma B-ADR
after O
cyclophosphamide B-DRUG
was O
used O
to O
treat O
his O
rheumatoid O
arthritis O

theophylline B-ADR
intoxication I-ADR
following O
viloxazine B-DRUG
induced O
decrease O
in O
clearance O

shortly O
after O
chemotherapy O
and O
an O
injection O
of O
pegfilgrastim B-DRUG
, O
the O
patient O
developed O
poorly O
defined O
, O
rapidly B-ADR
progressive I-ADR
erythema I-ADR
, O
edema O
, O
and O
pain O
in O
his O
right O
forearm O

while O
most O
physicians O
are O
aware O
of O
heparin-induced O
thrombocytopenia O
and O
skin B-ADR
necrosis I-ADR
, O
the O
association O
of O
heparin B-DRUG
and O
hyperkalemia O
is O
less O
well O
recognized O

lithium B-DRUG
treatment O
was O
terminated O
in O
1975 O
because O
of O
lithium B-ADR
intoxication I-ADR
with O
a O
diabetes O
insipidus-like O
syndrome O

it O
is O
suggested O
that O
the O
patient O
had O
sulfasalazine-induced O
lupus O
, O
which O
manifested O
with O
serositis B-ADR
and O
pulmonary O
parenchymal O
involvement O
in O
the O
absence O
of O
joint O
symptoms O

objective O
: O
to O
investigate O
the O
mechanisms O
involved O
in O
hypersensitivity B-ADR
reactions I-ADR
to O
cyclosporine B-DRUG
and O
determine O
the O
feasibility O
of O
future O
cyclosporine B-DRUG
use O

we O
describe O
a O
5-year-old O
girl O
showed O
recovery O
of O
vincristine B-DRUG
induced O
cranial B-ADR
polyneuropathy I-ADR
with O
pyridoxine O
and O
pyridostigmine O
treatment O

systemic B-ADR
allergic I-ADR
contact I-ADR
dermatitis I-ADR
to O
8-methoxypsoralen O
( O
8-mop B-DRUG

we O
report O
on O
three O
patients O
who O
developed O
acute O
liver B-ADR
damage I-ADR
during O
therapy O
with O
itraconazole B-DRUG
, O
and O
in O
whom O
liver O
biopsy O
specimens O
were O
obtained O

marked O
qt O
prolongation O
and O
torsades B-ADR
de I-ADR
pointes I-ADR
secondary O
to O
acute O
ischemia O
in O
an O
elderly O
man O
taking O
dofetilide B-DRUG
for O
atrial O
fibrillation O
: O
a O
cautionary O
tale O

we O
report O
the O
case O
histories O
of O
identical O
twin O
brothers O
who O
developed O
concordant O
acute O
lymphoblastic O
leukemia O
at O
the O
age O
of O
4 O
years O
and O
who O
later O
developed O
leukoencephalopathy B-ADR
and O
hydrocephalus O
related O
to O
central O
nervous O
system O
prophylaxis O
by O
, O
in O
the O
first O
case O
intrathecally O
administered O
methotrexate B-DRUG
and O
, O
in O
the O
second O
by O
intrathecally O
administered O
methotrexate B-DRUG
and O
cranial O
irradiation O

nine O
delirious B-ADR
patients O
suffering O
from O
lithium B-DRUG
intoxication O
were O
examined O
with O
the O
mini-mental O
state O
exam O
( O
mms O
) O
to O
describe O
the O
clinical O
course O
of O
the O
disorder O

we O
report O
the O
case O
of O
a O
40-year-old O
woman O
who O
developed O
fulminant O
hepatic O
failure O
and O
aplastic B-ADR
anaemia I-ADR
following O
a O
course O
of O
oral O
flucloxacillin B-DRUG

cefoxitin B-DRUG
therapy O
for O
mycobacterium O
fortuitum O
bacteremia O
with O
associated O
granulomatous B-ADR
hepatitis I-ADR

allergic B-ADR
contact I-ADR
angioedema I-ADR
to O
benzoyl B-DRUG
peroxide I-DRUG

according O
to O
the O
naranjo O
probability O
scale O
, O
the O
papular B-ADR
eruption I-ADR
was O
probably O
caused O
by O
methotrexate B-DRUG

since O
ethambutol B-DRUG
is O
actively O
excreted O
via O
the O
renal O
system O
, O
compromise O
of O
renal O
function O
such O
as O
due O
to O
renal O
tuberculosis O
may O
lead O
to O
serum O
concentration O
elevations O
of O
ethambutol B-DRUG
sufficient O
to O
produce O
optic B-ADR
neuropathy I-ADR

the O
sulfonamides B-DRUG
are O
the O
best O
verified O
drug-trigger O
for O
erythema O
multiforme O
and O
stevens-johnson B-ADR
syndrome I-ADR

when O
vague B-ADR
symptoms I-ADR
develop O
during O
desmopressin B-DRUG
therapy O
, O
hyponatremia O
must O
be O
considered O
as O
part O
of O
the O
differential O
diagnosis O

a O
case O
of O
oculogyric B-ADR
crisis I-ADR
induced O
by O
metoclopramide B-DRUG
is O
described O
in O
this O
paper O

physicians O
should O
be O
aware O
of O
the O
risk O
of O
severe O
aiha B-ADR
in O
cll O
patients O
with O
a O
history O
of O
aiha B-ADR
or O
positivation O
of O
the O
dat O
during O
previous O
fludarabine B-DRUG
administration O
, O
or O
in O
case O
of O
secondary O
fixation O
of O
complement O
to O
the O
red O
cell O
membrane O
occurring O
during O
fludarabine B-DRUG
treatment O

the O
authors O
report O
two O
cases O
of O
acute B-ADR
dystonic I-ADR
reactions I-ADR
( O
adrs O
) O
as O
a O
side O
effect O
of O
lamivudine B-DRUG

we O
present O
a O
case O
of O
hus B-ADR
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin B-DRUG
and O
gemcitabine O
, O
and O
described O
its O
favorable O
outcome O
after O
chemotherapy O
interruption O
and O
supportive O
care O
with O
a O
1 O
year O
follow-up O

we O
describe O
2 O
patients O
with O
prior O
amputation O
who O
experienced O
phantom B-ADR
limb I-ADR
pain I-ADR
( O
plp O
) O
after O
receiving O
paclitaxel B-DRUG
therapy O

fatal B-ADR
complication I-ADR
of O
intravesical O
formalin B-DRUG
during O
control O
of O
intractable O
hemorrhage O
from O
radiation O
cystitis O

hyperkalaemia O
with O
renal B-ADR
tubular I-ADR
dysfunction I-ADR
by O
sulfamethoxazole-trimethoprim B-DRUG
for O
pneumocystis O
carinii O
pneumonia O
in O
patients O
with O
lymphoid O
malignancy O

quinine B-DRUG
and O
its O
isomer O
quinidine O
are O
well-known O
causes O
of O
iatrogenic B-ADR
hypoglycaemia I-ADR
, O
due O
to O
excessive O
insulin O
secretion O

the O
authors O
report O
a O
case O
of O
urinary B-ADR
incontinence I-ADR
( O
ui O
) O
that O
occurred O
in O
a O
woman O
after O
administration O
of O
venlafaxine B-DRUG

hepatolithiasis B-ADR
( O
intrahepatic O
stone O
) O
during O
octreotide B-DRUG
therapy O
for O
acromegaly O
: O
a O
case O
report O

these O
cases O
and O
a O
review O
of O
the O
literature O
suggested O
that O
hepatotoxicity B-ADR
, O
though O
rare O
, O
should O
be O
added O
to O
the O
list O
of O
adverse O
reactions O
to O
d-penicillamine B-DRUG

possible O
interaction O
between O
lopinavir B-DRUG
/ O
ritonavir O
and O
valproic O
acid O
exacerbates O
bipolar B-ADR
disorder I-ADR

results O
: O
a O
44-year-old O
man O
taking O
naproxen B-DRUG
for O
chronic O
low O
back O
pain O
and O
a O
20-year-old O
woman O
on O
oxaprozin O
for O
rheumatoid O
arthritis O
presented O
with O
tense O
bullae O
and O
cutaneous B-ADR
fragility I-ADR
on O
the O
face O
and O
the O
back O
of O
the O
hands O

a O
62-year-old O
woman O
treated O
with O
pranlukast B-DRUG
for O
2 O
months O
developed O
interstitial O
pneumonitis O
with O
a O
high B-ADR
fever I-ADR

physicians O
should O
be O
aware O
that O
indinavir B-DRUG
nephrolithiasis O
may O
cause O
papillary B-ADR
necrosis I-ADR

radiologic O
recognition O
of O
adriamycin B-DRUG
cardiotoxicity B-ADR

conclusions O
: O
although O
mirtazapine B-DRUG
offers O
clinicians O
a O
combination O
of O
strong O
efficacy O
and O
good O
safety O
, O
we O
suggest O
bearing O
ss B-ADR
in O
mind O
when O
prescribing O
this O
drug O
, O
especially O
in O
frail O
, O
elderly O
patients O
with O
underlying O
chronic O
conditions O

this O
case O
emphasizes O
the O
importance O
of O
the O
evaluation O
of O
lithium-associated O
polyuria B-ADR
with O
a O
direct O
measurement O
of O
plasma O
vasopressin O
, O
interpreted O
with O
simultaneous O
plasma O
and O
urine O
osmolality O
to O
secure O
the O
correct O
diagnosis O
and O
ensure O
appropriate O
therapeutic O
management O

therefore O
, O
we O
concluded O
that O
this O
patient O
's O
pulmonary B-ADR
disease I-ADR
was O
caused O
by O
calcium B-DRUG
stearate I-DRUG
, O
an O
additive O
for O
an O
antihistaminic O
drug O

the O
disease-modifying O
drugs O
he O
was O
taking O
, O
cyclosporin B-DRUG
and O
methotrexate O
, O
were O
stopped O
, O
and O
the O
lymphoma B-ADR
resolved O
spontaneously O
without O
the O
use O
of O
chemotherapy O

we O
postulate O
that O
the O
bolus O
of O
sulprostone B-DRUG
resulted O
in O
possible O
coronary B-ADR
spasm I-ADR
that O
resulted O
in O
cardiac O
arrest O

these O
observations O
indicate O
that O
submassive O
hepatic O
necrosis O
may O
result O
from O
treatment O
with O
propylthiouracil B-DRUG
and O
are O
consistent O
with O
the O
notion O
that O
sensitization O
mechanisms O
may O
be O
responsible O
for O
the O
hepatic B-ADR
injury I-ADR
induced O
by O
this O
drug O

objectives O
: O
the O
authors O
described O
a O
case O
of O
hashimoto B-ADR
's I-ADR
disease I-ADR
during O
interferon-alpha O
( O
ifn-alpha B-DRUG
) O
treatment O
for O
chronic O
viral O
c O
hepatitis O
in O
a O
patient O
with O
the O
specific O
genetic O
susceptibility O
associated O
with O
the O
thyroid O
disease O

a O
case O
of O
severe B-ADR
acute I-ADR
hepatitis I-ADR
caused O
by O
cyproterone B-DRUG
acetate I-DRUG
in O
a O
71 O
year O
old O
man O
with O
prostatic O
carcinoma O
is O
reported O
with O
a O
review O
of O
the O
literature O
on O
hepatic O
reactions O
to O
this O
drug O

the O
findings O
were O
judged O
to O
be O
consistent O
with O
soft-tissue O
injury O
associated O
with O
intravenous O
administration O
of O
phenytoin B-DRUG
, O
also O
termed O
purple B-ADR
glove I-ADR
syndrome I-ADR

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension O
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever B-ADR

results O
: O
quetiapine B-DRUG
was O
associated O
with O
leucopenia B-ADR
in O
two O
patients O
and O
clinically O
apparent O
agranulocytosis O
in O
one O
patient O

here O
we O
present O
the O
case O
of O
a O
woman O
who O
received O
high O
doses O
of O
methylprednisolone B-DRUG
( O
1 O
g O
iv O
daily O
) O
for O
active O
graves' O
ophthalmopathy O
, O
and O
developed O
severe B-ADR
hypertension I-ADR
followed O
by O
myocardial O
infarction O
on O
the O
fifth O
day O
of O
treatment O

a O
girl O
with O
cystic O
fibrosis O
and O
cyclic O
neutropenia O
developed O
an O
erythematous B-ADR
papular I-ADR
eruption I-ADR
without O
fever O
or O
neutrophilia O
7 O
months O
after O
commencing O
therapy O
with O
g-csf B-DRUG

we O
describe O
the O
clinical O
response O
, O
as O
determined O
by O
increases B-ADR
in I-ADR
total I-ADR
hb I-ADR
and O
decreased O
transfusion O
needs O
, O
in O
five O
patients O
with O
thalassemia O
intermedia O
treated O
with O
hu B-DRUG
alone O
or O
in O
combination O
with O
spb O

coagulopathy B-ADR
associated O
with O
the O
use O
of O
cephalosporin O
or O
moxalactam B-DRUG
antibiotics O
in O
acute O
and O
chronic O
renal O
failure O

discussion O
: O
the O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea O
, O
nausea O
, O
liver O
enzyme O
elevation O
, O
hypertension O
, O
alopecia B-ADR
, O
and O
allergic O
skin O
reactions O

to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
case O
of O
lithium-associated O
cdi O
and O
ndi B-ADR
presenting O
concurrently O

we O
report O
a O
50-year-old O
male O
patient O
with O
a O
15-year O
history O
of O
psoriasis O
including O
mutilating O
psoriatic O
arthritis O
, O
in O
whom O
the O
withdrawal O
of O
cyclosporin B-DRUG
a I-DRUG
induced O
a O
generalised B-ADR
pustular I-ADR
exacerbation I-ADR
and O
a O
aggravation O
of O
the O
joint O
condition O

the O
female O
patient O
received O
clozapine B-DRUG
in O
a O
daily O
dose O
of O
400 O
mg O
, O
which O
induced O
agranulocytosis B-ADR
after O
2 O
months O

an O
unusual O
case O
of O
ecstasy B-ADR
poisoning I-ADR

when O
thrombosis B-ADR
develops O
during O
heparin B-DRUG
treatment O
, O
it O
is O
important O
to O
suspect O
hitts O
and O
to O
assay O
for O
the O
associated O
antibodies O
, O
regardless O
of O
the O
actual O
platelet O
count O

behavioral O
side O
effects O
associated O
with O
clonazepam B-DRUG
may O
include O
agitation O
, O
aggression O
, O
hyperactivity O
, O
irritability B-ADR
, O
property O
destruction O
, O
and O
temper O
tantrums O

the O
fifth O
patient O
exhibited O
paraesthesia B-ADR
and O
agitation O
caused O
by O
olanzapine B-DRUG
that O
was O
misdiagnosed O
as O
psychotic O
agitation O

the O
vomiting B-ADR
occurred O
on O
switching O
to O
different O
pancreatic O
enzymes O
preparations O
, O
ie O
, O
creon B-DRUG
10 I-DRUG
, O
viokase O
, O
and O
pancrease O
mt O
16 O

gold-induced O
pneumonitis B-ADR

cyclosporin B-DRUG
side O
effects O
included O
hirsutism O
, O
hypertension B-ADR
, O
increased O
blood O
levels O
of O
urea O
and O
creatinine O
, O
and O
abnormalities O
in O
liver O
function O
tests O

thalidomide B-DRUG
was O
withdrawn O
from O
world O
markets O
in O
1961 O
following O
recognition O
of O
its O
teratogenic B-ADR
effects I-ADR

a O
64 O
year O
old O
man O
with O
recurrent O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
head O
and O
neck O
developed O
severe O
skin O
rash O
and O
bone B-ADR
marrow I-ADR
aplasia I-ADR
4 O
and O
7 O
days O
, O
respectively O
, O
following O
a O
single O
dose O
of O
40 O
mg O
/ O
m2 O
methotrexate O
( O
mtx B-DRUG

severe O
serotonin B-ADR
syndrome I-ADR
induced O
by O
mirtazapine B-DRUG
monotherapy O

induction O
of O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR
by O
interferon-gamma B-DRUG
in O
a O
patient O
with O
rheumatoid O
arthritis O

priapism B-ADR
as O
a O
complication O
of O
heparin B-DRUG
therapy O

methods O
: O
the O
patient O
required O
insulin B-DRUG
desensitization O
for O
severe B-ADR
urticaria I-ADR
, O
angioedema O
, O
and O
occasional O
wheezing O
resulting O
from O
her O
insulin B-DRUG
dose O

case O
: O
we O
report O
a O
case O
of O
a O
woman O
with O
severe O
human B-DRUG
insulin-induced O
lipoatrophy B-ADR
who O
has O
been O
treated O
exclusively O
with O
recombinant O
dna O
human B-DRUG
insulin I-DRUG
since O
the O
onset O
of O
iddm O

the O
mild O
immunosuppression O
that O
occurs O
with O
methotrexate B-DRUG
therapy O
probably O
places O
patients O
with O
rheumatoid O
arthritis O
at O
added O
risk O
of O
developing O
lymphoproliferative B-ADR
diseases I-ADR
, O
but O
coincidence O
cannot O
be O
excluded O

itraconazole-related O
increased O
vincristine B-ADR
neurotoxicity I-ADR
: O
case O
report O
and O
review O
of O
literature O

we O
describe O
2 O
patients O
with O
cutaneous O
lupus O
erythematosus O
who O
developed O
severe O
dapsone B-DRUG
reaction O
after O
low O
dose O
therapy O
, O
with O
a O
fatal B-ADR
outcome O
in O
one O

a O
65-year-old O
woman O
, O
in O
the O
intensive O
care O
unit O
because O
of O
septic O
shock O
and O
acute O
renal O
failure O
, O
had O
a O
small-bowel B-ADR
obstruction I-ADR
due O
to O
amphojel B-DRUG
concretions O

linezolid-associated O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
and O
drug O
rash O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress O
) O
syndrome O

a O
patient O
suffering O
from O
heparin-associated O
thrombocytopenia B-ADR
( O
hat O
) O
, O
recurrent O
arteriothromboses O
, O
and O
acute O
renal O
failure O
after O
treatment O
with O
standard O
heparin B-DRUG
is O
described O

mequitazine O
seemed O
to O
play O
a O
part O
similar O
to O
chlorpromazine O
, O
and O
absence O
of O
mequitazine-induced O
photosensitivity B-ADR
may O
be O
due O
to O
a O
relatively O
low O
dosage O
of O
the O
drug O

we O
report O
a O
myeloma O
patient O
who O
developed O
severe B-ADR
paralytic I-ADR
ileus I-ADR
during O
bortezomib B-DRUG
therapy O
, O
which O
presented O
in O
the O
context O
of O
progressive O
constipation O
without O
other O
known O
causes O
and O
which O
regressed O
promptly O
with O
medical O
management O
after O
drug O
cessation O
, O
suggesting O
a O
direct O
causal O
relationship O

acute B-ADR
generalized I-ADR
exanthematous I-ADR
pustulosis I-ADR
induced O
by O
salazosulfapyridine B-DRUG
in O
a O
patient O
with O
ulcerative O
colitis O

intravenous O
verapamil B-DRUG
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial B-ADR
flutter I-ADR
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine O
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

the O
development O
of O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR
( O
sle O
) O
after O
38 O
months O
of O
therapy O
with O
recombinant O
human O
interferon O
gamma O
( O
rifn-gamma B-DRUG
) O
was O
observed O
in O
a O
patient O
with O
rheumatoid O
arthritis O

risperidone B-DRUG
is O
a O
frequently O
used O
member O
of O
a O
new O
class O
of O
atypical O
antipsychotics-the O
serotonin-dopamine O
antagonists O
( O
sdas O
)- O
due O
to O
its O
comparatively O
high O
efficacy O
and O
low O
d2 O
/ O
5ht2 O
binding O
ratio O
, O
which O
results O
in O
a O
low O
incidence O
of O
extrapyramidal O
side O
effects O
including O
tardive B-ADR
dyskinesia I-ADR
( O
td O

acute B-ADR
myopathy I-ADR
with O
selective O
degeneration O
of O
myosin O
filaments O
following O
status O
asthmaticus O
treated O
with O
methylprednisolone O
and O
vecuronium B-DRUG

fatal B-ADR
eosinophilia I-ADR
myalgia I-ADR
syndrome I-ADR
in O
a O
marrow O
transplant O
patient O
attributed O
to O
total O
parenteral O
nutrition O
with O
a O
solution O
containing O
tryptophan B-DRUG

pneumonitis B-ADR
is O
emerging O
as O
one O
of O
the O
most O
unpredictable O
and O
potentially O
serious O
, O
adverse O
effects O
of O
treatment O
with O
mtx B-DRUG

here O
we O
present O
the O
case O
of O
a O
woman O
who O
received O
high O
doses O
of O
methylprednisolone B-DRUG
( O
1 O
g O
iv O
daily O
) O
for O
active O
graves' O
ophthalmopathy O
, O
and O
developed O
severe O
hypertension O
followed O
by O
myocardial B-ADR
infarction I-ADR
on O
the O
fifth O
day O
of O
treatment O

reactivation B-ADR
of I-ADR
cytomegalovirus I-ADR
probably O
followed O
the O
treatment O
of O
wegener O
's O
granulomatosis O
with O
corticosteroids O
and O
azathioprine B-DRUG

we O
present O
a O
case O
of O
sotalol-induced O
bradycardia B-ADR
reversed O
by O
glucagon O

in O
case O
1 O
, O
a O
total O
daily O
dose O
of O
25 O
mg O
sertraline O
, O
with O
nondetectable O
sertraline O
and O
desmethylsertraline B-DRUG
blood O
levels O
, O
resulted O
in O
a O
doubling O
of O
the O
lamotrigine O
blood O
level O
with O
symptoms B-ADR
of I-ADR
toxicity I-ADR

eye B-ADR
movement I-ADR
disorders I-ADR
in O
bone O
marrow O
transplant O
patients O
on O
cyclosporin B-DRUG
and O
ganciclovir O

ptosis B-ADR
occurring O
24 O
h O
after O
chloroquine B-DRUG
therapy O
, O
with O
full O
recovery O
48 O
h O
after O
cessation O
of O
chloroquine B-DRUG
, O
has O
not O
been O
described O
previously O

despite O
administration O
of O
phenytoin O
and O
lorazepam O
, O
the O
seizures B-ADR
persisted O
and O
occurred O
only O
during O
amphotercin B-DRUG
b I-DRUG
administration O

coadministration O
of O
antidepressant O
agents O
such O
as O
nefazodone B-DRUG
, O
or O
any O
other O
drug O
that O
inhibits O
the O
cyp3a4 O
isoenzyme O
subfamily O
, O
should O
be O
anticipated O
to O
interfere B-ADR
with I-ADR
tacrolimus I-ADR
metabolism I-ADR

the O
reported O
cases O
of O
in O
utero O
exposure O
to O
cyclosposphamide B-DRUG
shared O
the O
following O
manifestations O
with O
our O
patient O
: O
growth O
deficiency O
, O
developmental O
delay O
, O
craniosynostosis O
, O
blepharophimosis O
, O
flat O
nasal O
bridge O
, O
abnormal O
ears O
, O
and O
distal B-ADR
limb I-ADR
defects I-ADR
including O
hypoplastic O
thumbs O
and O
oligodactyly O

background O
: O
gemcitabine O
has O
mild O
renal O
toxicity O
, O
but O
cases O
of O
gemcitabine-associated O
hemolytic-uremic B-ADR
syndrome I-ADR
( O
hus O
) O
have O
been O
reported O

seizure B-ADR
with O
hyponatremia O
in O
a O
child O
prescribed O
desmopressin B-DRUG
for O
nocturnal O
enuresis O

it O
is O
concluded O
that O
simultaneous O
administration O
of O
ciprofloxacin O
and O
tazobactam O
/ O
piperacillin B-DRUG
may O
cause O
marked O
thrombocytosis B-ADR

the O
development O
of O
erythroid O
leukemia O
plus O
carcinoma B-ADR
in O
these O
two O
men O
suggests O
mutagenic O
change O
secondary O
to O
cyclophosphamide B-DRUG
therapy O

we O
describe O
a O
patient O
with O
crest O
syndrome O
( O
calcinosis O
, O
raynaud O
's O
phenomenon O
, O
esophageal O
dysfunction O
, O
sclerodactyly O
, O
and O
telangiectasia O
) O
who O
paradoxically O
experienced O
worsening B-ADR
of I-ADR
raynaud I-ADR
's I-ADR
phenomenon I-ADR
when O
using O
yohimbine B-DRUG
for O
ed O

background O
: O
gemcitabine O
has O
mild O
renal O
toxicity O
, O
but O
cases O
of O
gemcitabine-associated O
hemolytic-uremic O
syndrome O
( O
hus B-ADR
) O
have O
been O
reported O

we O
introduce O
a O
case O
of O
a O
sixty O
years O
old O
woman O
with O
several O
previous O
episodes O
of O
rhinitis O
, O
conjunctivitis B-ADR
and O
perspiration O
immediately O
after O
the O
administration O
of O
salmon O
calcitonin O
with O
nasal O
spray O
or O
intramuscular O
administration O
( O
calsynar B-DRUG

this O
case O
showed O
sequential O
manifestation O
from O
transient O
thyrotoxicosis O
to O
the O
appearance O
of O
tsh-receptor O
autoantibodies O
, O
and O
then O
the O
occurrence O
of O
graves' B-ADR
hyperthyroidism I-ADR
during O
ifn B-DRUG
therapy O

neutrophilic B-ADR
dermatoses I-ADR
in O
two O
children O
with O
idiopathic O
neutropenia O
: O
association O
with O
granulocyte O
colony-stimulating O
factor O
( O
g-csf B-DRUG
) O
therapy O

objective O
: O
to O
report O
a O
case O
of O
linear O
immunoglobulin O
( O
ig O
) O
a O
bullous O
dermatosis O
( O
labd B-ADR
) O
induced O
by O
gemcitabine B-DRUG

although O
risk O
factors O
for O
mtx-induced O
pulmonary B-ADR
toxicity I-ADR
are O
poorly O
understood O
, O
the O
presence O
in O
3 O
out O
of O
5 O
of O
our O
patients O
of O
pre-existing O
lung O
disease O
, O
represented O
by O
diffuse O
interstitial O
changes O
on O
chest O
x-ray O
, O
and O
mild O
bronchial O
asthma O
in O
two O
ra O
patients O
and O
by O
pulmonary O
silicosis O
in O
the O
patient O
with O
psa O
may O
account O
for O
a O
predisposition O
to O
the O
development O
of O
mtx B-DRUG
pneumonitis O

rapid O
resolution O
of O
topiramate-induced O
angle-closure B-ADR
glaucoma I-ADR
with O
methylprednisolone B-DRUG
and O
mannitol O

we O
presented O
a O
patient O
with O
status O
asthmaticus O
treated O
with O
a O
combination O
of O
theophylline O
and O
prednisone B-DRUG
who O
developed O
a O
perforated B-ADR
gastric I-ADR
ulcer I-ADR

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever B-ADR
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine O
( O
cbz O
; O
tegretol B-DRUG
) O
used O
against O
benign O
rolandic O
epilepsy O

the O
exact O
mechanism O
of O
ivig-associated O
acute B-ADR
renal I-ADR
failure I-ADR
remains O
unclear O

the O
association O
of O
central B-ADR
diabetes I-ADR
insipidus I-ADR
( O
cdi O
) O
with O
lithium B-DRUG
use O
is O
rare O

we O
describe O
two O
patients O
with O
rheumatoid O
factor-positive O
, O
polyarticular-onset O
juvenile O
rheumatoid O
arthritis O
in O
whom O
accelerated B-ADR
nodulosis I-ADR
developed O
during O
methotrexate B-DRUG
therapy O

we O
consider O
asterixis O
to O
be O
an O
easily O
overlooked O
sign O
of O
neurotoxicity B-ADR
, O
which O
may O
occur O
even O
at O
low O
or O
moderate O
dosage O
levels O
, O
if O
certain O
drugs O
as O
lithium B-DRUG
or O
clozapine O
are O
used O
in O
combination O
with O
cbz O

the O
spectrum O
of O
nitrofurantoin B-DRUG
lung B-ADR
injury I-ADR
continues O
to O
widen O

suxamethonium B-DRUG
apnoea B-ADR
terminated O
with O
commercial O
serumcholinesterase O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram B-DRUG
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady B-ADR
gait I-ADR
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl O
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl O

mineral B-DRUG
oil I-DRUG
, O
a O
hydrocarbon O
, O
may O
not O
elicit O
a O
normal O
protective O
cough O
reflex O
and O
may O
impair B-ADR
mucociliary I-ADR
transport I-ADR

intra-neural B-ADR
ceroid-like I-ADR
pigment I-ADR
following O
the O
treatment O
of O
lepromatous O
leprosy O
with O
clofazimine B-DRUG
( O
b663 O
; O
lamprene O

we O
report O
a O
case O
of O
recurrent O
torsades B-ADR
de I-ADR
pointes I-ADR
following O
treatment O
with O
pentavalent O
antimonial O
drugs O
and O
amiodarone B-DRUG

we O
report O
4 O
patients O
, O
2 O
on O
methylphenidate O
and O
2 O
on O
dextroamphetamine B-DRUG
who O
presented O
with O
acral B-ADR
cyanosis I-ADR
, O
livedo O
reticularis O
, O
or O
raynaud O
phenomenon O

in O
a O
postural O
challenge O
test O
after O
administration O
of O
isosorbide B-DRUG
dinitrate I-DRUG
( O
5 O
mg O
) O
, O
blood O
pressure O
decreased O
from O
120 O
/ O
67 O
to O
65 O
/ O
35 O
mmhg O
, O
followed O
by O
syncope O
with O
a O
sudden B-ADR
decrease I-ADR
in I-ADR
pulse I-ADR
rate I-ADR
from O
85 O
to O
60 O
beats O
/ O
min O

we O
report O
a O
31-year-old O
women O
with O
recurrent O
hodgkin O
's O
lymphoma O
and O
unrecognized O
hmsn-1 O
who O
developed O
severe B-ADR
motor I-ADR
neuropathy I-ADR
3 O
weeks O
after O
the O
first O
cycle O
of O
treatment O
including O
2 O
mg O
of O
vincristine B-DRUG

we O
presented O
the O
case O
of O
a O
patient O
who O
developed O
a O
cutaneous B-ADR
reaction I-ADR
induced O
by O
captopril B-DRUG
with O
positive O
patch O
test O

a O
60 O
year-old O
woman O
with O
chronic O
renal O
failure O
developed O
acute O
proximal B-ADR
muscle I-ADR
weakness I-ADR
after O
receiving O
a O
regular O
dosage O
of O
colchicine B-DRUG

neurophysiological O
mechanisms O
which O
aid O
in O
elucidating O
the O
role O
of O
disulfiram B-DRUG
in O
the O
etiology O
of O
catatonia B-ADR
are O
discussed O

comparable O
adverse O
effects O
, O
such O
as O
disorientation O
and O
temporary B-ADR
amnesia I-ADR
, O
have O
been O
reported O
in O
patients O
in O
the O
analogous O
agent O
, O
propranolol B-DRUG

hepatotoxicity B-ADR
of O
hycanthone B-DRUG
in O
patients O
with O
metastatic O
breast O
cancer O

case O
report O
: O
we O
report O
a O
case O
of O
acute B-ADR
severe I-ADR
hepatitis I-ADR
resulting O
from O
erlotinib B-DRUG
monotherapy O
in O
a O
patient O
with O
locally O
advanced O
pancreatic O
cancer O

severe O
steroid-induced O
glaucoma B-ADR
following O
intravitreal O
injection O
of O
triamcinolone O
acetonide O

we O
report O
the O
case O
of O
a O
43-year-old O
man O
with O
itp O
refractory O
to O
steroids O
and O
intravenous O
immunoglobulin O
who O
developed O
acute O
respiratory O
distress O
syndrome O
( O
ards B-ADR
) O
after O
a O
single O
infusion O
of O
rituximab B-DRUG

the O
patient O
expired O
after O
seven O
cycles O
of O
treatment O
had O
been O
completed O
because O
of O
pulmonary B-ADR
fibrosis I-ADR
and O
the O
drug O
toxicity O
of O
bleomycin B-DRUG

methadone-induced O
myoclonus B-ADR
in O
advanced O
cancer O

we O
discuss O
a O
patient O
who O
developed O
severe O
renal O
tubular O
dysfunction O
secondary O
to O
short-term O
therapy O
with O
amikacin B-DRUG
, O
resulting O
in O
refractory O
hypokalemia O
, O
hypocalcemia O
, O
hypomagnesemia O
, O
metabolic B-ADR
alkalosis I-ADR
, O
and O
polyuria O

objective O
: O
the O
purpose O
of O
this O
study O
was O
to O
report O
the O
concomitant O
occurrence O
of O
multiple O
squamous O
cell O
carcinomas O
and O
diffuse B-ADR
nail I-ADR
hyperpigmentation I-ADR
associated O
with O
hydroxyurea B-DRUG
treatment O
, O
and O
to O
describe O
a O
successful O
therapeutic O
approach O
using O
imiquimod O
5 O

this O
case O
illustrates O
that O
the O
hemophagocytic B-ADR
syndrome I-ADR
associated O
with O
reactivation O
of O
ebv O
can O
occur O
as O
part O
of O
drug O
hypersensitivity O
reactions O
in O
ra O
patients O
taking O
sulfasalazine B-DRUG

adverse O
reaction O
in O
a O
patient O
with O
aspirin-induced O
asthma B-ADR
treated O
with O
zafirlukast O

it O
was O
highly O
suspected O
that O
finasteride B-DRUG
was O
associated O
with O
the O
anterior B-ADR
subcapsular I-ADR
opacity I-ADR
on I-ADR
the I-ADR
lens I-ADR
, O
and O
the O
patient O
therefore O
discontinued O
use O
of O
finasteride B-DRUG

amphotericin B-DRUG
b-induced O
seizures B-ADR
in O
a O
patient O
with O
aids O

he O
had O
an O
immediate O
hypersensitivity O
reaction O
during O
the O
initiation O
of O
the O
mtx B-DRUG
infusion O
with O
diffuse O
urticaria O
, O
facial B-ADR
swelling I-ADR
, O
cough O
, O
and O
chest O
tightness O

although O
both O
the O
spontaneous O
occurrence O
of O
sle B-ADR
and O
the O
psychosis O
as O
a O
sign O
of O
cns O
involvement O
of O
sle B-ADR
cannot O
be O
excluded O
, O
sle B-ADR
could O
be O
considered O
as O
an O
adverse O
effect O
of O
carbamazepine B-DRUG

case O
summary O
: O
a O
10-year-old O
white O
girl O
with O
bilateral O
optic O
glioma O
developed O
a O
hypersensitivity B-ADR
reaction O
to O
carboplatin B-DRUG
after O
nine O
courses O

acute O
onset O
of O
nephrotic B-ADR
syndrome I-ADR
during O
interferon-alpha B-DRUG
retreatment O
for O
chronic O
active O
hepatitis O
c O

a O
65-year-old O
woman O
with O
bipolar O
disorder O
and O
complicated O
cardiovascular O
disease O
who O
was O
on O
maintenance O
lithium O
therapy O
developed O
a O
movement B-ADR
disorder I-ADR
following O
high O
doses O
of O
trazodone B-DRUG
for O
treatment O
of O
an O
acute O
depression O

discussion O
: O
phenolphthalein B-DRUG
is O
the O
active O
ingredient O
in O
several O
over-the-counter O
laxative O
preparations O
and O
has O
only O
rarely O
been O
reported O
to O
cause O
ten B-ADR

method O
: O
case O
analysis O
of O
a O
poly-drug O
overdose O
( O
venlafaxine O
, O
topiramate O
, O
divalproex O
sodium O
, O
risperidone B-DRUG
, O
and O
carbamazepine O
) O
presenting O
with O
mixed O
ss O
/ O
nms B-ADR
features O
and O
whose O
clinical O
management O
suggests O
a O
practical O
algorithm O
for O
treatment O
of O
undifferentiated O
ss O
/ O
nms B-ADR
in O
critical O
care O
settings O

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion B-ADR
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

pancreatitis B-ADR
is O
a O
very O
rare O
adverse O
effect O
associated O
with O
the O
use O
of O
amiodarone B-DRUG
, O
and O
only O
four O
cases O
of O
amiodarone-induced O
pancreatitis O
have O
been O
reported O
in O
literature O

phenytoin B-ADR
toxicity I-ADR
due O
to O
concomitant O
antituberculosis O
therapy O

a O
toxic O
encephalopathy O
characterized O
by O
depressed O
level O
of O
consciousness O
, O
marked O
irritability O
, O
and O
ataxia B-ADR
developed O
in O
seven O
children O
, O
5 O
years O
of O
age O
and O
younger O
, O
following O
administration O
of O
an O
antiemetic O
combination O
of O
pentobarbital O
and O
pyrilamine B-DRUG
maleate I-DRUG

a O
case O
of O
acute O
cardiomyopathy O
and O
pericarditis B-ADR
associated O
with O
methylphenidate B-DRUG

the O
goal O
of O
this O
study O
is O
to O
describe O
three O
patients O
diagnosed O
with O
migraine O
and O
epilepsy O
( O
both O
under O
control O
) O
who O
evolved O
into O
status B-ADR
migrainosus I-ADR
after O
the O
introduction O
of O
oxcarbazepine O
( O
oxc O
) O
, O
as O
part O
of O
a O
switch O
off O
from O
carbamazepine O
( O
cbz B-DRUG

a O
74-year-old O
patient O
with O
idiopathic O
parkinson O
's O
disease O
was O
evaluated O
for O
unintended B-ADR
sleep I-ADR
episodes I-ADR
that O
occurred O
after O
long-term O
treatment O
with O
400 O
mg O
/ O
day O
of O
l-dopa B-DRUG

case O
report O
: O
we O
present O
a O
case O
of O
a O
28-yr-old O
male O
who O
developed O
a O
severe O
case O
of O
nephrotic B-ADR
syndrome I-ADR
while O
being O
treated O
for O
relapsing O
/ O
remitting O
multiple O
sclerosis O
( O
rrms O
) O
with O
weekly O
injections O
of O
interferon B-DRUG
beta I-DRUG
1a I-DRUG

the O
increasing O
prevalence O
of O
methamphetamine B-DRUG
abuse O
and O
the O
severity O
of O
the O
associated O
ulcers O
should O
alert O
ophthalmologists O
to O
the O
problem O
of O
methamphetamine-related O
keratitis B-ADR

interferon-induced O
psychosis B-ADR
as O
a O
" O
psychiatric O
contraindication O
" O
to O
hepatitis O
c O
treatment O
: O
a O
review O
and O
case-based O
discussion O

however O
, O
the O
occurrence O
and O
management O
of O
akathisia B-ADR
induced O
by O
fluvoxamine B-DRUG
have O
not O
been O
described O

docetaxel B-DRUG
induced O
meibomian B-ADR
duct I-ADR
inflammation I-ADR
and I-ADR
blockage I-ADR
is O
the O
likely O
cause O
of O
this O
presentation O
in O
a O
patient O
with O
no O
history O
of O
eyelid O
masses O
in O
the O
past O

a O
25-year-old O
woman O
sought O
medical O
attention O
because O
of O
iliocaval O
manifestations O
of O
retroperitoneal B-ADR
fibrosis I-ADR
while O
she O
was O
taking O
methysergide B-DRUG

three O
days O
after O
intravitreal O
injection O
of O
bevacizumab B-DRUG
, O
acute B-ADR
ocular I-ADR
ischemic I-ADR
syndrome I-ADR
occurred O

escape O
atrial O
complexes O
, O
which O
occurred O
following O
junctional O
premature O
complexes O
, O
failed O
to O
initiate O
tachycardia B-ADR
in O
the O
control O
state O
but O
tachycardia B-ADR
was O
always O
reinitiated O
by O
an O
identical O
escape O
sequence O
after O
procainamide B-DRUG

amphotericin B-DRUG
b I-DRUG
nephrotoxicity B-ADR
in O
humans O
decreased O
by O
salt O
repletion O

case O
summary O
: O
a O
46-year-old O
african-american O
man O
experienced O
recurrent O
grand B-ADR
mal I-ADR
seizures I-ADR
during O
intravenous O
infusion O
of O
amphotericin B-DRUG
b I-DRUG
, O
then O
petit O
mal O
seizures O
as O
the O
infusion O
was O
stopped O
and O
the O
drug O
concentrations O
decreased O
with O
time O

leishmania B-ADR
infantum I-ADR
leishmaniasis I-ADR
in O
corticosteroid B-DRUG
-- O
treated O
patients O

we O
describe O
a O
patient O
with O
m4 O
aml O
treated O
with O
standard O
chemotherapy O
followed O
by O
g-csf B-DRUG
who O
developed O
marked O
monocytosis B-ADR
on O
day O
8 O
of O
g-csf B-DRUG
therapy O

lithium-associated O
transient B-ADR
thyrotoxicosis I-ADR
in O
4 O
chinese O
women O
with O
autoimmune O
thyroiditis O

three O
diabetic O
cases O
of O
acute B-ADR
dizziness I-ADR
due O
to O
initial O
administration O
of O
voglibose B-DRUG

these O
two O
cases O
highlight O
the O
importance O
of O
considering O
lopinavir B-DRUG
/ O
ritonavir O
induced O
arrhythmias B-ADR
when O
dealing O
with O
hiv-positive O
individuals O

the O
possible O
development O
of O
a O
drug-induced O
vasculitis B-ADR
or O
lupus-like O
syndrome O
should O
be O
added O
to O
the O
list O
of O
rare O
toxic O
effects O
of O
vancomycin B-DRUG

nephropathy B-ADR
caused O
by O
methicillin B-DRUG
therapy O
for O
staphylococcal O
septicemia O

lower O
extremity O
arterial B-ADR
thrombosis I-ADR
following O
sonographically O
guided O
thrombin B-DRUG
injection O
of O
a O
femoral O
pseudoaneurysm O

cutaneous B-ADR
reactions I-ADR
to O
propylthiouracil B-DRUG
and O
methimazole O
occur O
in O
3 O
%- O
5 O
% O
of O
adults O

disopyramide-induced O
heart B-ADR
block I-ADR

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic B-ADR
jerks I-ADR
and O
unsteady O
gait O
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

a O
case O
is O
reported O
of O
theophylline B-ADR
intoxication I-ADR
due O
to O
a O
dramatic O
decrease O
in O
theophylline O
clearance O
following O
concomitant O
administration O
of O
viloxazine B-DRUG

clostridium B-ADR
difficile I-ADR
toxin-induced I-ADR
colitis I-ADR
after O
use O
of O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O

three O
of O
these O
patients O
had O
convulsions O
attributed O
to O
imipenem B-DRUG
/ O
cilastatin O
; O
3.6 O
% O
of O
the O
patients O
had O
seizure B-ADR
, O
or O
2 O
% O
of O
imipenem B-DRUG
/ O
cilastatin O
administrations O
was O
followed O
by O
a O
seizure B-ADR
attack O

retinopathy B-ADR
in O
hepatitis O
c O
patients O
due O
to O
combination O
therapy O
with O
pegylated B-DRUG
interferon I-DRUG
and O
ribavirin O

with O
the O
first O
cyclosporine B-DRUG
dose O
, O
the O
patient O
complained O
of O
leg B-ADR
pain I-ADR
that O
was O
most O
severe O
during O
the O
cyclosporine B-DRUG
infusion O

we O
report O
on O
a O
patient O
with O
acromegaly O
who O
developed O
severe O
drug-induced O
hepatitis B-ADR
during O
combined O
treatment O
with O
the O
long-acting O
somatostatin-analog O
octreotide B-DRUG
and O
the O
gh O
receptor O
antagonist O
pegvisomant O

myoglobinuria B-ADR
and O
acute O
renal O
failure O
were O
observed O
in O
two O
patients O
with O
vasopressin-treated O
gastrointestinal O
hemorrhage O

a O
patient O
developed O
optic B-ADR
neuropathy I-ADR
while O
being O
treated O
with O
isoniazid B-DRUG
and O
ethambutol O

to O
our O
knowledge O
, O
the O
syndrome O
of O
fever O
, O
pulmonary B-ADR
infiltrates I-ADR
, O
and O
pleural O
effusion O
following O
use O
of O
acyclovir B-DRUG
has O
not O
been O
previously O
reported O

metformin-associated O
lactic B-ADR
acidosis I-ADR
( O
mala O
) O
is O
a O
serious O
metabolic O
complication O
that O
occurs O
because O
of O
metformin O
accumulation O
in O
patients O
who O
become O
dehydrated O
or O
developed O
acute O
renal O
failure O

seizures O
and O
extrapyramidal B-ADR
symptoms I-ADR
in O
a O
patient O
with O
tourette O
's O
syndrome O
, O
asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
treated O
with O
interferon O
beta-1a O
and O
clomipramine B-DRUG

context O
: O
previous O
investigators O
have O
reported O
discrepancies B-ADR
between I-ADR
hematologic I-ADR
, I-ADR
marrow I-ADR
morphologic I-ADR
, I-ADR
and I-ADR
cytogenetic I-ADR
responses I-ADR
to O
imatinib B-DRUG
mesylate I-DRUG
among O
patients O
with O
chronic O
myeloid O
leukemia O
( O
cml O

objective O
: O
to O
describe O
a O
case O
of O
exacerbated O
mania B-ADR
potentially O
related O
to O
an O
interaction O
between O
lopinavir O
/ O
ritonavir O
and O
valproic B-DRUG
acid I-DRUG
( O
vpa O
) O
and O
propose O
a O
mechanism O
of O
action O
for O
this O
interaction O

we O
report O
on O
three O
observations O
of O
parkinsonian O
patients O
with O
levo-dopa-induced O
diphasic B-ADR
dyskinesias I-ADR
, O
who O
received O
subcutaneous O
apomorphine O
to O
reduce O
the O
duration O
of O
abnormal O
movements O

abnormalities B-ADR
of I-ADR
the I-ADR
pupil I-ADR
and O
visual-evoked O
potential O
in O
quinine B-DRUG
amblyopia O

we O
report O
on O
a O
patient O
with O
acromegaly O
who O
developed O
severe O
drug-induced O
hepatitis B-ADR
during O
combined O
treatment O
with O
the O
long-acting O
somatostatin-analog O
octreotide O
and O
the O
gh O
receptor O
antagonist O
pegvisomant B-DRUG

this O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate B-DRUG
( O
fosamax O
) O
and O
presented O
with O
postoperative O
hypophosphatemia B-ADR
and O
hypocalcemic O
tetany O
after O
bowel O
preparation O
with O
fleet O
phospho-soda O

ritonavir B-DRUG
should O
be O
added O
to O
the O
list O
of O
drugs O
that O
can O
induce O
adverse B-ADR
cutaneous I-ADR
reactions I-ADR
in O
hiv O
patients O

objective O
: O
to O
evaluate O
the O
efficacy O
of O
the O
administration O
of O
insulin O
by O
a O
jet-injector O
device O
in O
stopping O
and O
reversing O
severe O
human B-DRUG
insulin-induced O
lipoatrophy B-ADR

oxcarbazepine-induced O
drug O
reaction O
with O
eosinophilia O
and O
systemic O
symptoms O
( O
dress B-ADR

although O
various O
manifestations O
of O
pentamidine-induced O
cardiotoxicity O
have O
been O
reported O
, O
to O
our O
knowledge O
, O
second-degree B-ADR
heart I-ADR
block I-ADR
associated O
with O
this O
agent O
has O
not O
been O
described O

previous O
studies O
have O
demonstrated O
the O
interaction O
of O
mtx B-DRUG
and O
a O
variety O
of O
non-steroidal O
, O
anti-inflammatory O
drugs O
( O
nsaids O
) O
with O
various O
clinical O
manifestations O
including O
acute O
renal O
failure O
, O
pancytopenia O
, O
vomiting O
, O
diarrhea B-ADR
, O
elevated O
liver O
transaminases O
, O
jaundice O
, O
mucosal O
ulcerations O
, O
and O
pyrexia O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever O
, O
leukopenia O
and O
positive B-ADR
anti-nuclear I-ADR
antibody I-ADR
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine B-DRUG
( O
cbz O
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

adverse O
effects O
of O
amiodarone B-DRUG
including O
pulmonary O
toxicity O
, O
hepatotoxicity B-ADR
, O
aggravation O
of O
arrhythmia O
, O
and O
thyroid O
diseases O
are O
well O
understood O

a O
dapsone B-DRUG
hypersensitivity O
syndrome O
, O
consisting O
of O
fever O
, O
headache B-ADR
, O
nausea O
, O
vomiting O
, O
lymphadenopathy O
, O
hepatitis O
, O
hemolysis O
, O
leukopenia O
, O
and O
mononucleosis O
, O
has O
been O
described O
in O
patients O
treated O
with O
the O
drug O
for O
leprosy O

although O
transient O
increases O
in O
ectopy O
after O
bretylium B-DRUG
therapy O
have O
been O
described O
, O
presumably O
due O
to O
catecholamine O
release O
, O
the O
occurrence O
of O
life-threatening O
ventricular B-ADR
arrhythmia I-ADR
leading O
to O
cardiac O
arrest O
has O
not O
previously O
been O
emphasized O

objective O
: O
to O
describe O
a O
case O
of O
thrombocytopenia B-ADR
associated O
with O
the O
administration O
of O
lansoprazole B-DRUG

itch O
and O
skin B-ADR
rash I-ADR
from O
chocolate O
during O
fluoxetine B-DRUG
and O
sertraline O
treatment O
: O
case O
report O

six O
patients O
with O
no O
previous O
signs O
or O
symptoms O
suggestive O
of O
coronary O
artery O
disease O
developed O
acute B-ADR
coronary I-ADR
ischemia I-ADR
/ O
infarction O
shortly O
after O
cis-diamine-dichloroplatinum B-DRUG
ii I-DRUG
( O
cisplatin O
) O
- O
based O
chemotherapy O

sagittal O
sinus O
thrombosis O
associated O
with O
transient B-ADR
free I-ADR
protein I-ADR
s I-ADR
deficiency I-ADR
after O
l-asparaginase B-DRUG
treatment O
: O
case O
report O
and O
review O
of O
the O
literature O

scleritis B-ADR
complicating O
zoledronic B-DRUG
acid I-DRUG
infusion O

two O
cases O
of O
childhood-onset O
schizophrenia O
associated O
with O
clozapine-induced O
akathisia B-ADR
responsive O
to O
beta-blocker O
treatment O
are O
described O

however O
, O
other O
factors O
or O
drugs O
( O
e.g. O
cresol B-DRUG
) O
are O
thought O
to O
induce O
mh B-ADR

the O
patient O
was O
enrolled O
in O
a O
weight-loss O
clinic O
, O
and O
his O
diabetes O
medications O
were O
adjusted.subsequently O
, O
olanzapine B-DRUG
was O
discontinued O
because O
of O
weight O
gain O
and O
uncontrolled B-ADR
diabetes I-ADR

in O
the O
second O
case O
, O
five O
cardiac O
arrests O
due O
to O
ventricular O
tachycardia O
and O
fibrillation B-ADR
occurred O
during O
several O
hours O
after O
beginning O
a O
trial O
of O
bretylium B-DRUG
maintenance O
therapy O
for O
complex O
ventricular O
ectopy O

we O
have O
recently O
encountered O
a O
patient O
with O
acquired O
haemophilia O
who O
developed O
a O
thrombotic B-ADR
left I-ADR
middle I-ADR
cerebral I-ADR
artery I-ADR
distribution I-ADR
stroke I-ADR
while O
being O
treated O
with O
pfviii B-DRUG

the O
role O
of O
adriamycin B-DRUG
in O
the O
production O
of O
cardiotoxicity B-ADR
is O
reviewed O

tumor B-ADR
lysis I-ADR
syndrome I-ADR
after O
transcatheter O
arterial O
infusion O
of O
cisplatin B-DRUG
and O
embolization O
therapy O
for O
liver O
metastases O
of O
melanoma O

second O
, O
we O
report O
a O
case O
of O
neutropenia B-ADR
, O
which O
proved O
to O
be O
fatal O
in O
a O
schizophrenia O
patient O
receiving O
olanzapine O
and O
thiazide B-DRUG

we O
present O
a O
case O
of O
significant O
over-anticoagulation B-ADR
temporally O
associated O
with O
a O
bout O
of O
protracted O
diarrhea O
in O
a O
patient O
on O
warfarin B-DRUG
therapy O

acute O
vision O
loss O
after O
intravitreal O
injection O
of O
bevacizumab O
( O
avastin B-DRUG
) O
associated O
with O
ocular B-ADR
ischemic I-ADR
syndrome I-ADR

possible O
heart B-ADR
failure I-ADR
exacerbation I-ADR
associated O
with O
rosiglitazone B-DRUG
: O
case O
report O
and O
literature O
review O

the O
patient O
had O
recurrence O
of O
urticaria O
and O
angioedema B-ADR
a O
year O
and O
a O
half O
later O
, O
at O
which O
point O
the O
nph O
was O
stopped O
and O
she O
was O
desensitized O
to O
regular O
insulin B-DRUG

bilateral B-ADR
anterior I-ADR
uveitis I-ADR
associated O
with O
clomiphene B-DRUG
citrate I-DRUG

although O
his O
renal O
function O
recovered O
completely O
with O
high-dose O
leucovorin O
, O
hemodialysis O
, O
charcoal O
hemoperfusion O
, O
and O
carboxypeptidase O
g2 O
, O
we O
present O
this O
case O
to O
emphasize O
that O
signs O
of O
renal B-ADR
toxicity I-ADR
may O
be O
present O
as O
early O
as O
2 O
hours O
after O
the O
completion O
of O
a O
4-hour O
mtx B-DRUG
infusion O
, O
and O
to O
suggest O
that O
monitoring O
for O
mtx B-DRUG
toxicity O
should O
perhaps O
begin O
within O
a O
few O
hours O
after O
the O
completion O
of O
4-hour O
mtx B-DRUG
infusion O

conclusion O
: O
hypersensitivity O
reaction O
should O
be O
considered O
in O
patients O
who O
develop O
recurrent B-ADR
eosinophilia I-ADR
and O
deterioration O
of O
pulmonary O
function O
following O
the O
use O
of O
tobramycin B-DRUG
by O
inhalation O
or O
by O
intravenous O
administration O

we O
report O
4 O
patients O
, O
2 O
on O
methylphenidate B-DRUG
and O
2 O
on O
dextroamphetamine O
who O
presented O
with O
acral B-ADR
cyanosis I-ADR
, O
livedo O
reticularis O
, O
or O
raynaud O
phenomenon O

a O
47 O
year-old O
woman O
who O
had O
a O
4-year O
history O
of O
intramuscular O
pentazocine B-DRUG
injections O
in O
the O
lower O
extremities O
, O
developed O
gradual O
stiffness O
and O
weakness B-ADR
of I-ADR
the I-ADR
lower I-ADR
extremities I-ADR

an O
8-year-old O
child O
with O
familial O
mediterranean O
fever O
exhibited O
signs O
of O
colchicine B-ADR
intoxication I-ADR
while O
receiving O
prophylactic O
doses O
of O
the O
drug O

the O
frequency O
and O
relationship O
of O
granulocytopenia B-ADR
caused O
by O
sustained-release O
procainamide B-DRUG
in O
patients O
with O
tachyarrhythmias O
are O
briefly O
discussed O
, O
and O
prior O
reported O
cases O
are O
reviewed O

both O
had O
impaired O
lung O
function O
and O
abnormal B-ADR
computed I-ADR
tomographic I-ADR
scans I-ADR
, O
and O
their O
condition O
improved O
when O
nitrofurantoin B-DRUG
was O
withdrawn O
and O
corticosteroid O
treatment O
commenced O

hyperkalaemia B-ADR
with O
renal O
tubular O
dysfunction O
by O
sulfamethoxazole-trimethoprim B-DRUG
for O
pneumocystis O
carinii O
pneumonia O
in O
patients O
with O
lymphoid O
malignancy O

it O
is O
hoped O
that O
this O
case O
report O
creates O
awareness O
that O
ofloxacin-induced O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR
is O
possible O

anaphylaxis B-ADR
to O
calcitonin B-DRUG

a O
79-year-old O
man O
with O
ischemic O
heart O
disease O
, O
chronic O
atrial O
fibrillation O
, O
chronic O
renal O
failure O
, O
hypothyroidism O
, O
and O
gout O
arthritis O
was O
hospitalized O
because O
of O
fatigue B-ADR
, O
myalgia O
, O
and O
leg O
weakness O
, O
shortly O
after O
starting O
treatment O
with O
colchicine B-DRUG

intravenous O
verapamil B-DRUG
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden B-ADR
death I-ADR
; O
quinidine O
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

the O
development O
of O
an O
igg B-ADR
lambda-type I-ADR
monoclonal I-ADR
gammopathy I-ADR
and O
subsequent O
multiple O
myeloma O
in O
an O
epilepsy O
patient O
on O
diphenylhydantoin B-DRUG
( O
dilantin O
) O
therapy O
for O
20 O
years O
is O
reported O

we O
report O
a O
case O
of O
interstitial B-ADR
pulmonary I-ADR
disease I-ADR
that O
occurred O
together O
with O
lymphocytic O
colitis O
during O
treatment O
with O
ticlopidine B-DRUG

we O
describe O
two O
cases O
that O
illustrate O
the O
use O
of O
lithium B-DRUG
in O
the O
treatment O
of O
veterans O
with O
ptsd O
who O
complained O
of O
serious O
problems O
with O
irritability O
or O
angry B-ADR
outbursts I-ADR

methimazole-induced O
aplastic B-ADR
anemia I-ADR
in O
third O
exposure O
: O
successful O
treatment O
with O
recombinant O
human O
granulocyte O
colony-stimulating O
factor O

we O
describe O
the O
exceptional O
development O
of O
aml O
and O
lung B-ADR
cancer I-ADR
in O
a O
patient O
with O
previously O
diagnosed O
cll O
in O
minimal O
residual O
disease O
status O
after O
fludarabine B-DRUG
treatment O
followed O
by O
autologous O
peripheral O
blood O
stem-cell O
transplantation O

a O
second O
episode O
of O
jaundice B-ADR
followed O
the O
intravaginal O
administration O
of O
a O
mixture O
of O
furazolidone O
and O
nifuroxime B-DRUG

case O
report O
of O
withdrawal O
dyskinesia B-ADR
associated O
with O
amoxapine B-DRUG

albuterol-induced O
hypokalemia B-ADR
and O
its O
potential O
cardiac O
toxicity O
are O
discussed O
briefly O

we O
describe O
the O
development O
of O
ischemic B-ADR
colitis I-ADR
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic B-ADR
colitis I-ADR
, O
tegaserod B-DRUG
use O
, O
and O
irritable O
bowel O
syndrome O

we O
report O
a O
case O
of O
graves' B-ADR
hyperthyroidism I-ADR
induced O
by O
long-term O
interferon B-DRUG
( O
ifn O
) O
therapy O

central O
nervous O
system O
effects O
secondary O
to O
ciprofloxacin B-DRUG
treatment O
are O
uncommon O
and O
usually O
consist O
only O
of O
minor O
dizziness O
or O
mild B-ADR
headache I-ADR
, O
although O
rare O
occurrences O
of O
seizures O
and O
hallucinations O
have O
been O
reported O

results O
: O
a O
clinical O
diagnosis O
of O
fixed B-ADR
drug I-ADR
eruption I-ADR
owing O
to O
use O
of O
the O
pde5 O
inhibitor O
tadalafil O
( O
cialis B-DRUG
) O
was O
made O

olanzapine-induced O
hyperglycaemic O
coma O
and O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
: O
case O
report O
and O
review O
of O
literature O

our O
series O
of O
3 O
patients O
supports O
a O
causal O
connection O
between O
bleomycin B-DRUG
and O
scleroderma B-ADR

persistent B-ADR
light I-ADR
reactivity I-ADR
from O
systemic O
quinine B-DRUG

sotalol-induced O
bradycardia B-ADR
reversed O
by O
glucagon O

this O
is O
the O
first O
description O
, O
to O
our O
knowledge O
, O
of O
ductopenia B-ADR
apparently O
caused O
by O
clindamycin B-DRUG

though O
hypotension B-ADR
, O
dry O
mouth O
, O
and O
constipation O
are O
well-documented O
possible O
adverse O
effects O
, O
the O
possibility O
of O
clonidine-induced O
bradycardia O
is O
less O
well O
recognized O
and O
is O
rare O

a O
patient O
with O
ulcerative O
colitis O
developed O
skin B-ADR
pigmentation I-ADR
and O
diffuse O
pulmonary O
shadowing O
without O
respiratory O
symptomatology O
, O
while O
taking O
sulfasalazine B-DRUG

conclusions O
: O
this O
report O
indicates O
clindamycin B-DRUG
phosphate I-DRUG
vaginal O
cream O
as O
the O
most O
probable O
cause O
of O
cdic B-ADR
due O
to O
the O
temporal O
relationship O
between O
the O
occurrence O
of O
diarrhea O
and O
clindamycin O
administration O
, O
lack O
of O
concomitant O
medications O
, O
and O
documentation O
of O
c. O
difficile O
toxin O

agranulocytosis B-ADR
induced O
by O
vancomycin B-DRUG
in O
an O
esrd O
patient O
on O
capd O

background O
: O
methotrexate B-DRUG
( O
mtx O
) O
may O
induce O
liver O
damage O
, O
which O
in O
some O
psoriatics O
will O
lead O
to O
fibrosis B-ADR
or O
cirrhosis O

we O
report O
a O
case O
of O
reversible O
dka B-ADR
and O
new-onset O
dm O
that O
developed O
in O
a O
demented O
patient O
who O
was O
treated O
with O
quetiapine B-DRUG
for O
14 O
days O

approximately O
15 O
min O
after O
the O
first O
administration O
of O
nebulised O
morphine B-DRUG
the O
patient O
became O
markedly O
bradypneic B-ADR
( O
respiratory O
rate O
: O
4-5 O
bpm O
) O
, O
hypotensive O
( O
bp O
70 O
/ O
40 O
mmhg O
) O
, O
and O
responded O
only O
partially O
to O
command O

acute B-ADR
non-lymphocytic I-ADR
leukemia I-ADR
in O
patients O
with O
ovarian O
carcinoma O
following O
long-term O
treatment O
with O
treosulfan O
(= O
dihydroxybusulfan B-DRUG

we O
report O
five O
cases O
of O
restless O
legs O
syndrome O
( O
rls O
) O
and O
periodic B-ADR
limb I-ADR
movements I-ADR
during I-ADR
sleep I-ADR
( O
plms O
) O
that O
were O
probably O
associated O
with O
olanzapine B-DRUG

the O
potential O
development O
of O
sjs O
/ O
ten B-ADR
, O
a O
severe O
life-threatening O
illness O
, O
emphasizes O
the O
need O
for O
judicious O
use O
of O
tmp-sx B-DRUG
and O
close O
monitoring O
and O
follow-up O
for O
patients O
who O
were O
given O
tmp-sx B-DRUG
for O
sstis O

most O
cases O
of O
pancreatitis B-ADR
associated O
with O
l-asparaginase B-DRUG
toxicity O
are O
self-limiting O
and O
respond O
favorably O
to O
nasogastric O
decompression O
and O
intravenous O
hyperalimentation O

their O
parkinsonism B-ADR
improved O
on O
discontinuation O
of O
metoclopramide B-DRUG
therapy O

physicians O
should O
be O
aware O
of O
the O
potentially O
lethal B-ADR
side O
effects O
of O
dapsone B-DRUG

we O
report O
the O
case O
histories O
of O
identical O
twin O
brothers O
who O
developed O
concordant O
acute O
lymphoblastic O
leukemia O
at O
the O
age O
of O
4 O
years O
and O
who O
later O
developed O
leukoencephalopathy O
and O
hydrocephalus B-ADR
related O
to O
central O
nervous O
system O
prophylaxis O
by O
, O
in O
the O
first O
case O
intrathecally O
administered O
methotrexate B-DRUG
and O
, O
in O
the O
second O
by O
intrathecally O
administered O
methotrexate B-DRUG
and O
cranial O
irradiation O

rapamycin B-DRUG
/ O
sirolimus O
( O
sr O
) O
, O
trade O
named O
rapammune O
( O
wyeth-ayerst O
, O
sydney O
, O
australia O
) O
, O
is O
a O
potent O
immunosuppressive O
drug O
associated O
with O
myelosuppression B-ADR
, O
hypertension O
, O
hyperlipidemia O
, O
and O
infection O

however O
, O
dermatologists O
should O
be O
cautious O
about O
a O
photosensitivity B-ADR
reaction O
induced O
by O
mequitazine B-DRUG
or O
other O
phenothiazine-derivative O
drugs O

we O
experienced O
a O
case O
of O
chronic O
renal O
failure O
in O
a O
patient O
suffering O
from O
acute O
hemorrhagic O
gastritis O
associated O
with O
az B-ADR
intoxication I-ADR

the O
day O
after O
clozapine B-DRUG
was O
stopped O
, O
while O
he O
was O
still O
receiving O
clomipramine O
150 O
mg O
/ O
d O
, O
he O
began O
behaving O
oddly O
, O
started O
sweating O
profusely O
, O
shivering O
, O
and O
became O
tremulous O
, O
agitated B-ADR
, O
and O
confused O

in O
summary O
, O
we O
report O
herein O
the O
first O
case O
of O
siadh B-ADR
believed O
to O
be O
an O
adverse O
effect O
of O
mizoribin B-DRUG
, O
which O
may O
therefore O
needed O
to O
be O
added O
to O
the O
list O
of O
drugs O
which O
can O
induce O
siadh B-ADR

cyclophosphamide B-DRUG
can O
rarely O
cause O
interstitial B-ADR
pneumonitis I-ADR
and O
fibrosis O

this O
case O
report O
describes O
a O
patient O
who O
was O
previously O
prescribed O
alendronate O
( O
fosamax O
) O
and O
presented O
with O
postoperative O
hypophosphatemia O
and O
hypocalcemic B-ADR
tetany I-ADR
after O
bowel O
preparation O
with O
fleet B-DRUG
phospho-soda I-DRUG

ceftriaxone O
was O
approved O
in O
1997 O
for O
the O
treatment O
of O
otitis O
media O
despite O
previous O
studies O
that O
documented O
an O
association O
of O
ceftriaxone B-DRUG
with O
elevated O
hepato-biliary O
enzymes O
and O
transient B-ADR
biliary I-ADR
stasis I-ADR

six O
patients O
with O
no O
previous O
signs O
or O
symptoms O
suggestive O
of O
coronary O
artery O
disease O
developed O
acute O
coronary O
ischemia O
/ O
infarction B-ADR
shortly O
after O
cis-diamine-dichloroplatinum O
ii O
( O
cisplatin B-DRUG
) O
- O
based O
chemotherapy O

we O
report O
a O
patient O
with O
pulmonary O
adenocarcinoma O
complicated O
by O
the O
syndrome B-ADR
of I-ADR
inappropriate I-ADR
secretion I-ADR
of I-ADR
antidiuretic I-ADR
hormone I-ADR
( O
siadh O
) O
following O
systemic O
chemotherapy O
with O
cisplatin O
( O
cddp B-DRUG
) O
and O
vindesine O
( O
vds O

a O
40-year-old O
man O
with O
relapsing-remitting O
multiple O
sclerosis O
( O
ms O
) O
developed O
primary O
central O
nervous O
system O
lymphoma O
( O
pcnsl B-ADR
) O
after O
having O
received O
21 O
doses O
of O
natalizumab B-DRUG
monotherapy O

a O
31-year-old O
female O
developed O
multiple O
episodes O
of O
grand B-ADR
mal I-ADR
seizures I-ADR
after O
combination O
chemotherapy O
with O
cisplatin O
, O
vinblastine B-DRUG
and O
bleomycin O
for O
germ O
cell O
ovarian O
cancer O
stage O
ic O

carbamazepine-related O
hyponatremia B-ADR
following O
cardiopulmonary O
bypass O

a O
36-year-old O
man O
being O
treated O
with O
cisplatinum B-DRUG
, O
vinblastine O
, O
and O
bleomycin O
for O
testicular O
carcinoma O
developed O
a O
dense O
left O
homonymous O
hemianopsia O
, O
encephalopathy O
, O
and O
a O
partial B-ADR
nondominant I-ADR
parietal I-ADR
lobe I-ADR
syndrome I-ADR

sensorimotor B-ADR
polyneuropathy I-ADR
with O
5-aminosalicylic B-DRUG
acid I-DRUG
: O
a O
case O
report O

alopecia O
, O
nausea O
, O
and O
vomiting B-ADR
were O
attributed O
to O
the O
cyclophosphamide B-DRUG
component O
of O
the O
therapy O

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin O
rash O
, O
acute B-ADR
kidney I-ADR
injury I-ADR
, O
high-grade O
fever O
, O
eosinophilia O
, O
liver O
dysfunction O
, O
lymphadenopathy O
and O
an O
increase O
in O
antihuman O
herpesvirus-6 O
immunoglobulin O
g O
titer O

we O
describe O
2 O
patients O
with O
severe O
erosive O
rheumatoid O
arthritis O
and O
rheumatoid O
vasculitis O
, O
respectively O
, O
in O
whom O
infliximab B-DRUG
therapy O
was O
associated O
with O
peripheral O
neuropathy O
due O
to O
necrotizing B-ADR
vasculitis I-ADR
in O
one O
patient O
and O
to O
progression O
of O
preexisting O
mononeuritis O
multiplex O
in O
the O
other O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia B-ADR
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

we O
report O
the O
case O
of O
a O
patient O
with O
multiple O
myeloma O
who O
developed O
acute O
life-threatening B-ADR
water I-ADR
intoxication I-ADR
following O
treatment O
with O
oral O
indomethacin B-DRUG
and O
low O
dose O
intravenous O
cyclophosphamide O

warfarin-induced O
skin O
necrosis O
and O
heparin-induced O
thrombocytopenia B-ADR
following O
mitral O
valve O
replacement O
for O
marantic O
endocarditis O

administration O
of O
amantadine B-DRUG
was O
associated O
with O
psychotic B-ADR
decompensations I-ADR
in O
two O
schizophrenic O
patients O
being O
maintained O
on O
concomitant O
neuroleptic O
medication O

results O
: O
after O
4 O
- O
to O
14-month O
period O
of O
therapy O
with O
the O
combination O
of O
indapamide O
( O
2.5 O
mg O
/ O
day O
) O
and O
fosinopril B-DRUG
( O
10 O
mg O
/ O
day O
) O
in O
three O
patients O
and O
6-month O
period O
of O
monotherapy O
with O
indapamide O
( O
2.5 O
mg O
/ O
day O
) O
in O
one O
patient O
, O
glucose O
levels O
of O
all O
patients O
increased O
and O
achieve O
criteria O
of O
diabetes B-ADR
diagnoses O

we O
experienced O
a O
male O
patient O
with O
psoriasis O
and O
hypertension O
whose O
conditions O
were O
treated O
with O
tacalcitol O
ointment O
and O
thiazide B-DRUG
, O
respectively O
, O
resulting O
in O
hypercalciuria O
and O
hypercalcemia B-ADR

the O
current O
report O
describes O
a O
man O
who O
was O
prescribed O
zonisamide B-DRUG
for O
epilepsy O
and O
subsequently O
developed O
widespread O
skin O
rash O
, O
acute O
kidney O
injury O
, O
high-grade O
fever O
, O
eosinophilia O
, O
liver O
dysfunction O
, O
lymphadenopathy O
and O
an B-ADR
increase I-ADR
in I-ADR
antihuman I-ADR
herpesvirus-6 I-ADR
immunoglobulin I-ADR
g I-ADR
titer I-ADR

potential O
causes O
of O
methamphetamine-related O
keratitis B-ADR
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine O
; O
( O
b O
) O
the O
toxic O
effects O
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine B-DRUG
and O
quinine O
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture-related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O

we O
report O
on O
a O
56-year-old O
female O
who O
exhibited O
drug O
refractory O
paroxysmal O
atrial O
fibrillation O
, O
in O
which O
marked O
prolongation B-ADR
of I-ADR
the I-ADR
qt I-ADR
interval I-ADR
and O
t O
wave O
inversion O
on O
electrocardiogram O
was O
demonstrated O
reproducibly O
shortly O
after O
the O
administration O
of O
oral O
pirmenol B-DRUG
therapy O

pulmonary B-ADR
fibrosis I-ADR
subsequent O
to O
high O
doses O
of O
ccnu B-DRUG
for O
chronic O
myeloid O
leukemia O

amiodarone B-DRUG
hydrochloride I-DRUG
, O
a O
new O
antiarrhythmic O
agent O
, O
has O
been O
associated O
with O
pulmonary B-ADR
toxicity I-ADR
characterized O
by O
cough O
, O
dyspnea O
and O
diffuse O
pulmonary O
infiltrates O

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate O
with O
folinic B-DRUG
acid I-DRUG
rescue O
, O
resulted O
in O
the O
' O
phosphate O
shower O
syndrome O
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic B-ADR
acidosis I-ADR
and O
acute O
renal O
impairment O
) O
are O
described O

the O
patient O
continued O
to O
have O
fever O
and O
autonomic B-ADR
instability I-ADR
without O
evidence O
of O
infection O
which O
entirely O
resolved O
within O
24 O
hours O
of O
reinstitution O
of O
full O
preadmission O
dosing O
of O
oral O
baclofen B-DRUG

theoretical O
basal O
ganglia O
toxicologic O
mechanisms O
of O
methanol B-ADR
poisoning I-ADR
are O
reviewed O
, O
and O
the O
role O
of O
brain O
imaging O
studies O
will O
regard O
to O
diagnosis O
, O
prognosis O
and O
impact O
on O
management O
is O
discussed O

the O
development O
of O
cutaneous B-ADR
ecchymosis I-ADR
associated O
with O
a O
sudden O
fall O
in O
hemoglobin O
after O
the O
administration O
of O
alteplase B-DRUG
should O
strongly O
suggest O
the O
possibility O
of O
diffuse O
subfascial O
hematoma O

the O
patient O
's O
other O
comorbidities O
and O
medications O
have O
not O
been O
suggested O
as O
possible O
interactions O
with O
sertraline B-DRUG
that O
can O
cause O
rhabdomyolysis B-ADR

posterior B-ADR
leukoencephalopathy I-ADR
following O
cisplatin O
, O
bleomycin O
and O
vinblastine B-DRUG
therapy O
for O
germ O
cell O
tumor O
of O
the O
ovary O

vitiligo B-ADR
associated O
with O
alpha-interferon B-DRUG
in O
a O
patient O
with O
chronic O
active O
hepatitis O
c O

the O
purpose O
of O
this O
article O
is O
to O
present O
the O
first O
case-series O
of O
posterior O
reversible O
encephalopathy O
syndrome O
( O
pres B-ADR
) O
associated O
with O
l-asparaginase B-DRUG
treatment O

although O
vasculitis B-ADR
has O
been O
reported O
in O
the O
course O
of O
hairy O
cell O
leukaemia O
, O
it O
has O
only O
rarely O
been O
reported O
as O
the O
consequence O
of O
cladribine B-DRUG
treatment O

type O
i O
second-degree O
av O
block O
( O
mobitz B-ADR
type I-ADR
i I-ADR
, O
wenckebach O
av O
block O
) O
during O
ritodrine B-DRUG
therapy O
for O
preterm O
labor O

we O
report O
4 O
patients O
, O
2 O
on O
methylphenidate B-DRUG
and O
2 O
on O
dextroamphetamine O
who O
presented O
with O
acral O
cyanosis O
, O
livedo B-ADR
reticularis I-ADR
, O
or O
raynaud O
phenomenon O

we O
report O
a O
case O
of O
unintentional O
overdose O
of O
oral O
pilocarpine B-DRUG
tablets O
that O
resulted O
in O
bradycardia O
, O
mild B-ADR
hypotension I-ADR
, O
and O
muscarinic O
symptoms O
in O
a O
patient O
with O
sjogren O
's O
syndrome O

we O
report O
the O
case O
of O
a O
female O
acromegalic O
patient O
in O
whom O
multiple O
hepatic B-ADR
adenomas I-ADR
appeared O
soon O
after O
danazol B-DRUG
treatment O
for O
uterine O
fibromatosis O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness O
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular B-ADR
rash I-ADR
was O
noted O

gemcitabine B-DRUG
should O
be O
added O
to O
the O
list O
of O
drugs O
known O
to O
cause O
radiation B-ADR
recall I-ADR

this O
report O
suggests O
that O
anemia B-ADR
can O
occur O
due O
to O
mmf O
, O
in O
particular O
when O
it O
is O
given O
with O
prednisone O
, O
a O
side O
effect O
well O
documented O
in O
the O
transplantation O
literature O
when O
the O
triple O
combination O
of O
mmf O
, O
cyclosporine B-DRUG
and O
prednisone O
is O
used O

pancytopenia B-ADR
associated O
with O
5-aminosalicylic B-DRUG
acid I-DRUG
use O
in O
a O
patient O
with O
crohn O
's O
disease O

a O
patient O
with O
chronic O
myelomonocytic O
leukemia O
developed O
drug-induced O
pulmonary B-ADR
toxicity I-ADR
after O
using O
low O
dose O
oral O
etoposide B-DRUG

due O
to O
the O
severity O
of O
the O
rash B-ADR
, O
temozolomide B-DRUG
was O
permanently O
discontinued O

from O
1996 O
to O
2002 O
several O
medications O
were O
changed O
due O
to O
their O
adverse O
effects O
: O
indinavir O
( O
renal O
colic O
and O
fever O
) O
, O
nelfinavir O
( O
cutaneous O
rash O
) O
, O
and O
efavirenz B-DRUG
( O
nausea B-ADR
and O
temporary O
memory O
loss O

brugada B-ADR
type I-ADR
electrocardiographic I-ADR
changes I-ADR
induced O
by O
concomitant O
use O
of O
lithium B-DRUG
and O
propafenone O
in O
patient O
with O
wolff-parkinson-white O
syndrome O

we O
report O
a O
case O
in O
which O
hemorrhage B-ADR
occurred O
in O
an O
asymptomatic O
falx O
meningioma O
known O
beforehand O
, O
after O
the O
internal O
use O
of O
low-dose O
aspirin B-DRUG
for O
16 O
months O

we O
describe O
the O
development O
of O
ischemic O
colitis O
in O
a O
woman O
who O
was O
treated O
with O
tegaserod B-DRUG
and O
review O
the O
relationship O
among O
ischemic O
colitis O
, O
tegaserod B-DRUG
use O
, O
and O
irritable B-ADR
bowel I-ADR
syndrome I-ADR

conclusion O
: O
to O
the O
best O
of O
our O
knowledge O
, O
this O
is O
the O
first O
time O
colchicine B-ADR
intoxication I-ADR
in O
this O
age O
group O
has O
been O
described O
in O
the O
english O
literature O

ulcerating B-ADR
enteritis I-ADR
associated O
with O
flucytosine B-DRUG
therapy O

it O
was O
concluded O
that O
potassium B-ADR
loss I-ADR
occurred O
by O
a O
non-renal O
( O
intestinal O
) O
route O
in O
phosphate-induced O
hypokalemia O

we O
report O
a O
case O
of O
a O
23-year-old O
man O
who O
developed O
a O
vancomycin-induced O
anaphylactic B-ADR
reaction I-ADR
in O
the O
treatment O
of O
methicillin-resistant O
staphylococcus O
aureus O
infection O

vasomotor B-ADR
reactions I-ADR
after O
gold B-DRUG
sodium I-DRUG
thiomalate I-DRUG
are O
well O
recognized O

we O
present O
the O
first O
case O
of O
ovarian O
endometrioid O
carcinoma O
and O
endometriosis B-ADR
in O
a O
postmenopausal O
patient O
who O
was O
treated O
with O
tamoxifen B-DRUG
for O
breast O
cancer O

masculinization O
of O
a O
female O
fetus O
occurred O
in O
5 O
of O
39 O
( O
12.8 O
%) O
exposed O
to O
norethisterone B-DRUG
; O
all O
were O
cases O
of O
clitoral B-ADR
hypertrophy I-ADR
not O
requiring O
surgical O
treatment O

we O
describe O
a O
patient O
who O
experienced O
chronic O
nausea O
and O
an O
episode O
of O
confusion B-ADR
while O
treated O
with O
a O
small O
, O
stable O
dose O
of O
oral O
morphine B-DRUG
in O
the O
setting O
of O
mild O
renal O
insufficiency O

fever B-ADR
, O
lymphadenopathy O
, O
eosinophilia O
, O
lymphocytosis O
, O
hepatitis O
, O
and O
dermatitis O
: O
a O
severe O
adverse O
reaction O
to O
minocycline B-DRUG

in O
deciding O
if O
tamoxifen B-DRUG
therapy O
is O
warranted O
, O
all O
potentially O
life-threatening O
adverse O
events O
associated O
with O
tamoxifen B-DRUG
should O
be O
considered O
, O
including O
endometrial B-ADR
adenocarcinoma I-ADR
or O
uterine O
sarcoma O

we O
describe O
a O
case O
of O
advanced O
ovarian O
carcinoma O
who O
developed O
difficulty O
walking O
because O
of O
marked O
pain O
in O
the O
lower O
extremities O
and O
loss B-ADR
of I-ADR
proprioception I-ADR
25 O
days O
after O
treatment O
with O
weekly O
taxol B-DRUG
( O
80 O
mg O
/ O
m O
( O
2 O
) O
x3 O

reversal O
of O
gold-induced O
neutropenia B-ADR
with O
granulocyte O
colony-stimulating O
factor O
( O
g-csf O

despite O
the O
underlying O
hepatitis O
c O
, O
this O
case O
represents O
renal B-ADR
abnormalities I-ADR
consistent O
with O
ifnalpha B-DRUG
therapy O
for O
cml O

however O
, O
a O
recent O
post-marketing O
survey O
in O
japan O
revealed O
that O
interstitial B-ADR
pneumonia I-ADR
occurred O
in O
4 O
among O
approximately O
2 O
000 O
japanese O
patients O
treated O
with O
sorafenib B-DRUG

although O
gabapentin B-DRUG
withdrawal O
has O
been O
previously O
reported O
and O
usually O
consists O
of O
anxiety O
, O
diaphoresis O
, O
and O
palpitations B-ADR
, O
this O
is O
the O
first O
reported O
patient O
with O
generalized O
seizures O
and O
status O
epilepticus O
secondary O
to O
gabapentin B-DRUG
withdrawal O

none O
of O
them O
had O
a O
history O
of O
cardiac O
disease O
, O
and O
with O
the O
possible O
exception O
of O
one O
case O
of O
cardiac B-ADR
arrest I-ADR
, O
where O
the O
patient O
received O
doxorubicin B-DRUG
, O
no O
predisposing O
factors O
could O
be O
found O

the O
use O
of O
beclomethasone B-DRUG
diproprionate I-DRUG
inhaler O
complicated O
by O
the O
development O
of O
an O
eosinophilic B-ADR
pneumonia I-ADR
reaction I-ADR

we O
report O
here O
two O
cases O
of O
dyserythropoietic O
anaemia O
associated O
with O
long-term O
linezolid O
use O
that O
share O
striking O
similarities O
to O
chloramphenicol-associated O
myelotoxicity B-ADR

the O
authors O
report O
two O
cases O
of O
delayed B-ADR
elimination I-ADR
of O
methotrexate B-DRUG
in O
patients O
receiving O
ciprofloxacin O
, O
with O
severe O
toxicity O

toxic B-ADR
optic I-ADR
neuropathy I-ADR
associated O
with O
ethambutol B-DRUG
: O
implications O
for O
current O
therapy O

case O
summary O
: O
we O
report O
the O
case O
of O
a O
31-year-old O
patient O
hospitalized O
due O
to O
behavioral O
alterations O
and O
treated O
with O
oral O
zuclopenthixol B-DRUG
, O
an O
antipsychotic O
from O
the O
thioxanthene O
family O
, O
who O
developed O
an O
acute O
, O
painful B-ADR
erection I-ADR

concomitant O
administration O
of O
lithium B-DRUG
with O
olanzapine O
may O
place O
patients O
at O
risk O
for O
nms B-ADR

we O
report O
a O
fatal O
case O
of O
toxic O
epidermal O
necrolysis O
( O
ten B-ADR
) O
resulting O
from O
a O
high O
dose O
of O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O

these O
skin B-ADR
lesions I-ADR
may O
be O
induced O
or O
worsened O
during O
antiviral O
therapy O
with O
interferon-alpha B-DRUG
( O
ifn O

second B-ADR
cancers I-ADR
including O
various O
types O
of O
hematological O
malignancy O
have O
been O
reported O
in O
patients O
with O
hairy O
cell O
leukemia O
treated O
with O
chemotherapy O
or O
interferon B-DRUG
alfa I-DRUG

pericardial B-ADR
hemorrhage I-ADR
due O
to O
acetylsalicylic B-DRUG
acid I-DRUG
in O
a O
patient O
with O
essential O
thrombocythemia O

we O
describe O
children O
and O
adolescents O
with O
chronic O
hematologic O
and O
oncologic O
diseases O
who O
exhibited O
drug-seeking B-ADR
behavior I-ADR
or O
anticholinergic O
symptoms O
with O
the O
use O
of O
diphenhydramine B-DRUG

the O
patient O
's O
defects O
may O
be O
due O
to O
methimazole B-DRUG
teratogenicity B-ADR
or O
could O
represent O
a O
previously O
undescribed O
syndrome O
affecting O
ectodermal O
structures O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical B-ADR
lymphocytosis I-ADR
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole O
( O
smx B-DRUG
) O
treatment O

two O
patients O
with O
hlh O
developed O
etoposide-related O
secondary B-ADR
acute I-ADR
myeloid I-ADR
leukemia I-ADR
( O
saml O
) O
following O
therapy O
for O
hlh O

a O
51-year-old O
man O
developed O
type B-ADR
1 I-ADR
diabetes I-ADR
mellitus I-ADR
following O
24 O
weeks O
of O
treatment O
with O
recombinant O
alpha-2b B-DRUG
peginterferon I-DRUG
plus O
ribavirin O
for O
chronic O
hepatitis O
c O

interventions O
and O
results O
: O
cardiac B-ADR
complications I-ADR
were O
observed O
in O
five O
pediatric O
patients O
who O
received O
between O
4.6 O
and O
40.8 O
mg O
/ O
kg O
/ O
d O
of O
amphotericin B-DRUG
b I-DRUG

while O
the O
introduction O
of O
carmustine O
wafers O
( O
gliadel B-DRUG
wafers O
) O
into O
the O
tumor O
resection O
cavity O
has O
been O
shown O
to O
be O
a O
beneficial O
therapy O
for O
malignant O
glioma O
, O
it O
is O
recognized O
that O
clinically O
significant O
cerebral B-ADR
edema I-ADR
is O
a O
potential O
adverse O
effect O

we O
describe O
a O
73-year-old O
woman O
who O
developed O
serious O
systemic O
vasculitis O
with O
associated O
thrombocytopenia B-ADR
in O
the O
course O
of O
treatment O
with O
cladribine B-DRUG

the O
ulcer B-ADR
did O
not O
respond O
to O
antibiotic O
treatment O
and O
healed O
shortly O
after O
withholding O
atra B-DRUG

severe O
rhabdomyolysis O
following O
massive O
ingestion O
of O
oolong B-DRUG
tea I-DRUG
: O
caffeine B-ADR
intoxication I-ADR
with O
coexisting O
hyponatremia O

pigmentary B-ADR
disorders I-ADR
are O
recognized O
adverse O
effects O
of O
the O
semi-synthetic O
tetracycline O
derivative O
antibiotic O
, O
minocycline B-DRUG

l-asparaginase-induced O
posterior B-ADR
reversible I-ADR
encephalopathy I-ADR
syndrome O
during O
acute O
lymphoblastic O
leukemia O
treatment O
in O
children O

the O
second O
patient O
experienced O
mild B-ADR
nitritoid I-ADR
symptoms I-ADR
following O
several O
gstm B-DRUG
injections O
prior O
experiencing O
a O
cerebrovascular O
accident O
within O
several O
hours O
of O
her O
next O
injection O

we O
hypothesize O
that O
decreased O
renal O
elimination O
of O
mtx B-DRUG
induced O
by O
the O
cox-2 O
inhibitor O
resulted O
in O
enhanced O
hematopoietic O
toxicity O
and O
immunosuppression B-ADR
causing O
the O
ebv-associated O
lymphoproliferative O
disease O

an O
11-year-old O
boy O
who O
was O
treated O
with O
a O
relatively O
high O
dose O
of O
methotrimeprazine B-DRUG
meleate I-DRUG
( O
levemepromazine O
) O
a O
phenothiazine O
antipsychotic O
drug O
, O
was O
admitted O
to O
the O
pediatric O
intensive O
care O
unit O
suffering O
from O
respiratory B-ADR
distress I-ADR
syndrome I-ADR

case O
summary O
: O
a O
68-year-old O
woman O
developed O
a O
dry O
, O
irritating B-ADR
cough I-ADR
within O
one O
month O
of O
starting O
quinapril B-DRUG
therapy O
for O
the O
treatment O
of O
essential O
hypertension O

the O
toxic O
effects O
of O
methotrexate B-DRUG
included O
elevated O
liver O
transaminases O
( O
3 O
/ O
4 O
) O
, O
nausea O
( O
2 O
/ O
4 O
) O
, O
abdominal O
pain O
( O
2 O
/ O
4 O
) O
, O
bone O
pain O
( O
2 O
/ O
4 O
) O
, O
mild B-ADR
neutropenia I-ADR
( O
1 O
/ O
4 O
) O
, O
and O
mild O
pruritus O
( O
1 O
/ O
4 O

discussion O
: O
to O
our O
knowledge O
, O
this O
is O
the O
first O
case O
report O
illustrating O
neuralgic B-ADR
amyotrophy I-ADR
triggered O
by O
exposure O
to O
the O
antibiotics O
vancomycin O
, O
tobramycin O
, O
and O
piperacillin B-DRUG
/ O
tazobactam O

we O
believe O
the O
temporal O
association O
of O
the O
abnormal O
liver O
enzymes O
in O
this O
patient O
, O
in O
the O
absence O
of O
other O
offending O
agents O
, O
argues O
strongly O
in O
favor O
of O
6-tg B-DRUG
as O
a O
cause O
of O
liver B-ADR
enzyme I-ADR
abnormalities I-ADR

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity O
, O
gastrointestinal O
disturbances O
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid B-ADR
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis O

ards B-ADR
is O
rarely O
associated O
with O
rituximab B-DRUG
infusion O
for O
lympho-proliferative O
disorders O
, O
but O
it O
should O
be O
considered O
by O
those O
administering O
rituximab B-DRUG
, O
especially O
when O
a O
patient O
develops O
severe O
pulmonary O
symptoms O
soon O
after O
infusion O

conclusion O
: O
atovaquone B-DRUG
should O
be O
added O
to O
the O
list O
of O
agents O
causing O
vortex B-ADR
keratopathy I-ADR
involving O
the O
corneal O
epithelium O

in O
this O
report O
we O
described O
a O
case O
of O
juvenile O
idiopathic O
arthritis O
patient O
who O
developed O
thymic O
enlargement O
( O
true O
thymic O
hyperplasia O
) O
, O
mediastinal O
lymphadenopathy O
and O
pleurisy B-ADR
associated O
with O
systemic O
symptoms O
under O
etanercept B-DRUG
treatment O

sensorineural B-ADR
hearing I-ADR
loss I-ADR
due O
to O
quinine B-DRUG
therapy O
for O
malaria O
has O
frequently O
been O
mentioned O
in O
the O
literature O
but O
has O
not O
been O
a O
subject O
of O
research O
during O
the O
last O
decades O

a O
variety O
of O
movement O
disorders O
are O
known O
to O
occur O
in O
association O
with O
carbamazepine B-DRUG
( O
cbz O
) O
therapy O
in O
adults O
and O
children O
, O
but O
development O
of O
tics B-ADR
has O
been O
described O
infrequently O
and O
only O
in O
patients O
with O
underlying O
tourette O
's O
syndrome O
or O
other O
movement O
disorders O

ofloxacin B-DRUG
: O
a O
probable O
cause O
of O
toxic B-ADR
epidermal I-ADR
necrolysis I-ADR

the O
patient O
developed O
occipital O
infarcts O
and O
was O
found O
to O
have O
extremely B-ADR
elevated I-ADR
levels I-ADR
of I-ADR
ppa I-ADR
in O
his O
blood O
and O
dialysis O
fluid O

taxane-induced O
glaucoma B-ADR

three O
patients O
with O
no O
history O
of O
asthma O
or O
allergy O
developed O
bronchospasm B-ADR
while O
taking O
propranolol B-DRUG
for O
hypertension O

we O
report O
a O
case O
of O
ritalin-associated O
cataract B-ADR
and O
glaucoma O

objective O
: O
to O
report O
a O
case O
of O
multiple O
episodes O
of O
seizure B-ADR
activity O
in O
an O
aids O
patent O
following O
amphotericin B-DRUG
b I-DRUG
infusion O

the O
purpose O
of O
this O
study O
was O
to O
examine O
the O
incidence O
and O
cause O
of O
clostridium B-ADR
difficile I-ADR
colitis I-ADR
occurring O
after O
cisplatin-based O
combination O
chemotherapy O
in O
ovarian O
cancer O
patients O

background O
: O
reports O
on O
delated B-ADR
cutaneous I-ADR
reactions I-ADR
to O
captopril B-DRUG
have O
been O
seldom O
reported O

metoclopramide-induced O
parkinsonism B-ADR
is O
not O
rare O
, O
and O
appropriate O
dose O
reduction O
in O
patients O
with O
renal O
failure O
will O
help O
reduce O
the O
incidence O
of O
this O
morbidity O

life-threatening O
hyperkalemia B-ADR
induced O
by O
arginine B-DRUG

angio-oedema B-ADR
as O
an O
unusual O
tolerable O
side O
effect O
of O
voriconazole B-DRUG
therapy O

a O
patient O
with O
rheumatoid O
arthritis O
developed O
an O
acute O
intrahepatic B-ADR
cholestasis I-ADR
after O
100 O
mg O
of O
sodium B-DRUG
aurothiomalate I-DRUG

a O
48-year-old O
woman O
who O
was O
treated O
for O
thyrotoxicosis O
with O
methimazole B-DRUG
developed O
agranulocytosis B-ADR

objective O
: O
to O
report O
a O
case O
of O
cutaneous B-ADR
and I-ADR
hematologic I-ADR
toxicity I-ADR
in O
a O
patient O
treated O
with O
il-2 B-DRUG

an O
objective O
causality O
assessment O
indicated O
a O
probable O
relationship O
between O
clotting B-ADR
abnormality I-ADR
and O
warfarin B-DRUG
administration O
, O
although O
the O
degree O
of O
elevation O
of O
the O
inr O
was O
unusual O
in O
the O
light O
of O
the O
daily O
warfarin B-DRUG
dose O
and O
duration O
of O
its O
exposure O

five O
cases O
of O
clindamycin-associated O
pseudomembranous B-ADR
colitis I-ADR
in O
leukaemic O
patients O
are O
reported O

we O
report O
a O
girl O
with O
the O
rett O
syndrome O
who O
had O
acute B-ADR
encephalopathy I-ADR
probably O
induced O
by O
calcium O
hopantenate O
( O
hopa B-DRUG

the O
hyperpigmentation O
was O
diffuse O
scattered O
, O
flagellate O
like O
and O
linear O
streaking O
which O
was O
thought O
to O
be O
mainly O
related O
to O
the O
skin B-ADR
toxicity I-ADR
of O
bleomycin B-DRUG

we O
describe O
the O
infectious B-ADR
toxicities I-ADR
experienced O
by O
the O
first O
two O
patients O
in O
our O
institution O
treated O
with O
dexamethasone B-DRUG
( O
10 O
mg O
/ O
m O
( O
2 O
)/ O
day O
for O
4 O
weeks O
with O
gradual O
tapering O
) O
during O
induction O
according O
to O
the O
dexamethasone B-DRUG
arm O
of O
bfm O
2000 O
and O
review O
the O
relevant O
literature O
that O
suggests O
an O
increased O
risk O
of O
infectious O
complications O
with O
dexamethasone B-DRUG

although O
the O
literature O
on O
the O
use O
of O
risperidone B-DRUG
in O
elderly O
patients O
with O
dementia O
consists O
largely O
of O
uncontrolled O
trials O
, O
case O
reports O
, O
and O
chart O
reviews O
, O
it O
appears O
that O
this O
agent O
is O
effective O
for O
managing O
agitation O
in O
this O
population O
and O
does O
so O
with O
a O
low O
frequency O
of O
extrapyramidal O
symptoms O
( O
eps B-ADR

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis O
, O
and O
orthostatic B-ADR
hypotension I-ADR
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

chronic O
hydroxychloroquine B-DRUG
use O
associated O
with O
qt B-ADR
prolongation I-ADR
and O
refractory O
ventricular O
arrhythmia O

the O
second O
patient O
, O
who O
developed O
cholestasis O
after O
receiving O
trimethoprim-sulfamethoxazole B-DRUG
, O
had O
marked O
duct B-ADR
paucity I-ADR
in O
the O
liver O
biopsy O

both O
the O
longitudinal O
melanonychia O
and O
the O
multiple B-ADR
skin I-ADR
cancers I-ADR
first O
appeared O
after O
approximately O
6 O
months O
of O
hydroxyurea B-DRUG
treatment O

agranulocytosis B-ADR
during O
clozapine B-DRUG
therapy O

thus O
any O
case O
of O
severe B-ADR
neutropenia I-ADR
occurring O
in O
a O
patient O
receiving O
olanzapine B-DRUG
is O
alarming O
to O
clinicians O

the O
observations O
suggest O
that O
testicular B-ADR
swelling I-ADR
and O
pain O
are O
side O
effects O
of O
desipramine B-DRUG

although O
the O
essential O
cause O
of O
pv B-ADR
is O
unclear O
, O
its O
onset O
has O
occasionally O
been O
associated O
with O
drug O
therapy O
, O
in O
particular O
penicillamine B-DRUG

to O
date O
, O
there O
have O
been O
few O
reports O
of O
visual B-ADR
disturbances I-ADR
associated O
with O
btx-b B-DRUG
use O

we O
present O
a O
case O
of O
respiratory B-ADR
failure I-ADR
occurring O
in O
a O
woman O
at O
16 O
weeks' O
gestation O
who O
was O
being O
treated O
with O
nitrofurantoin B-DRUG
for O
a O
urinary O
tract O
infection O

we O
report O
an O
additional O
case O
of O
isotretinoin B-DRUG
teratogenicity B-ADR
in O
which O
the O
patient O
had O
agenesis O
of O
the O
cerebellar O
vermis O
, O
multiple O
leptomeningeal O
neuroglial O
heterotopias O
, O
hydrocephalus O
, O
and O
abnormalities O
of O
the O
corticospinal O
tracts O

methods O
: O
a O
retrospective O
report O
of O
the O
first O
case O
of O
gemcitabine-related O
hus B-ADR
, O
in O
a O
patient O
with O
metastatic O
pancreatic O
adenocarcinoma O
, O
treated O
with O
a O
variety O
of O
standard O
therapies O
in O
addition O
to O
rituximab O
is O
presented O

cases O
: O
two O
postmenopausal O
women O
treated O
with O
tamoxifen B-DRUG
and O
progestational O
agents O
for O
breast O
carcinoma O
developed O
uterine O
enlargement O
and O
intermittent B-ADR
spotting I-ADR

severe B-ADR
corneal I-ADR
toxicity I-ADR
after O
topical O
fluoroquinolone B-DRUG
therapy O
: O
report O
of O
two O
cases O

a O
25-year-old O
man O
with O
a O
history O
of O
mid-borderline O
( O
bb O
) O
hansen O
's O
disease O
developing O
a O
reversal B-ADR
reaction I-ADR
after O
starting O
dapsone B-DRUG
and O
rifampin O
therapy O
is O
presented O

in O
addition O
to O
its O
known O
effect O
on O
gallbladder O
stasis O
, O
octreotide B-DRUG
alters O
bile O
acid O
composition O
and O
may O
thus O
hasten B-ADR
intrahepatic I-ADR
sludge I-ADR
and O
stone O
formation O

we O
report O
five O
cases O
of O
restless O
legs O
syndrome O
( O
rls B-ADR
) O
and O
periodic O
limb O
movements O
during O
sleep O
( O
plms O
) O
that O
were O
probably O
associated O
with O
olanzapine B-DRUG

we O
report O
a O
case O
of O
aild B-ADR
in O
an O
80-year-old O
male O
who O
presented O
with O
a O
generalized O
pruritic O
maculopapular O
eruption O
and O
fever O
following O
doxycycline B-DRUG
administration O

liver O
transplantation O
for O
fulminant B-ADR
hepatitis I-ADR
related O
to O
nevirapine B-DRUG
therapy O

the O
administration O
of O
" O
sweet B-DRUG
spirits I-DRUG
of I-DRUG
nitre I-DRUG
" O
( O
4 O
% O
ethyl O
nitrite O
ch3ch2ono O
in O
70 O
% O
ethyl O
alcohol O
) O
was O
followed O
by O
acute O
methemoglobinemia O
and O
severe O
anoxic O
metabolic O
acidosis O
in O
infant O
twins O
, O
methylene O
blue O
administration O
reversed O
methemoglobinemia O
in O
both O
, O
but O
one O
twin O
died B-ADR
from O
the O
consequences O
of O
hypoxemia O

we O
report O
on O
a O
56-year-old O
female O
who O
exhibited O
drug O
refractory O
paroxysmal O
atrial O
fibrillation O
, O
in O
which O
marked O
prolongation O
of O
the O
qt O
interval O
and O
t B-ADR
wave I-ADR
inversion I-ADR
on O
electrocardiogram O
was O
demonstrated O
reproducibly O
shortly O
after O
the O
administration O
of O
oral O
pirmenol B-DRUG
therapy O

we O
report O
here O
a O
case O
of O
cardiovascular O
and O
neurological B-ADR
depression I-ADR
induced O
by O
oxymetalzoline B-DRUG
in O
a O
toddler O

the O
patient O
had O
recurrence O
of O
urticaria B-ADR
and O
angioedema O
a O
year O
and O
a O
half O
later O
, O
at O
which O
point O
the O
nph B-DRUG
was O
stopped O
and O
she O
was O
desensitized O
to O
regular O
insulin O

schneiderian B-ADR
first-rank I-ADR
symptoms I-ADR
associated O
with O
fluvoxamine B-DRUG
treatment O
: O
a O
case O
report O

as O
far O
as O
we O
know O
, O
this O
is O
the O
first O
case O
report O
of O
acute B-ADR
hemorrhagic I-ADR
gastritis I-ADR
associated O
with O
az B-DRUG
intoxication O

we O
report O
a O
case O
of O
fulminant O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
in O
a O
man O
aged O
70 O
developing O
within O
12 O
hours O
of O
starting O
six-hourly O
intravenous O
metoclopramide B-DRUG

in O
rare O
cases O
mitomycin B-DRUG
c I-DRUG
( O
mmc O
) O
may O
induce O
cancer-associated O
hemolytic O
uremic O
syndrome O
, O
which O
is O
characterized O
by O
hemolytic O
anemia O
, O
thrombocytopenia B-ADR
and O
progressive O
renal O
failure O

we O
describe O
2 O
patients O
with O
severe O
erosive O
rheumatoid O
arthritis O
and O
rheumatoid O
vasculitis O
, O
respectively O
, O
in O
whom O
infliximab B-DRUG
therapy O
was O
associated O
with O
peripheral B-ADR
neuropathy I-ADR
due O
to O
necrotizing O
vasculitis O
in O
one O
patient O
and O
to O
progression O
of O
preexisting O
mononeuritis O
multiplex O
in O
the O
other O

eosinophilia B-ADR
caused O
by O
clozapine B-DRUG
was O
observed O
in O
challenge O
, O
preceded O
by O
a O
faster O
neutrophil O
production O
and O
consecutive O
decrease O
( O
z O
= O
2.27 O
, O
p O
= O
0.01 O

background O
: O
reproductive B-ADR
endocrine I-ADR
disorders I-ADR
characterized O
by O
menstrual O
disorders O
, O
polycystic O
ovaries O
, O
and O
hyperandrogenism O
seem O
to O
be O
common O
among O
women O
treated O
with O
sodium B-DRUG
valproate I-DRUG
for O
epilepsy O

46-year-old O
woman O
developed O
painful B-ADR
ulcers I-ADR
over O
her O
lower O
abdomen O
in O
the O
form O
of O
reticulate O
erythema O
after O
injecting O
interferon B-DRUG
beta-1b I-DRUG
subcutaneously O
for O
multiple O
sclerosis O

this O
is O
the O
first O
reported O
case O
of O
suspected O
dian B-ADR
due O
to O
cefuroxime B-DRUG

skin B-ADR
rash I-ADR
began O
after O
2 O
weeks O
of O
treatment O
, O
and O
signs O
of O
hepatocellular O
failure O
developed O
3 O
weeks O
after O
phenobarbital B-DRUG
had O
been O
started O

a O
case O
of O
fluoxetine B-DRUG
induced O
seizures B-ADR
, O
in O
a O
person O
with O
down O
syndrome O
, O
is O
described O

serotonin B-ADR
syndrome I-ADR
caused O
by O
interaction O
between O
citalopram O
and O
fentanyl B-DRUG

a O
literature O
review O
revealed O
83 O
other O
reported O
cases O
of O
rifampicin-induced O
renal B-ADR
insufficiency I-ADR

ticlopidine-induced O
aplastic B-ADR
anemia I-ADR
: O
two O
new O
case O
reports O
, O
review O
, O
and O
meta-analysis O
of O
55 O
additional O
cases O

purpose O
: O
symptomatic O
visual B-ADR
field I-ADR
constriction I-ADR
thought O
to O
be O
associated O
with O
vigabatrin B-DRUG
has O
been O
reported O

we O
present O
a O
case O
of O
a O
diabetic O
patient O
taking O
glyburide O
who O
was O
prescribed O
ciprofloxacin B-DRUG
and O
developed O
prolonged B-ADR
hypoglycemia I-ADR
, O
which O
persisted O
for O
over O
24 O
hours O

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic O
meningitis O
, O
hemolytic O
anemia O
, O
hepatitis B-ADR
, O
and O
orthostatic O
hypotension O
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

findings O
: O
six O
children O
with O
growth B-ADR
retardation I-ADR
noted O
after O
treatment O
with O
high-dose O
fluticasone B-DRUG
propionate I-DRUG
were O
found O
to O
have O
adrenal O
suppression O

two O
other O
patients O
who O
did O
not O
receive O
prochlorperazine O
, O
developed O
retinal B-ADR
problems I-ADR
which O
later O
improved O
, O
one O
after O
only O
15 O
g O
of O
desferrioxamine B-DRUG

severe B-ADR
respiratory I-ADR
syncytial I-ADR
virus I-ADR
pulmonary I-ADR
infection I-ADR
in O
a O
patient O
treated O
with O
fludarabine B-DRUG
for O
chronic O
lymphocytic O
leukemia O

mr O
findings O
in O
methotrexate-induced O
cns B-ADR
abnormalities I-ADR

neutropenic B-ADR
colitis I-ADR
during O
standard O
dose O
combination O
chemotherapy O
with O
nedaplatin B-DRUG
and O
irinotecan O
for O
testicular O
cancer O

massive B-ADR
pulmonary I-ADR
embolism I-ADR
complicating O
streptokinase B-DRUG
treatment O
for O
deep O
vein O
thrombosis O

physicians O
should O
be O
aware O
of O
the O
potential O
for O
developing O
a O
gemcitabine-induced O
radiation O
recall O
reaction O
resulting O
in O
hemodynamically O
significant O
pericardial B-ADR
effusion I-ADR

cis-retinoic B-DRUG
acid I-DRUG
( O
ra O
) O
may O
further O
increase O
the O
risk O
of O
developing O
bmtn B-ADR

we O
report O
a O
patient O
receiving O
chronic O
lithium B-DRUG
therapy O
who O
presented O
with O
a O
transient O
cdi B-ADR
occurring O
in O
the O
setting O
of O
underlying O
chronic O
ndi O

amikacin-induced O
type O
5 O
bartter-like O
syndrome O
with O
severe B-ADR
hypocalcemia I-ADR

case O
report O
: O
we O
hereby O
report O
a O
case O
of O
radiation B-ADR
recall I-ADR
dermatitis I-ADR
and O
myositis O
occurring O
on O
gemcitabine B-DRUG
monotherapy O
, O
five O
months O
after O
completing O
chemoradiation O
for O
locally O
advanced O
pancreatic O
cancer O

paraplegia B-ADR
following O
prophylactic O
intrathecal O
cytosine B-DRUG
arabinoside I-DRUG
( O
ara-c O
) O
is O
described O
in O
a O
patient O
with O
acute O
myelogenous O
leukemia O
in O
remission O
who O
received O
doses O
of O
100 O
mg O
/ O
m2 O
/ O
d O
for O
5 O
consecutive O
days O

a O
33-year-old O
man O
with O
a O
history O
of O
recreational O
benztropine B-DRUG
abuse O
presented O
to O
the O
emergency O
department O
with O
confusion O
, O
abdominal O
pain O
, O
and O
distention B-ADR

in O
conclusion O
, O
rsds B-ADR
is O
a O
relevant O
osteoarticular O
complication O
in O
patients O
receiving O
either O
anticalcineurinic O
drug O
( O
cya O
or O
tacrolimus B-DRUG
) O
, O
even O
under O
monotherapy O
or O
with O
a O
low O
steroid O
dose O

the O
ocular B-ADR
toxicity I-ADR
of O
dcf B-DRUG
, O
previously O
described O
as O
conjunctivitis O
, O
appears O
to O
be O
a O
keratitis O
of O
moderate O
severity O
which O
requires O
further O
study O

methods O
: O
three O
patients O
with O
apparent O
itraconazole-induced O
liver B-ADR
injury I-ADR
were O
studied O

a O
57-year-old O
woman O
with O
right O
bundle O
branch O
block O
+ O
lph O
and O
ventricular O
premature O
contractions O
developed O
complete B-ADR
heart I-ADR
block I-ADR
( O
chb O
) O
following O
administration O
of O
disopyramide O
phosphate O
( O
norpace B-DRUG

this O
is O
a O
report O
of O
a O
renal O
transplant O
patient O
with O
pneumocystis O
pneumonia O
who O
developed O
chemical O
cellulitis O
and O
ulceration B-ADR
following O
the O
extravasation O
of O
intravenous O
pentamidine B-DRUG
into O
the O
soft O
tissues O
of O
the O
left O
hand O
and O
forearm O

this O
case O
study O
describes O
an O
atypical O
case O
of O
refractory O
, O
sodium B-DRUG
warfarin-induced O
necrotizing B-ADR
fasciitis I-ADR
and O
myonecrosis O

charcoal O
haemoperfusion O
and O
cysteamine O
therapy O
led O
to O
the O
rapid O
removal O
of O
the O
paracetamol B-DRUG
from O
the O
body O
and O
consequently O
prevented O
the O
development O
of O
severe B-ADR
hepatic I-ADR
necrosis I-ADR

simvastatin-induced O
rhabdomyolysis B-ADR
following O
cyclosporine B-DRUG
treatment O
for O
uveitis O

recognizing O
early O
signs O
of O
hmsn O
, O
such O
as O
areflexia O
and O
pes O
cavus O
deformity O
, O
can O
prevent O
severe B-ADR
neurotoxicity I-ADR
of O
polychemotherapy O
by O
avoiding O
vincristine B-DRUG

this O
severe B-ADR
illness I-ADR
was O
likely O
caused O
by O
minocycline B-DRUG
, O
and O
we O
speculate O
that O
minocycline B-DRUG
may O
have O
acted O
as O
a O
superantigen O
, O
causing O
lymphocyte O
over-activation O
and O
massive O
cytokine O
release O

increased O
lash O
length O
, O
thickness O
, O
and O
pigmentation B-ADR
are O
well-documented O
side O
effects O
of O
prostaglandin B-DRUG
analog O
glaucoma O
drops O

provocation O
of O
non-convulsive B-ADR
status I-ADR
epilepticus I-ADR
by O
tiagabine B-DRUG
in O
three O
adolescent O
patients O

fatal B-ADR
intravascular I-ADR
autoimmune I-ADR
hemolytic I-ADR
anemia I-ADR
after O
fludarabine B-DRUG
treatment O
for O
chronic O
lymphocytic O
leukemia O

we O
report O
a O
case O
of O
a O
patient O
with O
pulmonary O
hypertension O
and O
undifferentiated O
connective O
tissue O
disease O
who O
, O
after O
2 O
months O
of O
treatment O
with O
epoprostenol B-DRUG
, O
presented O
with O
rapidly O
progressive O
erythema O
, O
scaling O
, O
nausea O
and O
vomiting B-ADR
, O
and O
fever O

the O
possibility O
of O
phenytoin B-DRUG
hypersensitivity O
reactions O
should O
be O
considered O
when O
patients O
receiving O
phenytoin B-DRUG
have O
unusual O
symptoms O
, O
particularly O
fever O
, O
rash O
, O
and O
lymphadenopathy B-ADR

establishment O
of O
diuresis O
with O
fluids O
and O
iv O
administration O
of O
calcium O
may O
provide O
successful O
treatment O
of O
magnesium B-ADR
toxicosis I-ADR
in O
horses O

conclusions O
: O
fixed B-ADR
drug I-ADR
rash I-ADR
induced O
by O
methylphenidate B-DRUG
is O
a O
possible O
but O
rare O
phenomenon O

dapsone B-ADR
syndrome I-ADR
in O
cutaneous O
lupus O
erythematosus O

reversible O
valproic B-DRUG
acid-induced O
dementia B-ADR
: O
a O
case O
report O

in O
a O
postural O
challenge O
test O
after O
administration O
of O
isosorbide B-DRUG
dinitrate I-DRUG
( O
5 O
mg O
) O
, O
blood B-ADR
pressure I-ADR
decreased I-ADR
from O
120 O
/ O
67 O
to O
65 O
/ O
35 O
mmhg O
, O
followed O
by O
syncope O
with O
a O
sudden O
decrease O
in O
pulse O
rate O
from O
85 O
to O
60 O
beats O
/ O
min O

purpose O
: O
the O
case O
of O
a O
patient O
who O
developed O
aseptic O
meningitis O
, O
hemolytic B-ADR
anemia I-ADR
, O
hepatitis O
, O
and O
orthostatic O
hypotension O
simultaneously O
during O
treatment O
with O
trimethoprim-sulfamethoxazole O
is O
described O

a O
patient O
with O
alcoholic O
cerebellar O
degeneration O
had O
periodic B-ADR
alternating I-ADR
nystagmus I-ADR
during O
a O
period O
of O
phenytoin B-DRUG
intoxication O

hemorrhage B-ADR
from O
a O
falx O
meningioma O
after O
internal O
use O
of O
low-dose O
aspirin B-DRUG

conclusion O
: O
severe O
and O
sustained B-ADR
ocular I-ADR
hypertension I-ADR
may O
occur O
after O
intravitreal O
ranibizumab B-DRUG

we O
report O
a O
case O
of O
reversible O
encephalopathy B-ADR
syndrome I-ADR
in O
a O
16-year-old O
girl O
with O
acute O
myelogenous O
leukemia O
( O
aml O
) O
, O
who O
is O
undergoing O
during O
consolidation O
chemotherapy O
composed O
of O
bh-ac B-DRUG
( O
n4-behenoyl-1-beta-d-arabinofuranosyl O
cytosine O
) O
and O
idarubicin O

we O
describe O
a O
case O
of O
needle-track O
cutaneous B-ADR
seeding I-ADR
of O
hepatocellular O
carcinoma O
( O
hcc O
) O
after O
sonographically O
guided O
percutaneous O
ethanol B-DRUG
injection I-DRUG
( O
pei O

case O
: O
a O
malignant B-ADR
mixed I-ADR
mesodermal I-ADR
tumor I-ADR
was O
diagnosed O
in O
a O
64-year-old O
woman O
with O
a O
bicornuate O
uterus O
while O
she O
was O
taking O
raloxifene B-DRUG
for O
osteoporosis O
prevention O

conclusions O
: O
clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin B-ADR
syndrome I-ADR
with O
serious O
extrapyramidal O
reactions O
in O
patients O
receiving O
sertraline B-DRUG
or O
venlafaxine O
when O
metoclopramide O
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O

pulmonary B-ADR
toxicity I-ADR
with O
mefloquine B-DRUG

docetaxel-induced O
meibomian B-ADR
duct I-ADR
inflammation I-ADR
and I-ADR
blockage I-ADR
leading O
to O
chalazion O
formation O

inadvertent O
and O
accidental O
epinephrine B-DRUG
overdose O
might O
result O
in O
potentially O
lethal B-ADR
complications I-ADR

the O
nephrotic B-ADR
syndrome I-ADR
developed O
in O
a O
patient O
receiving O
therapy O
with O
gold B-DRUG
for O
rheumatoid O
arthritis O

the O
fifth O
patient O
exhibited O
paraesthesia O
and O
agitation B-ADR
caused O
by O
olanzapine B-DRUG
that O
was O
misdiagnosed O
as O
psychotic O
agitation B-ADR

the O
most O
common O
side O
effects O
associated O
with O
amifostine B-DRUG
are O
nausea B-ADR
, O
vomiting O
, O
hypotension O
, O
hypocalcemia O
and O
allergic O
reactions O

rapamycin B-DRUG
/ O
sirolimus-induced O
pneumonitis B-ADR
has O
been O
described O
previously O
in O
renal O
transplant O
recipients O
, O
and O
this O
report O
describes O
a O
stable O
heart-lung O
transplant O
recipient O
who O
developed O
a O
pulmonary O
infiltrate O
that O
reversed O
after O
ceasing O
sr O
therapy O

there O
is O
documentation O
of O
ocular B-ADR
toxicity I-ADR
with O
ethambutol B-DRUG
when O
administered O
at O
dosages O
generally O
pronounced O
as O
being O
safe O

a O
transient B-ADR
tonic I-ADR
pupillary I-ADR
response I-ADR
, O
denervation O
supersensitivity O
, O
and O
abnormal O
visual-evoked O
potentials O
in O
quinine B-DRUG
toxicity O
, O
to O
our O
knowledge O
, O
have O
not O
been O
previously O
reported O

purpose O
: O
to O
investigate O
the O
concentration-side O
effect O
relationship O
in O
a O
patient O
with O
severe O
acyclovir-induced O
neurotoxicity O
and O
to O
summarize O
the O
information O
available O
in O
the O
literature O
about O
central B-ADR
nervous I-ADR
system I-ADR
side I-ADR
effects I-ADR
due O
to O
acyclovir B-DRUG

severe B-ADR
diffuse I-ADR
interstitial I-ADR
pneumonitis I-ADR
induced O
by O
carmustine B-DRUG
( O
bcnu O

she O
was O
diagnosed O
with O
epstein-barr O
virus-associated O
polymorphic O
lymphoproliferative O
disorder O
( O
lpd O
) O
due O
to O
immunodeficiency B-ADR
caused O
by O
mtx B-DRUG
administration O

intravenous O
verapamil O
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine B-DRUG
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long B-ADR
qt I-ADR
interval I-ADR
syndrome I-ADR

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe B-ADR
acute I-ADR
5-fu I-ADR
reactions I-ADR
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic O
symptoms O
such O
as O
encephalopathy O
and O
coma O

we O
report O
a O
case O
of O
fulminant B-ADR
hepatic I-ADR
failure I-ADR
associated O
with O
didanosine B-DRUG
and O
masquerading O
as O
a O
surgical O
abdomen O
and O
compare O
the O
clinical O
, O
biologic O
, O
histologic O
, O
and O
ultrastructural O
findings O
with O
reports O
described O
previously O

posterior O
reversible O
encephalopathy O
syndrome O
( O
pres B-DRUG
) O
induced O
by O
cyclosporine B-ADR
use O
in O
a O
patient O
with O
collapsing O
focal O
glomeruloesclerosis O

we O
report O
a O
44-year-old O
woman O
with O
t-mds O
( O
refractory B-ADR
anemia I-ADR
with I-ADR
excess I-ADR
blasts I-ADR
) O
following O
treatment O
of O
recurrent O
anaplastic O
astrocytoma O
with O
temozolomide O
( O
tmz B-DRUG

comeoscleral B-ADR
perforation I-ADR
after O
pterygium O
excision O
and O
intraoperative O
mitomycin B-DRUG
c I-DRUG

we O
describe O
the O
clinical O
course O
of O
2 O
patients O
with O
crohn O
's O
disease O
( O
cd O
) O
in O
whom O
lymphoma B-ADR
was O
diagnosed O
after O
treatment O
with O
infliximab B-DRUG

in O
this O
case O
, O
interferon B-DRUG
alpha I-DRUG
induced O
polymyositis B-ADR
and O
cardiomyopathy O
is O
diagnosed O
in O
a O
33-yr-old O
male O
patient O
with O
history O
of O
chronic O
hepatitis O
b O

in O
patients O
with O
swallowing B-ADR
dysfunction I-ADR
and O
pneumonia O
, O
a O
history O
of O
mineral B-DRUG
oil I-DRUG
use O
should O
be O
obtained O
and O
a O
diagnosis O
of O
elp O
should O
be O
considered O
in O
the O
differential O
diagnoses O
if O
mineral B-DRUG
oil I-DRUG
use O
has O
occurred O

we O
have O
described O
three O
patients O
with O
hepatitis O
c O
for O
whom O
ifn-alpha B-DRUG
and O
ribavirin O
were O
prescribed O
and O
who O
developed O
two O
successive O
phases O
of O
silent O
thyroiditis B-ADR
followed O
by O
hyperthryroidism O
relapse O
due O
to O
graves' O
disease O

in O
this O
article O
, O
we O
describe O
a O
japanese O
patient O
with O
severe B-ADR
interstitial I-ADR
pneumonia I-ADR
probably O
caused O
by O
sorafenib B-DRUG
treatment O
for O
metastatic O
renal O
cell O
carcinoma O

we O
report O
the O
first O
case O
of O
chlorambucil-induced O
dress B-ADR
syndrome I-ADR
in O
a O
70-year-old O
man O
recently O
diagnosed O
with O
chronic O
lymphocytic O
leukaemia O

we O
report O
here O
on O
a O
heretofore O
undescribed O
respiratory O
syncytial O
virus O
( O
rsv O
) O
infection O
in O
a O
patient O
with O
a O
long-standing O
history O
of O
refractory O
cll O
that O
was O
treated O
with O
fludarabine B-DRUG
phosphate I-DRUG

flucloxacillin-induced O
aplastic O
anaemia O
and O
liver B-ADR
failure I-ADR

the O
authors O
describe O
a O
case O
of O
combined O
lithium O
and O
haloperidol B-DRUG
toxicity O
characterized O
by O
hyperpyrexia B-ADR
, O
severe O
rigidity O
, O
mutism O
, O
and O
development O
of O
irreversible O
tardive O
dyskinesia O

the O
male O
patient O
was O
treated O
with O
225-mg O
/ O
day O
clozapine B-DRUG
and O
the O
time O
to O
the O
diagnosis O
of O
agranulocytosis B-ADR
was O
6 O
weeks O

case O
1 O
, O
a O
62-year-old O
woman O
, O
developed O
bilateral B-ADR
optic I-ADR
neuritis I-ADR
with O
decreased O
sensation O
of O
vibration O
and O
increased O
deep O
tendon O
reflex O
in O
the O
lower O
extremities O
after O
a O
seven-month O
use O
of O
recombinant B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
for O
chronic O
active O
hepatitis O
c O

although O
taxol B-DRUG
has O
shown O
significant O
activity O
in O
advanced O
ovarian O
cancer O
, O
peripheral B-ADR
neuropathy I-ADR
is O
likely O
to O
become O
the O
major O
dose-limiting O
toxicity O

the O
field B-ADR
defects I-ADR
and O
some O
electrophysiological O
abnormalities O
persist O
when O
vigabatrin B-DRUG
therapy O
is O
withdrawn O

she O
received O
an O
accidental O
450-mg O
bolus O
injection O
of O
morphine B-DRUG
intrathecally O
and O
developed O
hypertension B-ADR
, O
status O
epilepticus O
, O
intracerebral O
hemorrhage O
, O
and O
respiratory O
failure O

isoniazid B-DRUG
and O
ethambutol O
as O
a O
cause O
of O
optic B-ADR
neuropathy I-ADR

although O
there O
is O
one O
case O
report O
of O
cholesterol O
crystal O
embolization O
following O
t-pa B-DRUG
therapy O
with O
only O
extrarenal O
manifestations O
( O
n O
engl O
j O
med O
321:1270 O
, O
1989 O
) O
, O
this O
is O
the O
first O
reported O
case O
of O
atheroembolic B-ADR
acute I-ADR
renal I-ADR
failure I-ADR
following O
t-pa B-DRUG
therapy O

symptomatic B-ADR
hypoglycemia I-ADR
secondary O
to O
a O
glipizide-trimethoprim O
/ O
sulfamethoxazole O
drug O
interaction O

moreover O
, O
treatment O
with O
immunosuppressive O
drugs O
such O
as O
cyclosporine O
, O
cisplatin B-DRUG
, O
tacrolimus O
, O
and O
interferon-alpha O
can O
induce O
a O
condition O
resembling O
rpls B-ADR

we O
report O
on O
a O
patient O
with O
subarachnoid O
haemorrhage O
who O
developed O
an O
acute O
life-threatening O
pseudo-obstruction B-ADR
of I-ADR
the I-ADR
colon I-ADR
, O
a O
variant O
of O
adynamic O
ileus O
, O
while O
being O
treated O
with O
intravenous O
nimodipine B-DRUG

we O
report O
a O
child O
with O
yolk O
sac O
tumor O
who O
developed O
localized B-ADR
pigmentation I-ADR
after O
the O
first O
course O
of O
chemotherapy O
regimen O
that O
included O
cisplatin O
, O
etoposide B-DRUG
and O
bleomycin O

recombinant B-DRUG
human I-DRUG
interferon-alpha I-DRUG
has O
been O
used O
in O
the O
treatment O
of O
several O
cancers O
, O
but O
there O
have O
been O
several O
reports O
that O
it O
may O
exacerbate B-ADR
psoriasis I-ADR
or I-ADR
trigger I-ADR
off I-ADR
its I-ADR
onset I-ADR

heat B-ADR
stroke I-ADR
in O
schizophrenia O
during O
clozapine B-DRUG
treatment O
: O
rapid O
recognition O
and O
management O

two O
days O
after O
administration O
of O
kalimate B-DRUG
enema O
, O
he O
had O
profuse B-ADR
hematochezia I-ADR
, O
and O
a O
sigmoidoscopy O
showed O
diffuse O
colonic O
mucosal O
necrosis O
in O
the O
rectum O
and O
sigmoid O
colon O

we O
report O
a O
case O
of O
pancytopenia B-ADR
in O
a O
23-year-old O
man O
with O
crohn O
's O
disease O
who O
was O
treated O
with O
5-aminosalicylic O
acid O
( O
pentasa B-DRUG
; O
nisshin O
, O
tokyo O
, O
japan O
) O
3.0 O
g O
/ O
day O

a O
49-year-old O
man O
with O
crohn O
's O
disease O
treated O
with O
prednisone O
and O
mesalamine O
( O
5-asa B-DRUG
) O
developed O
worsening B-ADR
respiratory I-ADR
distress I-ADR
and O
fever O

theophylline B-ADR
intoxication I-ADR
following O
viloxazine O
induced O
decrease O
in O
clearance O

olanzapine-induced O
hyperglycaemic B-ADR
coma I-ADR
and O
neuroleptic O
malignant O
syndrome O
: O
case O
report O
and O
review O
of O
literature O

the O
fever B-ADR
abated O
promptly O
following O
discontinuation O
of O
acyclovir B-DRUG
, O
and O
radiographic O
abnormalities O
resolved O
over O
ten O
days O

a O
patient O
with O
chronic O
myeloid O
leukaemia O
treated O
with O
busulphan B-DRUG
for O
4-5 O
years O
, O
developed O
signs O
of O
busulphan B-DRUG
toxicity O
and O
portal O
hypertension O
with O
ascites O
, O
oesophageal O
varices O
and O
jaundice B-ADR

it O
was O
concluded O
that O
anca B-ADR
is O
closely O
related O
to O
the O
pathogenesis O
of O
crescentic O
glomerulonephritis O
and O
that O
treatment O
with O
ptu B-DRUG
appeared O
to O
induce O
anca B-ADR

paradoxical B-ADR
ventricular I-ADR
tachycardia I-ADR
and O
fibrillation O
after O
intravenous O
bretylium B-DRUG
therapy O

conclusions O
: O
colchicine-induced O
myopathy B-ADR
should O
be O
excluded O
in O
patients O
with O
fmf O
who O
present O
with O
generalized O
muscle O
weakness O

the O
case O
of O
an O
adult O
who O
developed O
both O
hepatic O
dysfunction O
and O
an O
impaired B-ADR
macrophage I-ADR
migration I-ADR
after O
exposure O
to O
cimetidine B-DRUG
is O
discussed O

however O
, O
he O
developed O
acute O
renal O
failure O
, O
hyperkalemia B-ADR
, O
and O
hyperuricemia O
30 O
d O
after O
receiving O
the O
sorafenib B-DRUG
treatment O

acute B-ADR
endophthalmitis I-ADR
following O
intravitreal O
bevacizumab O
( O
avastin B-DRUG
) O
injection O

we O
describe O
a O
patient O
with O
metastatic O
prostate O
cancer O
who O
developed O
nonoliguric B-ADR
renal I-ADR
failure I-ADR
during O
treatment O
with O
suramin B-DRUG

duodenal B-ADR
ulceration I-ADR
: O
a O
complication O
of O
tolazoline B-DRUG
therapy O

radiation B-ADR
recall I-ADR
pneumonitis I-ADR
induced O
by O
gemcitabine B-DRUG

bull's-eye B-ADR
maculopathy I-ADR
associated O
with O
quinacrine B-DRUG
therapy O
for O
malaria O

preliminary O
results O
suggest O
that O
the O
higher O
concentrations O
of O
dextrose B-DRUG
induce O
increased B-ADR
histamine I-ADR
release I-ADR
from O
blood O
cells O
, O
and O
that O
this O
phenomenon O
is O
more O
marked O
in O
diabetic O
, O
and O
particularly O
diabetic-allergic O
, O
individuals O

this O
is O
the O
first O
case O
of O
hydroxyurea-induced O
acute B-ADR
interstitial I-ADR
pneumonitis I-ADR
reported O
in O
the O
literature O

we O
postulate O
that O
the O
bolus O
of O
sulprostone B-DRUG
resulted O
in O
possible O
coronary O
spasm O
that O
resulted O
in O
cardiac B-ADR
arrest I-ADR

delusional B-ADR
parasitosis I-ADR
associated O
with O
phenelzine B-DRUG

well-known O
signs O
of O
methotrexate B-ADR
toxicity I-ADR
include O
bone O
marrow O
suppression O
and O
oral O
and O
gastrointestinal O
ulceration O

discussion O
: O
after O
exclusion O
of O
other O
causes O
, O
the O
onset O
of O
thrombocytopenia O
after O
administration O
of O
lansoprazole B-DRUG
, O
the O
resolution O
of O
the O
adverse O
reaction O
after O
discontinuation O
of O
the O
drug O
, O
and O
the O
fact O
that O
no O
other O
medicines O
were O
introduced O
during O
this O
time O
frame O
lead O
us O
to O
believe O
that O
this O
was O
most O
likely O
an O
idiosyncratic O
thrombocytopenic B-ADR
response O
to O
lansoprazole B-DRUG

flucloxacillin-induced O
aplastic B-ADR
anaemia I-ADR
and O
liver O
failure O

other O
potential O
causes O
of O
renal B-ADR
failure I-ADR
were O
not O
present O
in O
our O
patient O
and O
his O
renal O
function O
gradually O
recovered O
with O
the O
cessation O
of O
suramin B-DRUG
treatment O

possible O
induction O
of O
diabetes B-ADR
by O
treatment O
of O
hypertension O
with O
indapamide B-DRUG
( O
with O
four O
case O
reports O

treatment O
of O
carbimazole-induced O
agranulocytosis O
and O
sepsis B-ADR
with O
granulocyte O
colony O
stimulating O
factor O

the O
patient O
completed O
a O
10-month O
follow-up O
, O
maintaining O
a O
complete O
resolution O
of O
the O
treated O
skin O
lesions O
; O
however O
, O
the O
development O
of O
a O
painful B-ADR
hand I-ADR
ulcer I-ADR
, O
possibly O
associated O
with O
the O
hydroxyurea B-DRUG
, O
and O
new O
skin O
cancers O
were O
observed O
at O
the O
last O
follow-up O
visit O

the O
latter O
form O
( O
macrodantin B-DRUG
) O
is O
reported O
to O
engender O
less O
gastrointestinal O
intolerance O
but O
it O
can O
produce O
the O
same O
adverse O
effects O
as O
the O
conventional O
form O
-- O
liver B-ADR
damage I-ADR
, O
acute O
and O
chronic O
pulmonary O
reactions O
, O
peripheral O
neuropathy O
, O
blood O
dyscrasias O
and O
allergic O
reactions O
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one O
such O
case O
is O
reported O
here O

studies O
performed O
10 O
years O
ago O
on O
25 O
patients O
with O
mtx-induced O
liver O
cirrhosis B-ADR
indicated O
that O
this O
type O
of O
cirrhosis B-ADR
was O
not O
of O
an O
aggressive O
nature O

patient O
b O
developed O
perioral B-ADR
and I-ADR
upper I-ADR
extremity I-ADR
paresthesias I-ADR
during O
the O
fourth O
cycle O
of O
cap B-DRUG
alone O
( O
2500 O
mg O
/ O
m2 O

in O
conclusion O
, O
rsds B-ADR
is O
a O
relevant O
osteoarticular O
complication O
in O
patients O
receiving O
either O
anticalcineurinic O
drug O
( O
cya B-DRUG
or O
tacrolimus O
) O
, O
even O
under O
monotherapy O
or O
with O
a O
low O
steroid O
dose O

cardiac B-ADR
toxicity I-ADR
related O
to O
bcnu B-DRUG
has O
not O
been O
described O
well O

she O
had O
been O
on O
copaxone B-DRUG
20 O
mg O
/ O
day O
treatment O
for O
2 O
years O
when O
she O
first O
exhibited O
gastrointestinal B-ADR
symptoms I-ADR

this O
article O
reports O
the O
case O
of O
an O
otherwise O
healthy O
patient O
who O
experienced O
permanent O
sensorineural B-ADR
hearing I-ADR
loss I-ADR
after O
a O
brief O
course O
of O
naproxen B-DRUG
and O
reviews O
the O
literature O
on O
nsaid-related O
permanent O
sensorineural B-ADR
hearing I-ADR
loss I-ADR

potential O
causes O
of O
methamphetamine-related O
keratitis B-ADR
can O
be O
divided O
into O
four O
categories O
resulting O
from O
( O
a O
) O
direct O
pharmacologic O
and O
physical O
effects O
of O
methamphetamine B-DRUG
; O
( O
b O
) O
the O
toxic O
effects O
of O
diluting O
or O
" O
cutting O
" O
agents O
such O
as O
lidocaine O
and O
quinine O
; O
( O
c O
) O
effects O
related O
to O
the O
route O
of O
drug O
administration O
( O
intravenous O
, O
inhalation O
, O
smoking O
) O
; O
and O
( O
d O
) O
manufacture-related O
effects O
of O
exposure O
to O
unintentional O
caustic O
contaminants O
in O
the O
final O
product O

conclusion O
: O
these O
cases O
suggest O
that O
moxifloxacin B-DRUG
may O
interfere O
with O
the O
healing O
of O
corneal B-ADR
ulcers I-ADR

conclusions O
: O
anastrozole B-DRUG
may O
be O
the O
causative O
factor O
in O
patients O
with O
sclerosing B-ADR
glomerulonephritis I-ADR

the O
incidence O
of O
angioedema B-ADR
secondary O
to O
losartan B-DRUG
, O
an O
angiotensin O
ii O
receptor O
antagonist O
, O
is O
unknown O

objective O
: O
to O
report O
the O
finding O
of O
squamous B-ADR
metaplasia I-ADR
within I-ADR
endometrial I-ADR
glands I-ADR
occurring O
as O
a O
result O
of O
progestin B-DRUG
therapy O
of O
hyperplasia O

central B-ADR
nervous I-ADR
system I-ADR
manifestations I-ADR
of O
an O
ibuprofen B-DRUG
overdose O
reversed O
by O
naloxone O

we O
report O
the O
occurrence O
of O
renal B-ADR
failure I-ADR
due O
to O
cholesterol O
crystal O
embolization O
following O
thrombolytic O
therapy O
with O
intravenous O
recombinant B-DRUG
tissue-type I-DRUG
plasminogen I-DRUG
activator I-DRUG
( O
t-pa O

amphotericin B-DRUG
b I-DRUG
( O
amb O
) O
is O
effective O
, O
but O
its O
use O
is O
limited O
by O
toxicity O
: O
renal B-ADR
impairment I-ADR
, O
anaemia O
, O
fever O
, O
malaise O
, O
and O
hypokalaemia O
are O
common O

psychosis B-ADR
in O
a O
12-year-old O
hiv-positive O
girl O
with O
an O
increased O
serum O
concentration O
of O
efavirenz B-DRUG

ticlopidine-induced O
marrow B-ADR
aplasia I-ADR
treated O
with O
cyclosporine O

fatal B-ADR
lung I-ADR
fibrosis I-ADR
caused O
by O
paclitaxel B-DRUG
toxicity O
has O
not O
been O
reported O
in O
this O
report O
, O
we O
describe O
the O
case O
of O
a O
62-year-old O
woman O
who O
received O
six O
cycles O
of O
paclitaxel B-DRUG
and O
carboplatin O
as O
combination O
chemotherapy O
for O
advanced O
ovarian O
cancer O

he O
had O
been O
taking O
trimethoprim-sulfamethoxazole O
for O
approximately O
eight O
days O
when O
he O
revisited O
his O
family O
physician O
, O
complaining O
of O
headaches O
, O
dizziness O
, O
difficulty O
with O
speech O
, O
weakness B-ADR
, O
and O
itching O
on O
the O
trunk O
of O
his O
body O
and O
legs O
, O
where O
a O
maculopapular O
rash O
was O
noted O

we O
report O
four O
cases O
of O
encephalopathy O
coincident O
with O
elevated B-ADR
aluminum I-ADR
levels I-ADR
as O
well O
as O
one O
patient O
who O
developed O
seizures O
while O
receiving O
continuous O
bladder O
irrigations O
with O
alum B-DRUG

bortezomib-induced O
paralytic O
ileus O
is O
a O
potential O
gastrointestinal B-ADR
side I-ADR
effect I-ADR
of O
this O
first-in-class O
anticancer O
proteasome O
inhibitor O

in O
two O
patients O
with O
mycosis O
fungoides O
, O
a O
squamous B-ADR
cell I-ADR
carcinoma I-ADR
developed O
during O
therapy O
with O
psoralens B-DRUG
plus O
long-wave O
ultraviolet O
radiation O
( O
puva O

the O
authors O
describe O
a O
case O
of O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
that O
occurred O
in O
a O
patient O
on O
amitriptyline B-DRUG
and O
lithium O
carbonate O

we O
have O
cared O
for O
three O
children O
in O
whom O
four O
episodes O
of O
dystonia O
proceeding O
to O
opisthotonus B-ADR
occurred O
in O
association O
with O
carbamazepine B-DRUG
use O

the O
concomitant O
use O
, O
however O
, O
of O
colchicine B-DRUG
and O
statin O
has O
been O
associated O
with O
the O
rapid O
onset O
of O
muscle B-ADR
weakness I-ADR

two O
patients O
with O
ovarian O
cancer O
who O
had O
received O
multiple O
courses O
of O
cisplatin B-DRUG
without O
complications O
experienced O
hypersensitivity O
reactions O
to O
cisplatin B-DRUG
: O
one O
, O
involving O
intrahepatic O
artery O
infusion O
, O
manifested O
general O
erythema O
, O
dyspnea O
, O
and O
hypotension B-ADR
; O
the O
other O
, O
involving O
intravenous O
infusion O
, O
manifested O
abdominal O
pain O
, O
general O
erythema O
, O
and O
fever O

although O
retinoic B-DRUG
acid I-DRUG
is O
well O
tolerated O
by O
the O
majority O
of O
patients O
with O
this O
disease O
, O
a O
potentially O
fatal B-ADR
complication I-ADR
of O
this O
kind O
of O
treatment O
has O
been O
reported O
: O
" O
the O
retinoic B-DRUG
acid I-DRUG
syndrome O

procainamide-induced O
incessant B-ADR
supraventricular I-ADR
tachycardia I-ADR
in O
the O
wolff-parkinson-white O
syndrome O

ziprasidone B-DRUG
is O
an O
atypical O
antipsychotic O
drug O
that O
is O
believed O
to O
have O
a O
low O
propensity O
for O
inducing O
extrapyramidal B-ADR
symptoms I-ADR
, O
including O
tardive O
dyskinesia O
( O
td O

thus O
, O
tardive B-ADR
seizures I-ADR
in O
our O
cases O
are O
thought O
to O
be O
related O
to O
piperacillin B-DRUG
and O
cefotiam O

temozolomide-induced O
desquamative B-ADR
skin I-ADR
rash I-ADR
in O
a O
patient O
with O
metastatic O
melanoma O

the O
potential O
for O
progressive O
brain B-ADR
injury I-ADR
and O
subsequent O
disability O
related O
to O
intraventricular O
il-2 B-DRUG
therapy O
is O
discussed O

carbamazepine-induced O
systemic B-ADR
lupus I-ADR
erythematosus I-ADR

conclusions O
: O
clinicians O
should O
be O
aware O
of O
a O
risk O
of O
serotonin B-ADR
syndrome I-ADR
with O
serious O
extrapyramidal O
reactions O
in O
patients O
receiving O
sertraline O
or O
venlafaxine O
when O
metoclopramide B-DRUG
is O
coadministered O
even O
in O
a O
single O
, O
conventional O
dose O

objective O
: O
to O
document O
a O
case O
of O
serotonin B-ADR
syndrome I-ADR
( O
ss O
) O
associated O
with O
mirtazapine B-DRUG
monotherapy O
, O
review O
the O
previously O
reported O
cases O
of O
ss O
associated O
with O
this O
tetracyclic O
antidepressant O
, O
and O
discuss O
the O
possible O
pathogenic O
mechanisms O
leading O
to O
this O
serious O
adverse O
drug O
reaction O

this O
report O
describes O
a O
case O
of O
neuroleptic B-ADR
malignant I-ADR
syndrome I-ADR
due O
to O
risperidone B-DRUG
in O
a O
child O
with O
joubert O
syndrome O

the O
occurrence O
of O
acute O
hepatitis B-ADR
is O
best O
known O
for O
ketoconazole B-DRUG

mitomycin B-DRUG
c I-DRUG
( O
mmc O
) O
is O
an O
alkylating O
agent O
that O
has O
been O
recently O
associated O
with O
the O
hemolytic-uremic B-ADR
syndrome I-ADR
( O
hus O

hyperammonemia O
secondary O
to O
valproic B-DRUG
acid I-DRUG
as O
a O
cause O
of O
lethargy B-ADR
in O
a O
postictal O
patient O

three O
nephrotic O
patients O
who O
had O
reduced O
renal O
function O
and O
active O
renal O
disease O
with O
progressive O
deterioration O
of O
renal O
function O
prior O
to O
the O
use O
of O
mp B-DRUG
developed O
transient B-ADR
renal I-ADR
failure I-ADR
following O
an O
mp B-DRUG
pulse O
therapy O

an O
intertrigo-like B-ADR
eruption I-ADR
from O
pegylated O
liposomal O
doxorubicin B-DRUG

case O
summary O
: O
a O
65-year-old O
patient O
chronically O
treated O
with O
the O
selective O
serotonin O
reuptake O
inhibitor O
( O
ssri O
) O
citalopram O
developed O
confusion O
, O
agitation O
, O
tachycardia O
, O
tremors O
, O
myoclonic O
jerks O
and O
unsteady B-ADR
gait I-ADR
, O
consistent O
with O
serotonin O
syndrome O
, O
following O
initiation O
of O
fentanyl B-DRUG
, O
and O
all O
symptoms O
and O
signs O
resolved O
following O
discontinuation O
of O
fentanyl B-DRUG

three O
of O
these O
patients O
had O
convulsions B-ADR
attributed O
to O
imipenem B-DRUG
/ O
cilastatin O
; O
3.6 O
% O
of O
the O
patients O
had O
seizure O
, O
or O
2 O
% O
of O
imipenem B-DRUG
/ O
cilastatin O
administrations O
was O
followed O
by O
a O
seizure O
attack O

although O
both O
patients O
recovered O
from O
the O
colitis B-ADR
after O
the O
administration O
of O
vancomycin O
, O
the O
first O
case O
demonstrated O
a O
relapse O
of O
the O
colitis B-ADR
after O
receiving O
a O
subsequent O
course O
of O
the O
same O
chemotherapy O
with O
cisplatin B-DRUG

musculoskeletal B-ADR
complaints I-ADR
were O
the O
presenting O
symptoms O
in O
four O
of O
44 O
children O
( O
9 O
%) O
treated O
for O
relapsed O
wilms' O
tumors O
with O
ifosfamide O
, O
a O
derivative O
of O
cyclophosphamide B-DRUG

self-limited B-ADR
edema I-ADR
is O
a O
well-recognized O
complication O
of O
insulin B-DRUG
therapy O

acute B-ADR
asthma I-ADR
associated O
with O
sustained-release O
verapamil B-DRUG

recently O
, O
her O
serum O
theophylline B-ADR
levels I-ADR
had I-ADR
increased I-ADR
to I-ADR
the I-ADR
toxic I-ADR
range I-ADR
( O
133.2 O
micromol O
/ O
l O
[ O
24 O
microg O
/ O
ml O
]) O
shortly O
after O
the O
addition O
of O
zafirlukast O
( O
accolate B-DRUG
, O
zeneca O
pharmaceuticals O
, O
wilmington O
, O
del O
) O
to O
her O
regimen O

amikacin-induced O
type B-ADR
5 I-ADR
bartter-like I-ADR
syndrome I-ADR
with O
severe O
hypocalcemia O

even O
though O
only O
a O
few O
cases O
of O
this O
adverse O
event O
have O
been O
reported O
in O
the O
literature O
, O
severe O
docetaxel-induced O
pulmonary B-ADR
toxicity I-ADR
needs O
to O
be O
considered O
in O
the O
differential O
diagnosis O
when O
such O
patients O
present O
with O
respiratory O
symptoms O

pulmonary B-ADR
fibrosis I-ADR
associated O
with O
nabumetone B-DRUG

drug O
induced O
liver B-ADR
injury I-ADR
secondary O
to O
interferon-beta B-DRUG
( O
ifn-beta O
) O
in O
multiple O
sclerosis O

discontinuation O
of O
the O
itraconazole B-DRUG
caused O
resolution O
of O
the O
drug B-ADR
eruption I-ADR

after O
the O
first O
oral O
dose O
of O
propranolol B-DRUG
, O
syncope O
developed O
together O
with O
atrioventricular B-ADR
block I-ADR

conclusions O
: O
we O
report O
a O
typical O
symptoms O
of O
charles-bonnet O
syndrome O
( O
cbs B-ADR
) O
in O
patients O
with O
severe O
amd O
after O
intravitreal O
avastin-injections O

the O
former O
patient O
had O
complained O
once O
that O
his O
visual B-ADR
acuity I-ADR
had I-ADR
decreased I-ADR
after O
the O
termination O
of O
ifn B-DRUG
therapy O
, O
and O
the O
latter O
patient O
complained O
twice O
during O
ifn B-DRUG
therapy O
that O
his O
visual B-ADR
acuity I-ADR
had I-ADR
decreased I-ADR

priapism B-ADR
associated O
with O
zuclopenthixol B-DRUG

glomerulonephritis O
in O
procainamide B-DRUG
induced O
lupus B-ADR
erythematosus I-ADR
: O
report O
of O
a O
case O
and O
review O
of O
the O
literature O

the O
most O
commonly O
recognized O
toxic O
effect O
of O
ethambutol B-DRUG
is O
optic B-ADR
neuropathy I-ADR
, O
which O
generally O
is O
considered O
uncommon O
and O
reversible O
in O
medical O
literature O

after O
treatment O
with O
cimetidine B-DRUG
, O
there O
was O
a O
rapid O
deterioration O
with O
decreased B-ADR
oxygen I-ADR
saturation I-ADR
and I-ADR
arterial I-ADR
po2 I-ADR
values O

after O
reviewing O
the O
literature O
we O
suggest O
the O
cpm B-ADR
was O
a O
complication O
of O
lithium B-DRUG
toxicity O
which O
affected O
the O
lateral O
geniculate O
nucleus O
which O
produced O
blindness O

ifosfamide B-DRUG
is O
a O
known O
nephrotoxic O
drug O
with O
demonstrated O
tubulopathies B-ADR

hyperpigmentation B-ADR
during O
interferon-alpha B-DRUG
therapy O
for O
chronic O
hepatitis O
c O
virus O
infection O

risperidone B-DRUG
is O
a O
frequently O
used O
member O
of O
a O
new O
class O
of O
atypical O
antipsychotics-the O
serotonin-dopamine O
antagonists O
( O
sdas O
)- O
due O
to O
its O
comparatively O
high O
efficacy O
and O
low O
d2 O
/ O
5ht2 O
binding O
ratio O
, O
which O
results O
in O
a O
low O
incidence O
of O
extrapyramidal O
side O
effects O
including O
tardive O
dyskinesia O
( O
td B-ADR

papillary B-ADR
necrosis I-ADR
associated O
with O
the O
hiv O
protease O
inhibitor O
indinavir B-DRUG

he O
had O
hypokalemia B-ADR
( O
k O
2.3 O
mmol O
/ O
l O
) O
induced O
by O
licorice B-DRUG
and O
also O
had O
received O
disopyramide O
for O
arrhythmia O
, O
bicalutamide O
for O
prostate O
cancer O
, O
and O
silodosin O
for O
prostate O
hypertrophy O

skin O
rash O
and O
splinter B-ADR
hemorrhages I-ADR
from O
ganciclovir B-DRUG

the O
authors O
suggest O
that O
in O
the O
absence O
of O
any O
proven O
benefit O
of O
itraconazole O
prophylaxis O
, O
and O
given O
the O
interaction O
of O
this O
drug O
with O
vincristine B-DRUG
leading O
to O
severe O
and O
even O
potentially O
fatal B-ADR
toxicities I-ADR
, O
the O
combination O
use O
of O
these O
drugs O
should O
be O
avoided O

sweet B-ADR
's I-ADR
syndrome I-ADR
is O
an O
acute O
febrile O
neutrophilic O
dermatosis O
that O
is O
a O
known O
complication O
of O
the O
administration O
of O
filgrastim B-DRUG
, O
a O
drug O
that O
causes O
increased O
neutrophil O
proliferation O
and O
differentiation O

hepatocellular B-ADR
damage I-ADR
following O
therapeutic O
intravenous O
iron B-DRUG
sucrose I-DRUG
infusion O
in O
a O
child O

our O
patient O
had O
headache O
, O
mild B-ADR
fever I-ADR
, O
nausea O
, O
vomiting O
, O
rash O
, O
and O
eosinophilia O
after O
3 O
weeks O
of O
disulfiram B-DRUG
therapy O

hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
following O
the O
infusion O
of O
oxaliplatin B-DRUG
: O
case O
report O

we O
report O
a O
case O
of O
an O
11-year-old O
boy O
who O
experienced O
an O
anaphylactic B-ADR
reaction I-ADR
after O
administration O
of O
bacitracin B-DRUG
ointment O

a O
patient O
is O
presented O
with O
typical O
hyperthyroidism O
, O
who O
developed O
a O
severe O
proximal O
muscle O
weakness O
and O
a O
raised B-ADR
creatine I-ADR
phosphokinase I-ADR
after O
treatment O
for O
hyperthyroidism O
with O
propylthiouracil B-DRUG
( O
100 O
mg O
orally O
, O
three O
times O
a O
day O

itraconazole-related O
increased O
vincristine B-ADR
neurotoxicity I-ADR
: O
case O
report O
and O
review O
of O
literature O

photo-onycholysis B-ADR
caused O
by O
olanzapine O
and O
aripiprazole B-DRUG

objective O
: O
1 O
) O
to O
describe O
a O
patient O
with O
rheumatoid O
arthritis O
receiving O
adalimumab B-DRUG
who O
developed O
fever O
, O
pancytopenia O
, O
splenomegaly O
, O
and O
extreme B-ADR
hyperferritinemia I-ADR

a O
22-year-old O
black O
man O
developed O
fever O
, O
chills O
, O
fatigue O
, O
night B-ADR
sweats I-ADR
, O
tender O
lymphadenopathy O
, O
and O
a O
generalized O
, O
pruritic O
, O
macular O
eruption O
3 O
weeks O
after O
starting O
minocycline B-DRUG
therapy O
for O
acne O

we O
describe O
a O
patient O
with O
acute O
myeloblastic O
leukemia O
( O
aml O
) O
who O
developed O
nephrotic B-ADR
syndrome I-ADR
after O
receiving O
several O
courses O
of O
chemotherapy O
, O
including O
macrophage-colony-stimulating O
factor O
( O
m-csf B-DRUG

a O
55-yr-old O
man O
developed O
prolonged O
jaundice O
and O
sicca B-ADR
complex I-ADR
after O
a O
course O
of O
thiabendazole B-DRUG
therapy O

autopsy O
findings O
were O
consistent O
with O
bleomycin O
and O
oxygen-induced O
pulmonary B-ADR
damage I-ADR

cyclophosphamide B-DRUG
pneumonitis B-ADR

on O
day O
7 O
of O
linezolid B-DRUG
treatment O
, O
the O
patient O
developed O
severe B-ADR
pruritus I-ADR
, O
macular O
rash O
, O
facial O
edema O
, O
eosinophilia O
, O
marked O
increase O
in O
serum O
creatinine O
level O
, O
and O
mild O
hepatitis O

here O
we O
report O
a O
patient O
with O
newly O
diagnosed O
acute O
promyelocytic O
leukemia O
who O
developed O
acute O
focal O
myositis O
, O
synovitis O
, O
and O
possible B-ADR
vasculitis I-ADR
, O
after O
receiving O
all-trans B-DRUG
retinoic I-DRUG
acid I-DRUG
therapy O

rifampin B-DRUG
( O
rfp O
) O
increases O
hepatic O
microsomal O
enzyme O
activity O
, O
and O
there O
are O
case O
reports O
of O
rfp-induced O
hypothyroidism B-ADR
, O
all O
associated O
with O
hashimoto O
's O
thyroiditis O

teicoplanin-induced O
agranulocytosis B-ADR
that O
followed O
vancomycin-induced O
agranulocytosis B-ADR
suggests O
a O
possible O
cross-reactivity O
between O
the O
2 O
drugs O

we O
report O
a O
case O
of O
penile B-ADR
fibrosis I-ADR
after O
intracavernous O
self-injection O
of O
a O
combination O
of O
phentolamine O
and O
papaverine B-DRUG

acute O
valproate B-DRUG
ingestion O
induces O
symptomatic B-ADR
methemoglobinemia I-ADR

when O
sasp O
was O
changed O
to O
5-aminosalicylic O
acid O
( O
5-asa B-DRUG
) O
, O
his O
skin O
eruptions O
were O
resolved O
, O
however O
, O
he O
developed O
weakness O
and O
atrophy O
in O
his O
right O
arm O
as O
well O
as O
progressive O
worsening O
of O
the O
dysesthesia O
in O
his O
legs O
and O
gait B-ADR
disturbance I-ADR

a O
patient O
presented O
with O
a O
painful B-ADR
, I-ADR
oedematous I-ADR
, I-ADR
cyanosed I-ADR
hand I-ADR
having O
injected O
a O
solution O
of O
diamorphine B-DRUG
and O
methylphenidate O
into O
his O
radial O
artery O

our O
objective O
is O
to O
present O
a O
retrospective O
analysis O
of O
the O
dwi O
findings O
in O
four O
patients O
who O
suffered O
subacute B-ADR
neurotoxicity I-ADR
after O
intrathecal O
mtx B-DRUG

colonic B-ADR
necrosis I-ADR
is O
known O
as O
a O
rare O
complication O
following O
the O
administration O
of O
kayexalate B-DRUG
( O
sodium O
polystryrene O
sulfonate O
) O
in O
sorbitol O

in O
addition O
to O
its O
known O
effect O
on O
gallbladder O
stasis O
, O
octreotide B-DRUG
alters B-ADR
bile I-ADR
acid I-ADR
composition I-ADR
and O
may O
thus O
hasten O
intrahepatic O
sludge O
and O
stone O
formation O

growth B-ADR
and I-ADR
adrenal I-ADR
suppression I-ADR
in O
asthmatic O
children O
treated O
with O
high-dose O
fluticasone B-DRUG
propionate I-DRUG

conclusion O
: O
in O
some O
abstainers O
who O
take O
cyanamide B-DRUG
for O
several O
years O
, O
thin O
septum-like O
liver O
fibrosis O
progresses O
along O
with O
the O
emergence O
of O
ground-glass B-ADR
hepatocytes I-ADR

a O
typical O
case O
of O
dextran-40 B-DRUG
associated O
acute B-ADR
renal I-ADR
failure I-ADR
is O
presented O

in O
this O
article O
lithium B-DRUG
is O
not O
discussed O
, O
although O
there O
are O
a O
number O
of O
concerns O
about O
lithium B-DRUG
's O
potential O
teratogenicity O
, O
and O
it O
has O
been O
implicated O
in O
epstein B-ADR
's I-ADR
anomaly I-ADR
, O
a O
congenital O
heart O
defect O
among O
infants O
born O
to O
women O
taking O
lithium B-DRUG
; O
as O
with O
other O
medications O
, O
however O
, O
the O
data O
have O
specific O
limitations O

these O
cases O
were O
chosen O
for O
study O
because O
they O
were O
all O
deaths B-ADR
as O
a O
result O
of O
suicidal O
ingestion O
of O
drugs O
in O
which O
quetiapine B-DRUG
was O
considered O
a O
significant O
factor O

methotrexate-induced O
pneumonitis B-ADR
in O
patients O
with O
rheumatoid O
arthritis O
and O
psoriatic O
arthritis O
: O
report O
of O
five O
cases O
and O
review O
of O
the O
literature O

conclusions O
: O
we O
report O
the O
first O
case O
of O
gemcitabine-induced O
labd B-ADR

eosinophilia B-ADR
has O
been O
encountered O
from O
0.2 O
to O
61.7 O
% O
in O
clozapine-treated O
patients O
, O
mostly O
with O
a O
transient O
course O
and O
spontaneous O
remission O

from O
1996 O
to O
2002 O
several O
medications O
were O
changed O
due O
to O
their O
adverse O
effects O
: O
indinavir O
( O
renal O
colic O
and O
fever O
) O
, O
nelfinavir B-DRUG
( O
cutaneous B-ADR
rash I-ADR
) O
, O
and O
efavirenz O
( O
nausea O
and O
temporary O
memory O
loss O

however O
, O
eo-induced O
noncardiogenic B-ADR
pulmonary I-ADR
edema I-ADR
has O
not O
been O
reported O
in O
human O

torsade B-ADR
de I-ADR
pointes I-ADR
represents O
a O
potential O
complication O
of O
chronic O
amiodarone B-DRUG
therapy O

the O
results O
clearly O
demonstrate O
that O
cph82 B-DRUG
was O
associated O
with O
suppression O
of O
the O
endogeneous O
production O
of O
acth O
and O
cortisol O
with O
a O
concomitant O
paradoxical O
picture O
of O
clinical O
hypercortisolism B-ADR

we O
present O
a O
case O
report O
of O
a O
patient O
with O
typhoid O
fever O
who O
experienced O
a O
hypersensitivity B-ADR
reaction I-ADR
subsequent O
to O
the O
infusion O
of O
chloramphenicol B-DRUG
sodium I-DRUG
succinate I-DRUG

the O
patient O
presented O
with O
fulminant O
microangiopathic O
hemolytic O
anemia O
and O
thrombocytopenia B-ADR
within O
48 O
hr O
of O
initiating O
therapy O
with O
trimethoprim-sulfamethoxazole O

atrioventricular O
block O
complicating O
amiodarone-induced O
hypothyroidism B-ADR
in O
a O
patient O
with O
pre-excitation O
and O
rate-dependent O
bilateral O
bundle O
branch O
block O

the O
authors O
present O
an O
elderly O
patient O
with O
mixed O
dementia O
who O
developed O
td O
at O
multiple O
sites O
, O
( O
including O
respiratory B-ADR
dyskinesia I-ADR
[ O
rd O
] O
, O
limb O
dyskinesia O
, O
and O
orofacial O
dyskinesia O
) O
following O
abrupt O
withdrawal O
of O
risperidone B-DRUG
therapy O

other O
upper B-ADR
tract I-ADR
neoplasms I-ADR
after O
cyclophosphamide B-DRUG
are O
reviewed O

antibiotic-associated O
colitis B-ADR
( O
pseudomembranous O
colitis B-ADR
) O
developed O
in O
four O
patients O
with O
spinal O
cord O
injury O
and O
taking O
oral O
trimethoprim-sulfamethoxazole O

although O
other O
nitrites O
induce O
methemoglobinemia B-ADR
, O
exposure O
to O
methyl B-DRUG
nitrite I-DRUG
during O
phenylpropanolamine O
production O
appears O
to O
be O
a O
new O
cause O
of O
occupational O
methemoglobinemia B-ADR

our O
review O
of O
194 O
ra O
patients O
and O
38 O
psa O
patients O
receiving O
mtx B-DRUG
has O
identified O
four O
ra O
patients O
and O
one O
psa O
patient O
with O
mtx-induced O
pneumonitis B-ADR
, O
giving O
a O
prevalence O
of O
2.1 O
% O
and O
0.03 O
% O
, O
respectively O

we O
described O
a O
very O
atypical O
case O
of O
a O
high O
stage O
, O
high O
grade O
endometrial B-ADR
cancer I-ADR
associated O
with O
tamoxifen B-DRUG
in O
a O
64-year-old O
woman O
with O
a O
past O
history O
of O
breast O
cancer O

we O
report O
the O
first O
biopsy O
confirmed O
occurrence O
of O
acute B-ADR
interstitial I-ADR
nephritis I-ADR
in O
a O
patient O
receiving O
treatment O
with O
sunitinib B-DRUG
for O
metastatic O
renal O
cell O
cancer O

a O
22-year-old O
drug-abuser O
injected O
flunitrazepam B-DRUG
tablets O
dissolved O
in O
tap O
water O
into O
her O
left O
femoral O
artery O
and O
presented O
with O
clinical O
signs O
of O
acute B-ADR
ischaemia I-ADR
of I-ADR
the I-ADR
left I-ADR
leg I-ADR

we O
report O
two O
patients O
with O
infectious B-ADR
mononucleosis-like I-ADR
syndrome I-ADR
induced O
by O
salazosulfapyridine B-DRUG
( O
sasp O

the O
first O
patient O
was O
a O
61-year-old O
man O
with O
a O
30-year O
history O
of O
fistulizing O
cd O
in O
whom O
b-cell B-ADR
non-hodgkin I-ADR
's I-ADR
lymphoma I-ADR
was O
diagnosed O
9 O
months O
after O
treatment O
with O
infliximab B-DRUG

after O
ruling O
out O
a O
hydrotelluric O
source O
of O
fluorine O
, O
the O
patient O
's O
fluorosis B-ADR
was O
linked O
to O
chronic O
use O
of O
niflumic B-DRUG
acid I-DRUG
, O
following O
the O
publication O
in O
1978 O
of O
the O
2 O
previously O
reported O
cases O
affected O
by O
this O
drug O

the O
fluorine O
contained O
in O
niflumic B-DRUG
acid I-DRUG
induced O
a O
marked O
densification B-ADR
of I-ADR
trabecular I-ADR
bone I-ADR
in O
all O
3 O
cases O

five O
cases O
( O
four O
from O
the O
literature O
and O
one O
new O
case O
) O
are O
presented O
in O
which O
patients O
unsuspected O
of O
having O
vitamin O
b12 O
deficiency O
developed O
subacute B-ADR
combined I-ADR
degeneration I-ADR
of I-ADR
the I-ADR
spinal I-ADR
cord I-ADR
following O
nitrous B-DRUG
oxide I-DRUG
anesthesia O

oesophageal B-ADR
ulceration I-ADR
due O
to O
emepronium B-DRUG
bromide I-DRUG

the O
third O
patient O
had O
been O
suffering O
from O
serious O
akathisia O
while O
on O
risperidone B-DRUG
, O
and O
was O
cured O
after O
switching O
to O
olanzapine O
, O
but O
thereafter O
the O
patient O
suffered O
from O
rls B-ADR
at O
nighttime O

we O
describe O
two O
dark-skinned O
patients O
who O
developed O
hyperpigmented O
skin O
and O
tongue B-ADR
lesions I-ADR
during O
combination O
therapy O
with O
ifn B-DRUG
and O
ribavirin O

acute B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
after O
rituximab B-DRUG
infusion O

abdominal O
wall O
ulceration O
and O
mucinosis B-ADR
secondary O
to O
recombinant B-DRUG
human I-DRUG
interferon-beta-1b I-DRUG

ovarian O
endometrioid O
carcinoma O
and O
endometriosis B-ADR
developing O
in O
a O
postmenopausal O
breast O
cancer O
patient O
during O
tamoxifen B-DRUG
therapy O
: O
a O
case O
report O
and O
review O
of O
the O
literature O

we O
postulate O
that O
cyclosporin O
, O
possibly O
together O
with O
ganciclovir B-DRUG
, O
can O
produce O
transient B-ADR
brain I-ADR
stem I-ADR
or I-ADR
neuromuscular I-ADR
dysfunction I-ADR
with O
eye O
movement O
abnormality O
in O
occasional O
patients O

among O
12 O
thyrotoxic O
patients O
, O
a O
patient O
with O
arrhythmogenic O
right O
ventricular O
dysplasia O
, O
who O
had O
been O
taking O
amiodarone B-DRUG
for O
4 O
years O
, O
developed O
thyrotoxicosis O
with O
subacute O
onset O
, O
accompanied O
by O
transiently O
positive O
thyrotropin O
( O
tsh O
) O
receptor O
antibody O
( O
trab O
) O
, O
or O
thyrotropin-binding O
inhibiting O
immunoglobulin O
( O
tbii O

a O
case O
of O
high-grade O
endometrial O
stromal O
sarcoma O
, O
confined O
into O
an O
intrauterine B-ADR
polypoid I-ADR
growth I-ADR
, O
in O
a O
woman O
with O
a O
history O
of O
breast O
cancer O
who O
was O
treated O
with O
adjuvant O
tamoxifen B-DRUG

we O
report O
a O
45-year-old O
psoriasis O
patient O
who O
developed O
eruptive B-ADR
mollusca I-ADR
contagiosa I-ADR
during O
an O
antipsoriatic O
treatment O
with O
efalizumab B-DRUG

mycobacterium B-ADR
marinum I-ADR
infection I-ADR
complicating O
crohn O
's O
disease O
, O
treated O
with O
infliximab B-DRUG

propafenone-induced O
ataxia B-ADR
: O
report O
of O
three O
cases O

we O
describe O
a O
57-year-old O
man O
with O
acral O
erythrocyanosis O
progressing O
to O
acute O
digital O
ischemia O
and O
gangrene B-ADR
that O
developed O
after O
combined O
chemotherapy O
( O
bleomycin B-DRUG
and O
methotrexate O
) O
used O
to O
treat O
a O
metastatic O
squamous O
cell O
carcinoma O
of O
the O
hypopharynx O

we O
describe O
a O
premenopausal O
woman O
who O
, O
while O
having O
tamoxifen B-DRUG
due O
to O
a O
diagnosis O
of O
in O
situ O
ductal O
carcinoma O
, O
developed O
endometriosis B-ADR
requiring O
surgery O

we O
report O
the O
case O
of O
a O
patient O
with O
increased B-ADR
cerebral I-ADR
cortical I-ADR
excitability I-ADR
following O
intoxication O
with O
flupirtine B-DRUG
, O
a O
centrally O
acting O
analgesic O
and O
antispastic O
drug O

the O
association O
between O
heparin B-DRUG
and O
priapism B-ADR
is O
often O
recognized O
; O
abnormal O
platelet O
aggregation O
could O
play O
a O
role O
in O
the O
pathogenesis O
of O
this O
side O
effect O

introduction O
of O
etanercept B-DRUG
was O
also O
clinically O
effective O
but O
followed O
by O
development O
of O
severe B-ADR
heart I-ADR
failure I-ADR

we O
experienced O
a O
case O
of O
chronic O
renal O
failure O
in O
a O
patient O
suffering O
from O
acute B-ADR
hemorrhagic I-ADR
gastritis I-ADR
associated O
with O
az B-DRUG
intoxication O

six O
days O
after O
starting O
acyclovir O
she O
exhibited O
signs O
of O
lithium B-ADR
toxicity I-ADR

nephrotic B-ADR
syndrome I-ADR
in O
a O
multiple O
sclerosis O
patient O
treated O
with O
interferon B-DRUG
beta I-DRUG
1a I-DRUG

lethargy O
in O
a O
newborn O
: O
lithium B-ADR
toxicity I-ADR
or O
lab O
error O

we O
report O
two O
adults O
who O
received O
gabapentin O
( O
gbp B-DRUG
) O
and O
subsequently O
developed O
behavioural B-ADR
side I-ADR
effects I-ADR

we O
stress O
the O
potential O
of O
benzarone B-DRUG
to O
cause O
hepatotoxicity B-ADR
, O
which O
usually O
resembles O
severe O
chronic O
active O
hepatitis O

background O
: O
interferon B-DRUG
( O
ifn O
)- O
associated O
retinopathy B-ADR
is O
typically O
characterized O
by O
retinal O
hemorrhages O
and O
cotton O
wool O
spots O
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O

we O
report O
the O
first O
case O
of O
fulminant O
adult O
respiratory O
distress O
syndrome O
( O
ards B-ADR
) O
associated O
with O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
( O
pegifnalpha-2a O
) O
and O
ribavirin O
use O
for O
hepatitis O
c O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O

clinicians O
should O
include O
phenolphthalein B-DRUG
in O
their O
list O
of O
possible O
causes O
of O
drug-induced O
ten B-ADR

the O
authors O
postulate O
that O
two O
types O
of O
combined O
lithium-neuroleptic O
toxicity O
occur O
: O
a O
neuroleptic B-ADR
malignant I-ADR
extrapyramidal I-ADR
syndrome I-ADR
and O
a O
lithium O
toxicity O
that O
occurs O
in O
combination O
with O
phenothiazines O
, O
primarily O
thioridazine B-DRUG

conclusion O
: O
during O
and O
after O
ifn B-DRUG
therapy O
, O
oct O
is O
a O
useful O
examination O
technique O
for O
revealing O
macular B-ADR
edema I-ADR
in O
patients O
who O
have O
decreased O
vision O

we O
report O
on O
a O
patient O
with O
renal O
artery O
stenosis O
who O
had O
only O
1 O
kidney O
and O
in O
whom O
acute O
renal O
impairment O
developed O
with O
transient B-ADR
anuria I-ADR
after O
the O
administration O
of O
captopril B-DRUG

the O
present O
observation O
suggests O
, O
that O
a O
batch O
of O
different O
testing O
doses O
, O
including O
lower O
testing O
doses O
may O
help O
to O
differentiate O
between O
an O
allergic O
type O
of O
contact O
dermatitis O
and O
an O
irritant B-ADR
type I-ADR
of I-ADR
reaction I-ADR
after O
treatment O
with O
calcipotriol B-DRUG

this O
experience O
supports O
the O
hypothesis O
that O
heparin B-DRUG
can O
be O
readministered O
early O
to O
patients O
with O
heparin-associated O
thrombocytopenia O
and O
thrombosis B-ADR
, O
provided O
antiplatelet O
therapy O
is O
given O

the O
authors O
report O
a O
case O
of O
balint O
syndrome O
with O
irreversible O
posterior B-ADR
leukoencephalopathy I-ADR
on O
mri O
following O
intrathecal O
methotrexate O
and O
cytarabine B-DRUG

objective O
: O
to O
study O
therapy O
with O
indapamide B-DRUG
impairing B-ADR
carbohydrate I-ADR
metabolism I-ADR
in O
essential O
hypertension O
patients O
and O
achieve O
earlier O
prevention O
, O
diagnoses O
and O
treatment O
of O
diabetes O
induced O
by O
indapamide B-DRUG

syringotropic B-ADR
hypersensitivity I-ADR
reaction I-ADR
associated O
with O
infliximab B-DRUG
and O
leflunomide O
combination O
therapy O
in O
a O
child O
with O
psoriatic O
arthritis O

vision B-ADR
declined I-ADR
after O
treatment O
with O
methylprednisolone B-DRUG
, O
after O
which O
fundus O
examination O
became O
consistent O
with O
progressive O
outer O
retinal O
necrosis O

intravenous O
verapamil O
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension O
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death B-ADR
; O
quinidine B-DRUG
may O
be O
related O
to O
the O
death B-ADR
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

the O
purpose O
of O
this O
report O
is O
to O
document O
a O
new O
case O
of O
in O
utero O
cp B-DRUG
exposure O
with O
multiple B-ADR
congenital I-ADR
anomalies I-ADR
and O
to O
establish O
an O
apparent O
cp B-DRUG
embryopathy O
phenotype O

the O
center O
for O
disease O
control O
has O
received O
numerous O
reports O
of O
an O
eosinophilia-myalgia B-ADR
syndrome I-ADR
related O
to O
products O
containing O
l-tryptophan B-DRUG

during O
intravenous O
treatment O
with O
terlipressin B-DRUG
for O
recurrent O
gastrointestinal O
( O
gi O
) O
bleeding O
, O
a O
50-year-old O
male O
with O
no O
history O
of O
heart O
disease O
developed O
a O
newly O
prolonged B-ADR
qt I-ADR
interval I-ADR
and O
torsade O
de O
pointes O

conclusions O
: O
in O
our O
reported O
case O
, O
a O
local O
hyperproduction B-ADR
of I-ADR
tnf-alpha I-ADR
from O
macrophages O
that O
was O
induced O
by O
the O
injected O
insulin B-DRUG
could O
explain O
the O
dedifferentiation O
of O
the O
adipocytes O
of O
the O
subcutaneous O
tissue O
and O
the O
reversion O
that O
was O
induced O
by O
the O
local O
injection O
of O
dexamethasone O

usefulness O
of O
antiplatelet O
drugs O
in O
the O
management O
of O
heparin-associated O
thrombocytopenia B-ADR
and O
thrombosis O

we O
report O
in O
detail O
an O
unusual O
adverse O
reaction O
to O
infliximab B-DRUG
therapy O
, O
a O
drug-induced O
lupus-like B-ADR
clinical I-ADR
syndrome I-ADR

hypertension B-ADR
develops O
in O
most O
patients O
after O
transplantation O
when O
immunosuppression O
is O
based O
on O
cyclosporine O
and O
prednisone B-DRUG

introduction O
: O
we O
describe O
the O
neurointensive O
care O
( O
nic O
) O
management O
of O
a O
patient O
with O
severe O
cerebral O
swelling O
and O
raised B-ADR
intracranial I-ADR
pressure I-ADR
( O
icp O
) O
after O
severe O
sodium O
valproic O
acid O
( O
vpa B-DRUG
) O
intoxication O

after O
discontinuation O
of O
danazol B-DRUG
the O
diabetes B-ADR
completely O
resolved O

a O
5-month-old O
infant O
became O
lethargic O
and O
poorly B-ADR
responsive I-ADR
after O
receiving O
1 O
drop O
of O
brimonidine B-DRUG
in O
each O
eye O

he O
developed O
recurrent O
skin O
rash O
, O
fever O
, O
hypereosinophilia B-ADR
, O
and O
acute O
renal O
failure O
after O
rechallenge O
with O
chlorambucil B-DRUG

the O
authors O
report O
two O
cases O
of O
delayed B-ADR
elimination I-ADR
of O
methotrexate O
in O
patients O
receiving O
ciprofloxacin B-DRUG
, O
with O
severe O
toxicity O

type B-ADR
1 I-ADR
diabetes I-ADR
mellitus I-ADR
provoked O
by O
peginterferon O
alpha-2b O
plus O
ribavirin B-DRUG
treatment O
for O
chronic O
hepatitis O
c O

two O
patients O
are O
described O
who O
developed O
testicular O
swelling O
and O
pain B-ADR
during O
treatment O
with O
desipramine B-DRUG

while O
40 O
mg O
/ O
day O
of O
prednisolone B-DRUG
improved O
hepatic O
dysfunction O
dramatically O
, O
her O
diabetic B-ADR
milieu I-ADR
deteriorated I-ADR
seriously O

an O
83-year-old O
man O
receiving O
glipizide O
10 O
mg O
bid O
developed O
symptomatic B-ADR
hypoglycemia I-ADR
within O
three O
days O
of O
adding O
trimethoprim O
/ O
sulfamethoxazole O
( O
tmp B-DRUG
/ O
smx O
) O
to O
his O
regimen O

these O
findings O
mean O
that O
the O
effect O
of O
the O
mp B-DRUG
pulse O
therapy O
on O
renal O
function O
depends O
on O
the O
clinical O
state O
of O
the O
patient O
and O
that O
renal O
deterioration O
after O
the O
pulse O
therapy O
may O
be O
more O
marked O
in O
patients O
who O
are O
more O
nephrotic O
and O
more O
impaired O
in O
renal O
function O
and O
suggest O
that O
increasing O
sodium O
and O
water O
retention O
during O
an O
mp B-DRUG
therapy O
and O
the O
associated O
renal O
interstitial O
edema O
, O
proposed O
as O
one O
of O
the O
mechanisms O
of O
acute O
renal O
failure O
occurring O
in O
patients O
with O
minimal-change O
nephrotic O
syndrome O
, O
may O
be O
responsible O
for O
the O
mp-induced O
transient B-ADR
renal I-ADR
failure I-ADR

it O
was O
hypothesized O
that O
valproic O
acid O
may O
interfere O
with O
glucuronidation O
of O
lamotrigine B-DRUG
, O
leading O
to O
increased O
serum O
lamotrigine B-DRUG
levels O
, O
or O
perhaps O
alter O
the O
drug O
's O
metabolism O
, O
resulting O
in O
accumulation B-ADR
of I-ADR
a I-ADR
toxic I-ADR
intermediate I-ADR
metabolite I-ADR

alopecia O
, O
nausea B-ADR
, O
and O
vomiting O
were O
attributed O
to O
the O
cyclophosphamide B-DRUG
component O
of O
the O
therapy O

although O
useful O
in O
the O
management O
of O
chronic O
alcoholism O
, O
disulfiram B-DRUG
is O
being O
increasingly O
associated O
with O
a O
wide O
spectrum O
of O
side O
effects O
and O
untoward O
medical O
sequelae O
, O
which O
now O
include O
catatonia B-ADR

we O
report O
the O
case O
of O
a O
27-year-old O
indian O
woman O
who O
developed O
maculopapular O
rash O
and O
angioedema B-ADR
secondary O
to O
carbamazepine B-DRUG
administration O

exfoliative B-ADR
dermatitis I-ADR
secondary O
to O
tobramycin B-DRUG
sulfate I-DRUG

hypokalemia B-ADR
after O
normal O
doses O
of O
neubulized O
albuterol O
( O
salbutamol B-DRUG

sporadic B-ADR
rippling I-ADR
muscle I-ADR
disease I-ADR
unmasked O
by O
simvastatin B-DRUG

a O
small O
number O
of O
oxaliplatin-related O
hemolytic B-ADR
and I-ADR
/ I-ADR
or I-ADR
thrombocytopenic I-ADR
reactions I-ADR
have O
been O
reported O

because O
of O
a O
hypersensitivity B-ADR
reaction I-ADR
, O
initial O
therapy O
with O
penicillin B-DRUG
g I-DRUG
and O
gentamicin O
was O
stopped O
and O
substituted O
with O
cefazolin O

massive O
cbz B-DRUG
od O
may O
produce O
a O
reversible O
encephalopathy O
that O
includes O
cortical B-ADR
hyperexcitability I-ADR
, O
a O
profound O
burst-suppression O
eeg O
pattern O
, O
and O
cranial O
nerve O
areflexia O

we O
report O
on O
a O
patient O
with O
renal O
artery O
stenosis O
who O
had O
only O
1 O
kidney O
and O
in O
whom O
acute B-ADR
renal I-ADR
impairment I-ADR
developed O
with O
transient O
anuria O
after O
the O
administration O
of O
captopril B-DRUG

a O
73-year-old O
woman O
with O
non-hodgkin O
's O
lymphoma O
had O
two O
episodes O
of O
severe O
, O
bilateral O
, O
sensori-neural B-ADR
hearing I-ADR
loss I-ADR
after O
vincristine B-DRUG
therapy O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin B-ADR
eruptions I-ADR
, O
cervical O
lymphadenopathy O
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim O
( O
tmp O
)- O
sulfamethoxazole B-DRUG
( O
smx O
) O
treatment O

there O
have O
been O
more O
than O
20 O
observations O
of O
the O
appearance O
or O
aggravation O
of O
this O
granulomatosis B-ADR
with O
interferon O
alfa O
and O
more O
recently O
with O
the O
combination O
of O
interferon O
alfa O
plus O
ribavirin B-DRUG

knowledge O
regarding O
potential O
adverse O
effects O
of O
cap B-DRUG
is O
paramount O
and O
dose O
modification O
is O
indicated O
with O
development O
of O
neurotoxicity B-ADR

we O
believe O
that O
the O
acute B-ADR
renal I-ADR
failure I-ADR
in O
our O
patient O
was O
associated O
with O
anastrozole B-DRUG

the O
authors O
describe O
a O
case O
of O
combined O
lithium B-DRUG
and O
haloperidol O
toxicity O
characterized O
by O
hyperpyrexia O
, O
severe B-ADR
rigidity I-ADR
, O
mutism O
, O
and O
development O
of O
irreversible O
tardive O
dyskinesia O

the O
first O
patient O
developed O
mild O
nitritoid O
symptoms O
and O
pain O
in O
a O
band-like O
distribution O
, O
corresponding O
to O
t10-t12 B-ADR
dermatomes I-ADR
, O
shortly O
after O
gold O
sodium O
thiomalate O
( O
gstm B-DRUG
) O
injection O

background O
: O
we O
describe O
the O
ophthalmic O
features O
and O
clinical O
course O
of O
two O
cases O
of O
acute O
syphilitic O
posterior O
placoid O
chorioretinitis O
( O
asppc B-ADR
) O
that O
developed O
after O
intravitreal O
triamcinolone O
acetonide O
( O
ivta B-DRUG
) O
injection O

interestingly O
, O
the O
use O
of O
carboplatin O
( O
cbdca O
) O
and O
vds O
in O
the O
subsequent O
treatment O
course O
was O
well O
tolerated O
indicating O
that O
the O
siadh B-ADR
was O
most O
likely O
to O
have O
been O
induced O
by O
administration O
of O
cddp B-DRUG

nail B-ADR
staining I-ADR
from O
hydroquinone B-DRUG
cream O

background O
: O
interferon B-DRUG
( O
ifn O
)- O
associated O
retinopathy O
is O
typically O
characterized O
by O
retinal B-ADR
hemorrhages I-ADR
and O
cotton O
wool O
spots O
at O
the O
posterior O
fundus O
, O
but O
visual O
function O
is O
usually O
maintained O

we O
report O
a O
43-year-old O
woman O
who O
developed O
sore O
throat O
, O
swelling B-ADR
of I-ADR
the I-ADR
lips I-ADR
and I-ADR
oral I-ADR
cavity I-ADR
and O
dysphagia O
, O
2 O
weeks O
after O
the O
use O
of O
budesonide O
spray O
( O
budefat B-DRUG
) O
for O
treatment O
of O
bronchial O
asthma O

painful B-ADR
neutrophilic O
skin O
lesions O
were O
observed O
in O
two O
children O
receiving O
granulocyte O
colony-stimulating O
factor O
( O
g-csf B-DRUG
) O
for O
treatment O
of O
idiopathic O
neutropenia O

paradoxical O
ventricular O
tachycardia O
and O
fibrillation B-ADR
after O
intravenous O
bretylium B-DRUG
therapy O

after O
a O
second O
dose O
of O
metoclopramide B-DRUG
, O
these O
symptoms O
recurred O
and O
were O
associated O
with O
confusion B-ADR
, O
agitation O
, O
fever O
, O
diaphoresis O
, O
tachypnea O
, O
tachycardia O
, O
and O
hypertension O

intravenous O
verapamil B-DRUG
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension O
, O
and O
bradycardia B-ADR
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine O
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

we O
report O
the O
case O
of O
a O
43-year-old O
man O
with O
itp O
refractory O
to O
steroids O
and O
intravenous O
immunoglobulin O
who O
developed O
acute B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
( O
ards O
) O
after O
a O
single O
infusion O
of O
rituximab B-DRUG

severe B-ADR
raynaud I-ADR
's I-ADR
phenomenon I-ADR
with O
yohimbine B-DRUG
therapy O
for O
erectile O
dysfunction O

although O
this O
type O
of O
hyperpigmentation B-ADR
has O
been O
previously O
seen O
in O
patients O
with O
cancer O
who O
are O
receiving O
bleomycin B-DRUG
, O
this O
is O
, O
to O
our O
knowledge O
, O
the O
first O
reported O
case O
of O
bleomycin-induced O
hyperpigmentation B-ADR
in O
an O
aids O
patient O
and O
should O
be O
added O
to O
the O
growing O
list O
of O
cutaneous O
eruptions O
seen O
in O
these O
patients O

intrahepatic O
cholestasis O
and O
cutaneous B-ADR
bullae I-ADR
associated O
with O
glibenclamide B-DRUG
therapy O

an O
encephalopathy O
and O
cardiomyopathy B-ADR
developed O
in O
a O
seventeen-year-old O
girl O
with O
chemotherapy-induced O
renal O
failure O
while O
receiving O
an O
intravesical O
aluminum B-DRUG
infusion O
for O
hemorrhagic O
cystitis O

objective O
: O
to O
report O
the O
case O
of O
a O
young O
woman O
with O
graves' O
disease O
in O
whom O
ototoxicity O
developed O
because O
of O
propylthiouracil O
( O
ptu B-DRUG
)- O
induced O
antineutrophil O
cytoplasmic O
antibody O
( O
anca O
)- O
associated O
vasculitis O

results O
: O
in O
a O
22-year-old O
thai O
woman O
with O
graves' O
disease O
, O
tinnitus O
, O
hearing O
impairment O
in O
the O
left O
ear O
( O
with O
progression O
to O
the O
right O
ear O
) O
, O
and O
vertigo O
developed O
after O
3 O
years O
of O
therapy O
with O
ptu B-DRUG

purpose O
: O
a O
case O
of O
probable O
enoxaparin-induced O
hepatotoxicity B-ADR
is O
described O

we O
have O
cared O
for O
three O
children O
in O
whom O
four O
episodes O
of O
dystonia B-ADR
proceeding O
to O
opisthotonus O
occurred O
in O
association O
with O
carbamazepine B-DRUG
use O

currently O
the O
use O
of O
zidovudine B-DRUG
is O
one O
of O
the O
few O
specific O
measures O
available O
, O
and O
as O
a O
potentially O
teratogenic O
and O
fetotoxic O
agent O
, O
any O
decision O
for O
its O
use O
requires O
evaluation O
of O
the O
potential O
for O
fetal B-ADR
damage I-ADR

the O
principle O
treatment O
for O
dpd-deficient O
patients O
with O
severe B-ADR
acute I-ADR
5-fu I-ADR
reactions I-ADR
is O
supportive O
care O
; O
however O
, O
the O
administration O
of O
thymidine O
potentially O
may O
reverse O
severe O
5-fu-induced O
neurologic O
symptoms O
such O
as O
encephalopathy O
and O
coma O

background O
: O
cyanamide B-DRUG
, O
an O
aversive O
agent O
widely O
used O
in O
japan O
, O
is O
known O
to O
induce O
various O
degrees O
of O
hepatic B-ADR
lesion I-ADR
with I-ADR
ground-glass I-ADR
inclusion I-ADR
bodies I-ADR

three O
patients O
, O
in O
whom O
tumour O
overkill O
by O
cytotoxic O
treatment O
, O
including O
high O
dose O
methotrexate B-DRUG
with O
folinic O
acid O
rescue O
, O
resulted O
in O
the O
' O
phosphate B-ADR
shower I-ADR
syndrome I-ADR
' O
( O
hyper-uricaemia O
, O
hyperkalaemia O
and O
hyperphosphataemia O
with O
hypocalcaemia O
and O
tetany O
, O
with O
metabolic O
acidosis O
and O
acute O
renal O
impairment O
) O
are O
described O

acute B-ADR
eosinophilic I-ADR
pneumonia I-ADR
caused O
by O
calcium B-DRUG
stearate I-DRUG
, O
an O
additive O
agent O
for O
an O
oral O
antihistaminic O
medication O

objective O
: O
to O
report O
2 O
cases O
of O
serotonin O
syndrome O
with O
serious O
extrapyramidal B-ADR
movement I-ADR
disorders I-ADR
occurring O
when O
metoclopramide O
was O
coadministered O
with O
sertraline O
or O
venlafaxine B-DRUG

a O
case O
of O
normotensive B-ADR
scleroderma I-ADR
renal I-ADR
crisis I-ADR
after O
high-dose O
methylprednisolone B-DRUG
treatment O

colchicine-induced O
rhabdomyolysis B-ADR

conclusions O
: O
the O
use O
of O
fluorouracil O
treatment O
with O
careful O
monitoring O
can O
be O
considered O
in O
a O
patient O
with O
mild O
allergic B-ADR
reactions I-ADR
to O
capecitabine B-DRUG

chromosome B-ADR
abnormalities I-ADR
after O
chlorambucil B-DRUG
therapy O
of O
polycythaemia O
vera O

although O
lung O
specimens O
were O
lacking O
from O
these O
three O
patients O
, O
it O
is O
suggested O
that O
the O
pulmonary B-ADR
toxicity I-ADR
of O
ccnu B-DRUG
may O
be O
dose-related O

a O
case O
of O
erythema B-ADR
multiforme I-ADR
bullosum I-ADR
in O
patient O
of O
lepromatous O
leprosy O
with O
pulmonary O
tuberculosis O
due O
to O
rifampicin B-DRUG
is O
described O

we O
report O
a O
case O
of O
sjs B-ADR
in O
a O
14-year-old O
male O
with O
nephrotic O
syndrome O
, O
who O
was O
treated O
with O
oral O
prednisolone B-DRUG
for O
6 O
weeks O

both O
patients O
were O
then O
treated O
with O
a O
carboplatin O
alternative O
to O
cisplatin B-DRUG
in O
the O
following O
courses O
, O
which O
resulted O
in O
neither O
a O
relapse O
of O
the O
colitis B-ADR
nor O
a O
recurrence O
of O
the O
malignancies O
up O
to O
this O
time O

we O
reviewed O
the O
records O
of O
3 O
patients O
with O
lymphoproliferative O
disorders O
who O
experienced O
acute B-ADR
coronary I-ADR
syndromes I-ADR
associated O
with O
their O
initial O
infusion O
of O
rituximab B-DRUG

we O
describe O
a O
patient O
who O
presented O
with O
bloody B-ADR
diarrhoea I-ADR
after O
15 O
mg O
meloxicam B-DRUG
daily O
for O
10 O
days O
for O
osteoarthritis O

discussion O
: O
methotrexate-induced O
papular B-ADR
eruption I-ADR
is O
rarely O
reported O
shortly O
after O
beginning O
methotrexate O
therapy O
in O
patients O
with O
acute O
exacerbation O
of O
collagen O
vascular O
diseases O

severe B-ADR
hemolytic I-ADR
uremic I-ADR
syndrome I-ADR
in O
an O
advanced O
ovarian O
cancer O
patient O
treated O
with O
carboplatin O
and O
gemcitabine B-DRUG

fatal B-ADR
interstitial I-ADR
pneumonitis I-ADR
associated O
with O
docetaxel B-DRUG
administration O
in O
a O
patient O
with O
hormone-refractory O
prostate O
cancer O

in O
a O
postural O
challenge O
test O
after O
administration O
of O
isosorbide B-DRUG
dinitrate I-DRUG
( O
5 O
mg O
) O
, O
blood O
pressure O
decreased O
from O
120 O
/ O
67 O
to O
65 O
/ O
35 O
mmhg O
, O
followed O
by O
syncope B-ADR
with O
a O
sudden O
decrease O
in O
pulse O
rate O
from O
85 O
to O
60 O
beats O
/ O
min O

graves' O
hyperthyroidism O
following O
transient B-ADR
thyrotoxicosis I-ADR
during O
interferon B-DRUG
therapy O
for O
chronic O
hepatitis O
type O
c O

we O
cared O
for O
a O
patient O
with O
progressive O
renal O
impairment O
who O
presented O
with O
blurred O
vision O
, O
qrs O
broadening O
and O
cardiac B-ADR
failure I-ADR
due O
to O
chronic O
cibenzoline B-DRUG
intoxication O

we O
present O
a O
case O
of O
photo-onycholysis B-ADR
in O
a O
patient O
treated O
with O
doxycycline B-DRUG
for O
acne O
vulgaris O

we O
describe O
a O
patient O
with O
transitional O
cell O
carcinoma O
of O
the O
renal O
pelvis O
who O
developed O
respiratory O
dysfunction O
and O
an O
abnormal B-ADR
chest I-ADR
x-ray I-ADR
with I-ADR
diffuse I-ADR
interstitial I-ADR
opacities I-ADR
while O
on O
chemotherapy O
with O
piritrexim B-DRUG
, O
a O
methotrexate O
analog O

studies O
performed O
10 O
years O
ago O
on O
25 O
patients O
with O
mtx-induced O
liver B-ADR
cirrhosis I-ADR
indicated O
that O
this O
type O
of O
cirrhosis O
was O
not O
of O
an O
aggressive O
nature O

after O
therapy O
for O
diabetic O
coma O
with O
insulin O
( O
containing O
the O
preservative O
cresol B-DRUG
) O
and O
electrolyte O
solutions O
was O
started O
, O
the O
patient O
complained O
of O
increasing B-ADR
myalgia I-ADR
, O
developed O
a O
high O
fever O
and O
respiratory O
and O
metabolic O
acidosis O
and O
lost O
consciousness O

hepatobiliary B-ADR
disorders I-ADR
associated O
with O
orally O
administered O
terbinafine B-DRUG
have O
rarely O
been O
reported O

favorable O
outcome O
of O
de O
novo O
hepatitis B-ADR
b I-ADR
infection I-ADR
after O
liver O
transplantation O
with O
lamivudine O
and O
adefovir B-DRUG
therapy O

pulmonary B-ADR
toxicity I-ADR
associated O
with O
erlotinib B-DRUG

a O
case O
is O
reported O
of O
a O
child O
with O
fatal B-ADR
pulmonary I-ADR
fibrosis I-ADR
following O
bcnu B-DRUG
therapy O

both O
pan B-DRUG
and O
methotrexate O
have O
been O
independently O
demonstrated O
to O
cause O
sensorineural B-ADR
hearing I-ADR
loss I-ADR

we O
report O
a O
patient O
with O
recurrent O
, O
increasingly O
severe O
episodes O
of O
ppe O
, O
ultimately O
complicated O
by O
a O
severe O
bullous B-ADR
eruption I-ADR
, O
following O
successive O
cycles O
of O
high-dose O
cytarabine B-DRUG
for O
the O
treatment O
of O
acute O
lymphoblastic O
leukaemia O

vancomycin B-DRUG
is O
widely O
used O
against O
methicillin-resistant O
staphylococcus O
aureus O
infections O
, O
but O
it O
is O
associated O
with O
many O
adverse O
effects O
such O
as O
nephrotoxicity O
, O
ototoxicity O
, O
gastrointestinal B-ADR
disturbances I-ADR
, O
blood O
disorders O
, O
and O
two O
types O
of O
hypersensitivity O
reactions O
- O
an O
anaphylactoid O
reaction O
known O
as O
" O
red O
man O
syndrome O
" O
and O
anaphylaxis O

ballistic O
movements O
due O
to O
ischemic B-ADR
infarcts I-ADR
after O
intravenous O
heroin B-DRUG
overdose O
: O
report O
of O
two O
cases O

severe B-ADR
hepatotoxicity I-ADR
from O
phenobarbital B-DRUG
occurred O
in O
an O
infant O
boy O
who O
had O
a O
complicated O
illness O
with O
chronic O
bilateral O
subdural O
hematomas O
and O
sepsis O

we O
present O
a O
case O
of O
hemolytic-uremic B-ADR
syndrome I-ADR
that O
developed O
during O
the O
4th O
cycle O
of O
combination O
chemotherapy O
with O
oxaliplatin O
, O
5-fluorouracil O
and O
leucovorin B-DRUG

a O
67-year-old O
patient O
, O
with O
primary O
polymyositis O
and O
without O
previous O
evidence O
of O
liver O
disease O
, O
developed O
clinical O
and O
biochemical O
features O
of O
severe B-ADR
cholestasis I-ADR
3 O
months O
after O
initiation O
of O
azathioprine B-DRUG
therapy O

however O
, O
a O
new O
episode O
of O
neutropenia B-ADR
, O
with O
a O
wbc O
count O
of O
2.8 O
x O
10 O
( O
3 O
)/ O
mm3 O
and O
anc O
of O
0.448 O
x O
10 O
( O
3 O
)/ O
mm3 O
, O
occurred O
11 O
days O
after O
teicoplanin B-DRUG
initiation O

rifampin O
( O
rfp B-DRUG
) O
increases O
hepatic O
microsomal O
enzyme O
activity O
, O
and O
there O
are O
case O
reports O
of O
rfp-induced O
hypothyroidism B-ADR
, O
all O
associated O
with O
hashimoto O
's O
thyroiditis O

gabapentin B-DRUG
withdrawal O
presenting O
as O
status B-ADR
epilepticus I-ADR

a O
55-year-old O
woman O
presented O
an O
episode O
of O
acute O
urticaria O
and O
labial B-ADR
angioedema I-ADR
60 O
minutes O
after O
ingesting O
500 O
mg O
of O
cloxacillin B-DRUG
for O
a O
skin O
abscess O

edema B-ADR
associated O
with O
ibuprofen B-DRUG
therapy O

fever O
and O
maculopapular B-ADR
rashes I-ADR
appeared O
at O
10 O
days O
after O
phenytoin B-DRUG
initiation O
, O
and O
then O
the O
drug O
was O
discontinued O

the O
chemotherapeutics O
, O
including O
vincristine O
, O
actinomycin B-DRUG
d I-DRUG
, O
and O
epirubicin O
in O
case O
1 O
and O
vincristine O
and O
actinomycin B-DRUG
d I-DRUG
in O
case O
2 O
, O
were O
given O
before O
the O
hepatotoxicity B-ADR
developed O

sarcoma B-ADR
complicating O
therapy O
with O
cyclophosphamide B-DRUG

we O
report O
a O
case O
of O
intrathecal O
methotrexate B-DRUG
neurotoxicity B-ADR
manifesting O
as O
left O
arm O
weakness O
and O
aphasia O

the O
second O
patient O
, O
who O
developed O
cholestasis B-ADR
after O
receiving O
trimethoprim-sulfamethoxazole B-DRUG
, O
had O
marked O
duct O
paucity O
in O
the O
liver O
biopsy O

sulfasalazine B-DRUG
has O
been O
associated O
with O
bronchopulmonary O
complications O
of O
inflammatory O
bowel O
disease O
( O
ibd B-ADR
) O
in O
adults O

introduction-the O
aim O
of O
this O
case O
report O
is O
to O
present O
a O
15-year O
follow-up O
of O
a O
patient O
with O
phenytoin B-DRUG
( O
pht O
) O
intoxication O
with O
unilateral B-ADR
gingival I-ADR
hyperplasia I-ADR
( O
gh O

there O
are O
no O
previous O
reports O
in O
the O
literature O
about O
the O
emergence O
of O
cml B-ADR
during O
treatment O
with O
hydroxyurea B-DRUG

presented O
is O
a O
case O
of O
acute B-ADR
renal I-ADR
failure I-ADR
induced O
by O
acetazolamide B-DRUG
therapy O
for O
glaucoma O

several O
case O
reports O
of O
aplastic B-ADR
anemia I-ADR
with O
use O
of O
acetazolamide O
, O
and O
two O
cases O
with O
use O
of O
methazolamide B-DRUG
, O
have O
appeared O
in O
the O
literature O

exacerbations B-ADR
of I-ADR
the I-ADR
heart I-ADR
failure I-ADR
were O
temporally O
related O
to O
the O
administration O
of O
the O
antitumor O
antibiotics O
actinomycin-d O
( O
nsc-3053 O
) O
and O
mithramycin O
( O
nsc-24559 B-DRUG

cytarabine-induced O
cerebellar B-ADR
syndrome I-ADR
: O
case O
report O
and O
literature O
review O

conclusions O
: O
we O
conclude O
that O
a O
high O
dose O
combined O
with O
a O
short O
infusion O
time O
increases O
the O
risk O
of O
anaphylactoid B-ADR
reactions I-ADR
with O
the O
administration O
of O
intraperitoneal O
cisplatin B-DRUG

discussion O
: O
the O
main O
adverse O
effects O
of O
leflunomide B-DRUG
consist O
of O
diarrhea O
, O
nausea B-ADR
, O
liver O
enzyme O
elevation O
, O
hypertension O
, O
alopecia O
, O
and O
allergic O
skin O
reactions O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity B-ADR
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia O
, O
icterus O
, O
protein-losing O
enteropathy O
, O
myositis O
, O
and O
nephritis O
, O
is O
described O

one O
case O
of O
priapism B-ADR
occurred O
during O
heparin B-DRUG
therapy O
for O
a O
previous O
surgical O
operation O
to O
the O
knee O
is O
reported O

etoposide-related O
myocardial B-ADR
infarction I-ADR

it O
was O
concluded O
that O
anca B-ADR
is O
closely O
related O
to O
the O
pathogenesis O
of O
crescentic O
glomerulonephritis O
and O
that O
treatment O
with O
ptu B-DRUG
appeared O
to O
induce O
anca B-ADR

splenic B-ADR
hemorrhage I-ADR
: O
a O
complication O
of O
tissue B-DRUG
plasminogen I-DRUG
activator I-DRUG
treatment O

we O
describe O
a O
patient O
in O
whom O
noncardiogenic B-ADR
pulmonary I-ADR
edema I-ADR
developed O
during O
intrabiliary O
infusion O
of O
monooctanoin B-DRUG

we O
discuss O
a O
patient O
who O
developed O
severe O
renal O
tubular O
dysfunction O
secondary O
to O
short-term O
therapy O
with O
amikacin B-DRUG
, O
resulting O
in O
refractory O
hypokalemia O
, O
hypocalcemia O
, O
hypomagnesemia O
, O
metabolic O
alkalosis O
, O
and O
polyuria B-ADR

objective O
: O
to O
report O
the O
occurrence O
of O
acute B-ADR
cytolytic I-ADR
hepatitis I-ADR
in O
a O
patient O
exposed O
to O
pulse O
itraconazole B-DRUG
therapy O
for O
24 O
weeks O
and O
provide O
a O
concise O
review O
of O
the O
literature O
on O
cases O
of O
itraconazole-induced O
hepatitis O

a O
patient O
developed O
papilloedema O
and O
hepatic B-ADR
dysfunction I-ADR
while O
being O
treated O
with O
perhexiline B-DRUG
maleate I-DRUG

this O
review O
presents O
the O
first O
case O
series O
of O
dic O
associated O
with O
acute O
hemoglobinemia O
or O
hemoglobinuria B-ADR
following O
anti-d B-DRUG
igiv I-DRUG
administration O
for O
itp O

a O
51-year O
old O
physically O
fit O
woman O
experienced O
angio-oedema B-ADR
and O
hypotensive O
shock O
after O
irbesartan B-DRUG
ingestion O
requiring O
noradrenaline O
infusion O

usefulness O
of O
antiplatelet O
drugs O
in O
the O
management O
of O
heparin-associated O
thrombocytopenia O
and O
thrombosis B-ADR

reversible O
findings O
of O
restricted O
diffusion O
in O
5-fluorouracil B-DRUG
neurotoxicity B-ADR

exacerbation O
of O
anthracycline-induced O
early B-ADR
chronic I-ADR
cardiomyopathy I-ADR
with O
atra O
: O
role O
of O
b-type O
natriuretic O
peptide O
as O
an O
indicator O
of O
cardiac O
dysfunction O

the O
polycystic O
changes O
disappeared O
from O
the O
ovaries O
in O
2 O
of O
the O
women O
after O
valproate B-DRUG
therapy O
was O
discontinued O
, O
and O
the O
2 O
women O
who O
had O
gained O
weight O
and O
developed O
amenorrhea B-ADR
while O
being O
treated O
with O
valproate B-DRUG
lost O
weight O
and O
resumed O
menstruating O
after O
the O
change O
in O
medication O

an O
episode O
of O
leukoencephalopathy B-ADR
is O
reported O
in O
a O
13-year-old O
girl O
who O
, O
after O
standard O
radiotherapy O
for O
a O
posterior O
fossa O
medulloblastoma O
, O
received O
8 O
treatments O
with O
a O
protocol O
containing O
a O
4-hour O
infusion O
of O
500 O
mg O
/ O
m2 O
methotrexate B-DRUG
and O
12 O
mg O
intrathecal O
methotrexate B-DRUG

bisphosphonate-related O
osteonecrosis B-ADR
of I-ADR
the I-ADR
skull I-ADR
base I-ADR

intravenous O
verapamil B-DRUG
therapy O
in O
babies O
may O
cause O
apnea O
, O
hypotension B-ADR
, O
and O
bradycardia O
; O
continued O
episodes O
of O
atrial O
flutter O
in O
a O
child O
may O
cause O
sudden O
death O
; O
quinidine O
may O
be O
related O
to O
the O
death O
; O
children O
with O
" O
familial O
seizure O
disorders O
" O
may O
in O
fact O
have O
the O
long O
qt O
interval O
syndrome O

the O
induced O
hyperglycaemia O
could O
not O
be O
controlled O
sufficiently O
, O
despite O
a O
high O
dose O
of O
insulin B-DRUG
(> O
110 O
units O
/ O
day O
) O
, O
suggesting O
the O
existence O
of O
insulin B-DRUG
insensitivity O
and O
hyperinsulinaemia B-ADR

recurrent O
septicemia B-ADR
with O
lethal O
outcome O
during O
and O
after O
cyclosporine B-DRUG
therapy O
in O
severe O
ulcerative O
colitis O

two O
patients O
treated O
with O
5-fluorouracil O
( O
5-fu B-DRUG
) O
for O
disseminated O
adenocarcinoma O
of O
the O
colon O
developed O
cerebellar B-ADR
dysfunction I-ADR
typical O
of O
5-fu B-DRUG
neurotoxicity O

to O
our O
knowledge O
, O
this O
is O
the O
first O
report O
of O
an O
angio-oedema B-ADR
associated O
with O
vrc B-DRUG

patients O
receiving O
amifostine B-DRUG
who O
develop O
only O
fever O
should O
be O
evaluated O
for O
an O
adverse O
drug O
reaction O
, O
as O
well O
as O
for O
sepsis B-ADR
and O
fevers O
of O
neutropenia O
, O
and O
it O
may O
be O
necessary O
to O
discontinue O
the O
drug O

the O
case O
demonstrates O
that O
hypersensitivity O
reaction O
to O
pranlukast B-DRUG
and O
resultant O
atin B-ADR
is O
possible O
, O
and O
that O
periodic O
urine O
testing O
in O
patients O
receiving O
pranlukast B-DRUG
should O
be O
considered O

the O
latter O
form O
( O
macrodantin B-DRUG
) O
is O
reported O
to O
engender O
less O
gastrointestinal O
intolerance O
but O
it O
can O
produce O
the O
same O
adverse O
effects O
as O
the O
conventional O
form O
-- O
liver O
damage O
, O
acute O
and O
chronic O
pulmonary O
reactions O
, O
peripheral B-ADR
neuropathy I-ADR
, O
blood O
dyscrasias O
and O
allergic O
reactions O
-- O
and O
does O
so O
just O
as O
rapidly O
and O
floridly O
; O
one O
such O
case O
is O
reported O
here O

we O
report O
the O
first O
case O
of O
herpes B-ADR
esophagitis I-ADR
in O
a O
renal O
transplant O
patient O
treated O
with O
cyclosporine B-DRUG
a I-DRUG
while O
on O
chronic O
steroid O
therapy O

in O
the O
third O
child O
, O
the O
tics B-ADR
ceased O
after O
cbz B-DRUG
discontinuation O

in O
this O
article O
, O
we O
describe O
another O
case O
of O
subcutaneous O
changes O
following O
repeated O
glatiramer B-DRUG
acetate I-DRUG
injection O
, O
presented O
as O
localized B-ADR
panniculitis I-ADR
in O
the O
area O
around O
the O
injection O
sites O
, O
in O
a O
46-year-old O
female O
patient O
who O
was O
treated O
with O
glatiramer B-DRUG
acetate I-DRUG
for O
18 O
months O

hyperkalaemia O
with O
renal B-ADR
tubular I-ADR
dysfunction I-ADR
by O
oral O
therapy O
of O
sulfamethoxazole-trimethoprim O
( O
co-trimoxazole B-DRUG
) O
is O
described O
in O
2 O
elderly O
japanese O
patients O
with O
lymphoid O
malignancy O
, O
who O
developed O
pneumocystis O
carinii O
pneumonia O
and O
improved O

a O
case O
of O
liver B-ADR
damage I-ADR
following O
treatment O
with O
danazol B-DRUG
for O
fibrocystic O
breast O
disease O
is O
reported O

bisphosphonate B-DRUG
induced O
osteochemonecrosis B-ADR
of I-ADR
the I-ADR
jaw I-ADR
mimicking O
a O
tumour O

obsessive-compulsive B-ADR
symptoms I-ADR
suddenly O
emerged O
10 O
days O
after O
starting O
risperidone B-DRUG
and O
resolved O
within O
3 O
days O
of O
discontinuation O

capecitabine-induced O
multifocal B-ADR
leukoencephalopathy I-ADR
: O
a O
report O
of O
five O
cases O

the O
authors O
report O
a O
case O
of O
acute O
pancreatitis B-ADR
( O
ap O
) O
occurring O
in O
a O
patient O
under O
treatment O
with O
carbamazepine B-DRUG
( O
cbz O
) O
for O
post-traumatic O
petit O
mal O
epilepsy O
, O
and O
review O
the O
current O
literature O
of O
drug-induced O
ap O

after O
reviewing O
the O
literature O
we O
suggest O
the O
cpm O
was O
a O
complication O
of O
lithium B-DRUG
toxicity O
which O
affected O
the O
lateral O
geniculate O
nucleus O
which O
produced O
blindness B-ADR

five O
and O
one-half O
years O
after O
the O
diagnosis O
of O
myeloma O
, O
while O
in O
remission O
on O
cyclophosphamide B-DRUG
therapy O
, O
the O
patient O
experienced O
severe O
abdominal O
right O
lower O
quadrant O
pain O
due O
to O
a O
large O
cecal B-ADR
lymphoma I-ADR

the O
case O
demonstrates O
that O
hypersensitivity O
reaction O
to O
pranlukast B-DRUG
and O
resultant O
atin B-ADR
is O
possible O
, O
and O
that O
periodic O
urine O
testing O
in O
patients O
receiving O
pranlukast B-DRUG
should O
be O
considered O

conclusion O
: O
we O
believe O
this O
to O
be O
the O
first O
reported O
case O
of O
rhgh-induced O
hypercalcemia B-ADR
in O
an O
hiv-infected O
patient O

we O
describe O
a O
patient O
with O
transitional O
cell O
carcinoma O
of O
the O
renal O
pelvis O
who O
developed O
respiratory B-ADR
dysfunction I-ADR
and O
an O
abnormal O
chest O
x-ray O
with O
diffuse O
interstitial O
opacities O
while O
on O
chemotherapy O
with O
piritrexim B-DRUG
, O
a O
methotrexate O
analog O

a O
14-year-old O
female O
developed O
systemic O
lupus O
erythematosus O
( O
sle O
)- O
like O
symptoms O
, O
rash O
, O
fever B-ADR
, O
leukopenia O
and O
positive O
anti-nuclear O
antibody O
( O
ana O
) O
two O
weeks O
after O
administration O
of O
carbamazepine B-DRUG
( O
cbz O
; O
tegretol O
) O
used O
against O
benign O
rolandic O
epilepsy O

warfarin-associated O
bleeding B-ADR
generally O
is O
considered O
deleterious O
; O
however O
, O
in O
our O
patient O
it O
unmasked O
an O
early O
stage O
of O
colon O
cancer O
and O
thus O
may O
have O
saved O
the O
patient O
's O
life O

the O
elicitation O
of O
a O
movement B-ADR
disorder I-ADR
by O
trazodone B-DRUG
: O
case O
report O

in O
this O
case O
report O
, O
we O
have O
described O
a O
patient O
with O
crohn O
's O
disease O
who O
developed O
subfulminant B-ADR
hepatitis I-ADR
b I-ADR
after O
the O
fourth O
infusion O
of O
infliximab B-DRUG
due O
to O
an O
unrecognized O
hbs-antigen O
carrier O
state O

methotrexate-induced O
hepatic B-ADR
necrosis I-ADR
requiring O
liver O
transplantation O
in O
a O
patient O
with O
rheumatoid O
arthritis O

after O
taking O
cholestyramine B-DRUG
ii I-DRUG
sachets O
twice O
daily O
for O
two O
months O
she O
presented O
with O
lethargy B-ADR
, O
confusion O
and O
drowsiness O

a O
67-year-old O
man O
with O
bipolar O
disorder O
developed O
a O
creutzfeldt-jakob B-ADR
like I-ADR
syndrome I-ADR
during O
lithium B-DRUG
carbonate I-DRUG
treatment O

a O
child O
in O
whom O
a O
phenobarbital B-DRUG
hypersensitivity O
drug O
reaction O
developed O
which O
consisted O
of O
fever O
, O
a O
pruritic O
desquamating O
erythrodermic O
rash O
, O
alopecia O
, O
icterus O
, O
protein-losing O
enteropathy O
, O
myositis O
, O
and O
nephritis B-ADR
, O
is O
described O

case O
report O
: O
we O
hereby O
report O
a O
case O
of O
radiation O
recall O
dermatitis O
and O
myositis B-ADR
occurring O
on O
gemcitabine B-DRUG
monotherapy O
, O
five O
months O
after O
completing O
chemoradiation O
for O
locally O
advanced O
pancreatic O
cancer O

supravenous B-ADR
hyperpigmentation I-ADR
in O
association O
with O
chop B-DRUG
chemotherapy O
of O
a O
cd30 O
( O
ki-1 O
)- O
positive O
anaplastic O
large-cell O
lymphoma O

drug O
induced O
polymyositis B-ADR
secondary O
to O
leuprolide O
acetate O
( O
lupron B-DRUG
) O
therapy O
for O
prostate O
carcinoma O

based O
on O
the O
history O
and O
clinical O
features O
, O
a O
diagnosis O
of O
insulin-induced O
lipohypertrophy B-ADR
was O
made O

seizures O
and O
extrapyramidal B-ADR
symptoms I-ADR
in O
a O
patient O
with O
tourette O
's O
syndrome O
, O
asperger O
's O
syndrome O
, O
and O
multiple O
sclerosis O
treated O
with O
interferon B-DRUG
beta-1a I-DRUG
and O
clomipramine O

method O
: O
the O
authors O
followed O
a O
patient O
with O
chronic O
hcv O
who O
received O
interferon B-DRUG
and O
ribavirin O
and O
who O
developed O
hallucinations B-ADR
ultimately O
requiring O
psychiatric O
hospitalization O

protease O
inhibitors O
( O
ritonavir O
and O
saquinavir O
) O
were O
added O
to O
the O
treatment O
and O
the O
patient O
developed O
progressive O
ataxia O
related O
to O
carbamazepine B-ADR
toxicity I-ADR

we O
have O
described O
three O
patients O
with O
hepatitis O
c O
for O
whom O
ifn-alpha B-DRUG
and O
ribavirin O
were O
prescribed O
and O
who O
developed O
two O
successive O
phases O
of O
silent O
thyroiditis O
followed O
by O
hyperthryroidism B-ADR
relapse O
due O
to O
graves' O
disease O

this O
paper O
reports O
on O
a O
6.9-year-old O
autistic O
male O
who O
developed O
repeated O
episodes O
of O
acute B-ADR
dystonic I-ADR
reactions I-ADR
associated O
with O
pimozide O
administration O
at O
the O
doses O
of O
0.096 O
mg O
/ O
kg O
/ O
day O
and O
0.032 O
mg O
/ O
kg O
/ O
day O
and O
32 O
hours O
following O
pimozide O
withdrawal O
, O
as O
well O
as O
during O
subsequent O
thioridazine B-DRUG
administration O

acute B-ADR
myocardial I-ADR
ischemia I-ADR
following O
accidental O
intravenous O
administration O
of O
epinephrine B-DRUG
in O
high O
concentration O

purpose O
: O
topiramate-induced O
angle-closure B-ADR
glaucoma I-ADR
( O
tiacg O
) O
is O
believed O
to O
be O
related O
to O
its O
sulfonamide O
moiety O

case O
report O
: O
we O
report O
a O
case O
of O
intracerebral B-ADR
hemorrhage I-ADR
occurring O
in O
a O
middle-aged O
man O
who O
suffered O
from O
chronic O
sinusitis O
and O
had O
been O
ingesting O
pseudoephedrine B-DRUG
daily O
for O
one O
year O

hepatotoxicity B-ADR
related O
to O
itraconazole B-DRUG
: O
report O
of O
three O
cases O

fludarabine B-DRUG
induced O
lung B-ADR
toxicity I-ADR
must O
be O
considered O
in O
all O
patients O
who O
develop O
unexplained O
lung O
disease O
while O
receiving O
fludarabine O

we O
present O
a O
fatal O
case O
of O
subacute O
methanol B-DRUG
toxicity O
with O
associated O
diffuse B-ADR
brain I-ADR
involvement I-ADR
, O
including O
bilateral O
putaminal O
necrosis O
and O
cerebral O
edema O
with O
ventricular O
compression O

based O
on O
the O
naranjo O
probability O
scale O
, O
serotonin B-ADR
syndrome I-ADR
was O
a O
probable O
adverse O
reaction O
associated O
with O
co-administration O
of O
citalopram B-DRUG
and O
fentanyl O

a O
patient O
with O
chronic O
myeloid O
leukaemia O
treated O
with O
busulphan B-DRUG
for O
4-5 O
years O
, O
developed O
signs O
of O
busulphan B-DRUG
toxicity O
and O
portal O
hypertension O
with O
ascites B-ADR
, O
oesophageal O
varices O
and O
jaundice O

a O
27-year-old O
man O
who O
had O
a O
history O
of O
bronchial O
asthma O
, O
eosinophilic O
enteritis O
, O
and O
eosinophilic O
pneumonia O
presented O
with O
fever O
, O
skin O
eruptions O
, O
cervical B-ADR
lymphadenopathy I-ADR
, O
hepatosplenomegaly O
, O
atypical O
lymphocytosis O
, O
and O
eosinophilia O
two O
weeks O
after O
receiving O
trimethoprim B-DRUG
( O
tmp O
)- O
sulfamethoxazole O
( O
smx O
) O
treatment O

while O
doxorubicin B-DRUG
was O
administered O
, O
the O
patient O
presented O
thoracic O
pain O
and O
breathing B-ADR
distress I-ADR
due O
to O
superior O
vena O
cava O
perforation O
by O
the O
central O
catheter O
and O
subsequent O
extravasation O
of O
the O
drug O
into O
the O
mediastinum O

conclusions O
: O
life-threatening O
adrenal B-ADR
suppression I-ADR
, O
requiring O
hydrocortisone O
supplementation O
and O
intensive O
therapy O
, O
was O
observed O
and O
successfully O
treated O
in O
a O
newborn O
, O
whose O
mother O
had O
received O
high-dose O
methylprednisolone B-DRUG
in O
late O
pregnancy O

methods O
: O
repeated O
blood O
samples O
were O
drawn O
in O
a O
patient O
with O
severe O
acyclovir B-DRUG
overdose O
who O
developed O
coma B-ADR
and O
nonoliguric O
renal O
failure O

eeg B-ADR
abnormalities I-ADR
were O
observed O
in O
two O
of O
the O
nine O
children O
during O
chlorambucil B-DRUG
therapy O

rapid O
resolution O
of O
topiramate-induced O
angle-closure B-ADR
glaucoma I-ADR
with O
methylprednisolone O
and O
mannitol O

we O
report O
a O
case O
of O
stevens-johnson O
syndrome O
/ O
toxic O
epidermal O
necrolysis O
( O
sjs O
/ O
ten B-ADR
) O
secondary O
to O
trimethoprim-sulfamethoxazole B-DRUG
( O
tmp-sx O
) O
therapy O
for O
presumed O
community-associated O
methicillin-resistant O
staphylococcus O
aureus O
( O
ca-mrsa O
) O
infection O

in O
rare O
cases O
mitomycin B-DRUG
c I-DRUG
( O
mmc O
) O
may O
induce O
cancer-associated O
hemolytic B-ADR
uremic I-ADR
syndrome I-ADR
, O
which O
is O
characterized O
by O
hemolytic O
anemia O
, O
thrombocytopenia O
and O
progressive O
renal O
failure O

the O
patient O
experienced O
hallucinations O
, O
agitation O
, O
vomiting O
, O
tachycardia O
and O
seizures B-ADR
after O
ingestion O
of O
1050 O
( O
48 O
mg O
/ O
kg O
) O
of O
extended-release O
bupropion B-DRUG

six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten-week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable O
affect O
, O
including O
feelings O
of O
agitation O
and O
depression O
and O
periods O
of O
crying O
and O
insomnia B-ADR

severe B-ADR
apnea I-ADR
in O
an O
infant O
exposed O
to O
lamotrigine B-DRUG
in O
breast O
milk O

tenofovir-associated O
nephrotoxicity B-ADR
in O
two O
hiv-infected O
adolescent O
males O

a O
previous O
study O
of O
patients O
with O
" O
quinine-associated O
ttp B-ADR
/ I-ADR
hus I-ADR
" O
found O
that O
adamts13 O
activities O
were O
not O
abnormal O
in O
12 O
/ O
12 O
patients O

can O
magnesium B-DRUG
sulfate I-DRUG
therapy O
impact O
lactogenesis B-ADR

large O
dose O
of O
methylphenidate B-DRUG
may O
cause O
cataract O
and O
glaucoma B-ADR

bortezomib-induced O
paralytic B-ADR
ileus I-ADR
is O
a O
potential O
gastrointestinal O
side O
effect O
of O
this O
first-in-class O
anticancer O
proteasome O
inhibitor O

we O
report O
the O
first O
case O
of O
fulminant O
adult B-ADR
respiratory I-ADR
distress I-ADR
syndrome I-ADR
( O
ards O
) O
associated O
with O
pegylated B-DRUG
interferon I-DRUG
alpha-2a I-DRUG
( O
pegifnalpha-2a O
) O
and O
ribavirin O
use O
for O
hepatitis O
c O
, O
complicated O
by O
subsequent O
and O
ultimately O
fatal O
sepsis O
and O
multiorgan O
failure O

we O
report O
the O
case O
of O
a O
man O
, O
treated O
with O
mesalazine B-DRUG
for O
crohn O
's O
disease O
who O
developed O
drug-induced O
pericarditis B-ADR

complications O
of O
chemotherapy O
for O
a O
synovial O
sarcoma O
in O
an O
eight-year O
old O
boy O
included O
cisplatinum B-DRUG
nephrotoxicity B-ADR
and O
adriamycin O
cardiotoxicity O

one O
patient O
required O
nursing O
home O
placement O
and O
a O
feeding O
gastrostomy O
as O
a O
result O
of O
the O
worsening B-ADR
parkinsonism I-ADR
during O
risperidone B-DRUG
treatment O
, O
but O
was O
able O
to O
return O
home O
and O
have O
the O
gastrostomy O
removed O
after O
switching O
from O
risperidone B-DRUG
to O
clozapine O

we O
report O
a O
girl O
with O
the O
rett O
syndrome O
who O
had O
acute B-ADR
encephalopathy I-ADR
probably O
induced O
by O
calcium B-DRUG
hopantenate I-DRUG
( O
hopa O

hydroxyurea-induced O
acute B-ADR
interstitial I-ADR
pneumonitis I-ADR
in O
a O
patient O
with O
essential O
thrombocythemia O

here O
we O
present O
the O
case O
of O
a O
generalized B-ADR
lichen I-ADR
nitidus I-ADR
with O
involvement O
of O
the O
palms O
in O
a O
patient O
with O
hepatitis O
c O
after O
systemic O
treatment O
with O
interferon B-DRUG
alpha I-DRUG
and O
ribavirin O

reye O
syndrome O
( O
rs B-ADR
) O
is O
believed O
to O
occur O
infrequently O
among O
children O
receiving O
long-term O
aspirin B-DRUG
therapy O

because O
nephrotic B-ADR
syndrome I-ADR
may O
be O
induced O
by O
ifn B-DRUG
therapy O
, O
the O
ifn B-DRUG
was O
stopped O

in O
deciding O
if O
tamoxifen B-DRUG
therapy O
is O
warranted O
, O
all O
potentially O
life-threatening O
adverse O
events O
associated O
with O
tamoxifen B-DRUG
should O
be O
considered O
, O
including O
endometrial B-ADR
adenocarcinoma I-ADR
or O
uterine O
sarcoma O

six O
of O
13 O
outpatients O
with O
schizophrenia O
who O
participated O
in O
a O
ten-week O
open O
trial O
of O
risperidone B-DRUG
had O
an O
initial O
good O
response O
to O
the O
medication O
followed O
by O
development O
of O
intolerable B-ADR
affect I-ADR
, O
including O
feelings O
of O
agitation O
and O
depression O
and O
periods O
of O
crying O
and O
insomnia O

we O
describe O
the O
case O
of O
acute B-ADR
hepatitis I-ADR
induced O
by O
gliclazide B-DRUG
, O
a O
second O
generation O
sulfonylurea O

